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Abstract 
IRF-I (Interferon Regulatory Factor 1) is a transcription factor first identified as a 
regulator of Interferon expression. Two decades after its discovery, IRF-l has 
been shown to be involved in numerous other pathways including apoptosis, cell 
cycle regulation, DNA damage/repair, immune cell development and 
inflammation. Transcriptional regulation of IRF -1 by a number of external agents 
has been extensively studied, however almost nothing is known about the post-
translational regulation of IRF-l activity. In this study IRF-l is shown to be 
phosphorylated at Thr l80 by GSK3p (Glycogen Synthase Kinase 3P). 
Phosphorylated Thr l80 promotes interaction with the ubiquitin E3 ligase 
SCFFbxw7u, (Skpl-Cull-Fbxw7a) which increases turnover of IRF-I protein. 
Phosphorylation dependent ubiquitination of IRF -1 was confirmed, as substitution 
of Thr l80 to alanine reduced IRF -1 ubiquitination and increased stability. 
Enhanced phosphorylation of IRF-l (by increasing GSK3p expression) promotes 
increased ubiquitinationldegradation. Transactivation of the TRAIL (TNFa 
Related Apoptosis Inducing Ligand) promoter by IRF -1 was found to be 
dependent on GSK3(3 phosphorylation of Thr l80 by use of reporter assays and 
inducible expression of IRF-I in breast cancer cell lines. Importantly IRF-I 
activity on the TRAIL promoter is dependent on proper turnover by the UPS 
(Ubiquitin Proteasome System), as chemical inhibition of the proteasome, or 
reduction in IRF -1 ubiquitination reduced activity in reporter assays. This 
suggests that phosphorylation of IRF-1 by GSK3p acts as a destruction signal 
through association with SCFFbxw7a. This signal dependent turnover of IRF-l IS 
required for proper transcriptional activation of the TRAIL promoter. 
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Chapter 1. Introduction 
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1.1.1. Transcription 
The cells ability to control the expression of its genes in an orderly fashion 
IS a fundamental process. In order to activate expression of a particular gene 
transcription IS employed. Transcription is the process by which DNA is 
converted to RNA, and is the first step in gene expression. Every gene in a cell 
genome contains the regulatory sequences required to control its expression. 
Often (although not always) these regulatory elements are found in the promoter 
region which is often found close to the transcriptional start site of the coding 
gene. Promoters contain binding elements for the basal transcription factors as 
well as for specific transcription factors. Transcription factors (TFs) are proteins 
that are able to recognise specific DNA sequences. A huge number of TFs are 
present in eukaryotic cells, which imparts specificity to gene expression, as 
different combination of TF binding sites are present on each gene promoter. 
Protein coding gene transcription is regulated by RNA Polymerase II (RNA Pol 
II), while RNA Pol I is involved in generating ribosomal RNA transcripts and 
RNA Pol III is involved in the transcription of transfer RNA molecules. RNA Pol 
II cannot initiate transcription alone, but numerous other factors including TFs, 
coactivators, kinases and chromatin remodelling complexes are also needed this 
conglomeration of proteins can be defined as a pre-initation complex (PIC). To 
initate transcription, the RNA Pol II complex must gain access to the template 
strand of DNA; this is aided by a helicase enzyme recruited by RNA Pol II which 
partially unwinds the DNA. RNA Pol II is phosphorylated and disengages from 
the other proteins in the PIC. The RNA Pol II enzyme then elongates through the 
the gene, generating an RNA copy. Upon reaching the 3' end of the template, the 
RNA Pol II disengages from the DNA, and the released RNA is polyadenylated. 
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Polyadenylation is required for the stability of the mRNA (messanger RNA) and 
for its export to the cytosol for translation into a protein. In addition to 
polyadenylation, the 5' end of the mRNA is chemically modified (capped) which 
is important for its ability to be translated. Introns are spliced out of the RNA by 
the splicesome complex to yield a mature mRNA. The mRNA is exported out of 
the nucleus to enable translation into a protein (Alberts et al. 2002). 
1.1.2 Post translational modification (PTM) 
At least two remarkable processes have enabled eukaryotes to expand the 
functions of their genes. First, each gene can encode multiple transcripts through 
the use of alternative splicing, secondly via chemical modifications of proteins 
leading to changes in their physical characteristics. These modifications are 
termed post-translational modifications. PTMs include addition of functional 
groups such as phosphate, addition of polypeptides (for example ubiquitin), 
chemical modifications of amino acids (isomerisation of proline) or structural 
changes involving disulphide bridges. Of the twenty amino acids that make up 
proteins, 15 can be modified by PTMs (Hunter 2007). A selection of PTMs is 
given in table 1.1. 
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Modification Residue Addition enzymes 
modified Chemical Group 
Acetylation Lysine acetyltransferases (addition) 0 
Lysine ~ R RLysine de-acetylases (removal) 
Methylation Lysine Methyltransferases. Arginine may 
be mono, di or tri methylated. R CH3 
Arginine Demethylases (removal) 
Serine 0 
Phosphorylation Kinases (addition) II 
Threonine R- O- P- OH 
Phosphatases (removal) I 
Tyrosine OH 
O-Glycosylation Serine 
Acetylga lactosa mi nyltra nsferase. OH 
Threonine 
t 
0 
I 
Sulfation Tyrosine Sulfotra nsferases o=p-o 
I 
0 -
Arginine, 
">4: 
ADP-Ribosylation ADP Ribosyltransferases (addition) / -- • 
Glutamic acid, ADP Ribosyl-Arginine hydrolases 0 0 I " If 
'0 , 00: °o:'Q (removal) W 
Aspartic acid 
, ~ ~ OH ;0 
" 
... 
Isomerisation 
Proline Proline isomerases 
-f!-S XAA 
Ubiquitination, 
SUMO-ylation, E3 enzymes (specific fo r Ubiquitin, 
Lysine 
SUMO-l/2/3, NEDD, ISG-15 etc) . 
NEDDylation Removal enzymes include de-
ubiquitinases and de-SUMOylases. 
ISG-1Sylation 
Table 1.1. PTMs. A selection of PTMs are listed along with the residues 
modified, the enzymes involved, and the structure of the functional groups. The 
protein in the ubiquitination column is human ubiquitin, SUMO, NEDD8 and 
ISG-15 are not illustrated. 
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1.1.3. Crosstalk between PTMs 
An emerging theme of PTM study is the concept of "crosstalk" in which 
one modification modulates another. This effect can be on the same, neighbouring 
or a distant residue. Crosstalk can be agonistic or antagonistic and can have 
drastic effects on the activity of the protein. Crosstalk between modifications can 
be brought about by one modification altering the subcellular localization of a 
protein exposing the protein to new PTM enzymes. PTM crosstalk may also be 
due to changes in the structure of the protein exposing or preventing residues from 
being modified by a second PTM. In addition specialized domains that recognize 
residues that have been modified can "read" a specific PTM and lay down an 
additional modification on the substrate protein. Some of the better studied PTM 
binding modules are listed in table 1.2 (Seet et af. 2006). 
PTM 
Phospho-serine 
Phospho-threonine 
Phospho-tyrosine 
Methyl-lysine 
Acetyl-lysine 
Ubiquityl-Iysine 
Sumoyl-Iysine 
Glycosyl-asparagine 
Domain 
14-3-3, MH2, WW, BRCT, Polo 
Box,FF 
FHA, WD40 
PTB,SH2 
Chromodomain, PHD, Tudor 
Bromodomain 
UIM, UBA 
SIM 
FBA 
Table 1.2. PTM binding modules. A selection of PTM binding modules is 
shown for each modified amino acid. Abbreviations MH2 (MAD Homology 2), 
BRCT (BRCA domain), FHA (Forkhead Associated), PTB (Phospho-Tyrosine 
Binding), SH2 (Src Homology), PHD (Plant Homeodomain), UIM (Ubiquitin 
Interacting Motif), UBA (Ubiquitin Associated), SIM (SUMO Interaction Motif), 
FBA (Fbox Associated). 
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1.1.4. Negative crosstalk 
Some amino acids can be modified by more than one PTM. Different 
PTMs cannot co-occupy the same amino acid, and as such there is direct 
competition for different PTMs on single amino acids. Ser (serine) and Thr 
(threonine) residues can be both phosphorylated and O-glycosylated, and as such 
these two modifications compete. Thr58 of c-Myc can be both phosphorylated and 
O-glycosylated, although it is believed that should Thr58 be unavailable for 0-
Glycosylation a neighbouring residue will be O-glycosylated instead (Chou et al. 
1995). Sulfation and phosphorylation compete for the hydroxyl group of Tyr, 
while nitration of the aromatic ring of Tyr prevents phosphorylation (Reinehr et 
al. 2004). The most striking example of direct competition is for lysine, in which 
acetylation, methylation, hydroxylation, ubiquitination, SUMOylation and 
NEDDylation can occur (Yang and Seto 2008). Consequently there are numerous 
examples in which one modification excludes another. Acetylation prevents 
ubiquitination in p53, SUMOylation in Sp3 and methylation in histone 3 (Hunter 
2007). 
Neighbouring amino acids can influence the addition of PTMs. The 0-
GlcNAc modification on Serl49 of p53 reduces phosphorylation of Thr155, which 
then prevents ubiquitination and proteasome dependent degradation (Yang et al. 
2006). Methylation of arginine within a PKB (Protein Kinase B) consensus site of 
FOXOI (Forkhead Box 01) prevents phosphorylation, which consequently 
prevents cytoplasmic re-Iocalisation and degradation (Yamagata et al. 2008). Lys9 
of histone 3 can be acetylated, which enables interaction with the HP 1 
17 
Post Translational Regulation of the Tumour Suppressor IRF-l 
(Heterochromatin Protein 1) protein. Should the adjacent SerIO be phosphorylated 
however, this interaction is blocked (Berger 2002). 
1.1.5. Positive crosstalk 
Addition of a single PTM may promote the addition of other distinct 
PTMs. Phosphorylation of one Ser or Thr residue can promote the 
phosphorylation of another Ser/Thr by GSK3 (Glycogen Synthase Kinase 3) 
enzymes, as this group of kinases often requires phosphorylated "primed" 
residues to interact with their substrates (see section 1.6.2). Some ubiquitin ligases 
contain domains which recognise SUMO (Small Ubiquitin like Modifier) chains. 
Consequently these ligases promote ubiquitination and degradation of 
SUMOylated proteins (Perry et al. 2008). Phosphorylation can promote 
SUMOylation, this so called phospho-sumoyl switch is found in a number of 
proteins, including HSFI (Heat Shock Factor 1), and PPARy (Peroxisome 
Proliferator Activated Receptor y). The phosphorylated residue is found within the 
consensus site (lJI-K-x-E-xx-S) needed for substrate recognition by the 
SUMOylation machinery. It has been suggested that since many SUMOylated 
substrates contain a negatively charged amino acids at a +5 position relative to the 
recognition site, the phosphorylated residues mimic this effect (Mohideen et al. 
2009). 
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1.1.6. Ubiquitination 
Ubiquitin (Ubq) is an extremely well conserved 76 amino acid protein 
that, as the name suggests is ubiquitously expressed. Ubiquitin serves as a protein 
tag for destruction by the 26S proteasome. Ubiquitination has since been shown to 
be involved in numerous other processes that are quite distinct from protein 
turnover, including the DNA damage response, mediation of protein-protein 
interactions and altering subcellular localisation (Schwartz and Ciechanover 
2009). Addition of ubiquitin proteins to their substrates requires an enzymatic 
cascade of three enzymes. The EI enzyme (ubiquitin activating enzyme) activates 
the C tenninal glycine residue of ubiquitin by conversion into a high energy 
thioester. There are two known E 1 enzymes in the human genome, with the 
second enzyme only recently being characterised (Pelzer et ale 2007). E2 enzymes 
are involved in ubiquitin transfer, and E3 enzymes recognise substrates for 
ubiquitination by E2 enzymes. There are approximately thirty seven E2 enzymes 
and up to six hundred E3 enzymes encoded in the human genome. There are two 
main classes of E2 enzymes, HECT (Homologous to E6-AP C tenninus) and 
RING (Really Interesting New Gene) fingers (Deshaies and Joazeiro 2009). 
Ubiquitin is transferred to the E-NH2 group of an internal lysine residue in the 
substrate protein. E3 enzymes can recognise their substrates through specific 
amino acid motifs called degrons. A degron can be defined as the minimal 
element sufficient for recognition and degradation by the proteasome pathway. 
Some degrons can be modified by phosphorylation, which greatly enhances the 
interaction with the E3 protein. These degrons are called phospho-degrons (see 
section 1.1.8). 
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Ubiquitin itself can become a substrate for ubiquitination on any of the seven 
lysines in its structure (see figure 1.1). This leads to the formation of ubiquitin 
polymers. Various combinations of mono, multi-mono and poly-ubiquitination 
can occur on a single substrate. To be recognised as a substrate for degradation by 
the proteasome, the substrate must be poly-ubiquitinated with at least four 
ubiquitin proteins. Some forms of ubiquitination do not signal destruction for their 
substrates, for example K63 linked ubiquitination (Komander 2009). Further 
details of the different ubiquitin chain types are given in figure 1.1. 
Approximately 95 de-ubiquitinating enzymes (DUBs) are present within the 
human genome. These DUBs are involved in removing and editing ubiquitin 
chains from substrate molecules (Sowa et al. 2009). DUB enzymes recognise 
ubiquitinated substrates via specialised protein-protein interaction motifs that 
recognise ubiquitin. There are at least twenty ubiquitin interacting motifs in the 
proteome. These motifs are also found in other proteins and it is now apparent that 
ubiquitin can serve as a mediator of protein-protein interactions (Hurley et al. 
2006). 
20 
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Chain type Comments 
Met 1 
lys 6 
lys 11 
lys 27 
lys 29 
Lys 33 
lys 48 
lys 63 
Linear ubiquitin chains can be added to substrates of the NFkB signalling 
pathway. Linear ubiquitin chains are not thought to promote degradation of 
su bstrates. 
Very little is known about Lys6 linked ubiquitin chains, possibly involved in DNA 
damage repair signalling. 
Promotes proteasomal degradation of substrates. Involved in enodoplsamic 
reticulum associated degradation (ERAD) . APC (Anaphase Promoting Complex) 
attaches Lys 11 Ubq chains to substrates suggesting a role in cell cycle 
regulation . 
Function not yet established, possibly involved in proteasome mediated 
degradation . 
Lysosomal degradation of substrates . May be involved in N end rule degradation 
of substrates. 
Function not yet established, possibly involved in kinase inactivation . 
Predominantly involved in proteasome mediated degradation. The most stud ied 
chain type. 
Non degradative, involved in endocytosis, DNA damage signalling, chromatin 
regulation (H2A) and TNFa signalling. 
Figure 1.1 Schematic of ubiguitin protein. A) Schematic of the seven lysine 
re idues to which ubiquitin can conjugate to it elf in addition to the po ition of 
Met 1 (methionine I) which i u ed for g nerating linear chain of ubiquitin . The 
relative proportion of each chain type in S cerevisiae i highlighted in red . B) 
De cription of the known role for each ubiquitin chain type. From Komander 
2009. 
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1.1. 7. The proteasome 
The 26S proteasome is a large, evolutionary conserved, barrel shaped 
multi-subunit protein complex which recognises proteins that have been 
polyubiquitinated. The proteasome functions to break down proteins into short 
peptides, which are further processed into amino acids and re-used for new 
proteins. The proteasome is required for regulating the quantity and quality of 
proteins - destroying misfolded protein that may harm the cell. Structurally, the 
proteasome is composed of a central core (the 20S subunit) and two regulatory 
caps (19S) either side of the 20S subunit. The central core is hollow, allowing 
substrates to enter, with the 19S "lids" opening to allow entry (see figure 1.2). 
The substrate is partially unfolded and translocated through the 20S subunit. 
Three different proteolytic activities, a trypsin like, chymotrypsin like and 
peptidyl-glutamyllike proteases are responsible for degrading substrates (Murata 
et at. 2009). Several inhibitors of the proteasome have been developed, with 
MG 132 and lactacystin being commonly used as tools to understand proteasome 
dependent regulation of proteins. Proteasome inhibitors are also being 
investigated for their therapeutic potential as anti cancer agents, with Bortezomib 
being licensed for use against multiple myeloma and' mantle cell lymphoma 
(Schwartz and Ciechanover 2009). The proteasome can also be found within the 
nucleus, as several components contain nuclear localisation signals (von Mikecz 
2006). Components of the 19S subunit have been shown to be recruited to 
transcriptionally active genes by TFs suggesting the proteasome is intimately 
involved in transcription (see section 1.1.10) (Reid et al. 2003). 
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It i not yet fully understood how the proteasome is able to recog111se poly-
ubiquitinated proteins. At least one component of the proteasome (S5a) can make 
direct contact with poly-Ubq chains via its UIM domain. Additional proteins 
(Rad23 and Dsk2) also interact with poly-Ubq chains through their UBA domains, 
however neither of the e proteins are direct components of the proteasome. It is 
likely that a valiety of accessory and chaperone proteins help to deliver 
polyubiquitinated proteins to the proteasome. It has also been suggested that 
ubiquitin E2 and E3 enzymes may associate with the proteasome, allowing 
efficient transfer of polyubiquitinated substrates (Hatimann-Petersen et al. 2003). 
a 
195 regulatory 
particle 
16S proteasome lOS proteasome { 
19S regulatory 
partic le 
RPN 3, 5-91Ud 
n, 12. 15 J 
RPN1, 2. 13 
Base 
lURing 
} ~ - R i n g g
Figure 1.2. Schematic diagram of the human proteasome. The individual 
subunits that make up the protea ome are highlighted. From Murata et al. 2009. 
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1.1.8. The SCF E3 ubiguitin ligases 
The SCF (Skp l-Cull-Fbox) complex is a multimeric ubiquitin E3 li gase 
complex made up from four proteins. A scaffo ld protein called Cullin I interacts 
with RBX I (Ring Box-I) through its C telminus, while it interacts with SKP 1 (S-
phase kinase associated protein -I) through its terminus. RBX I is required for 
interaction with the E2 enzyme, and was di covered after the initial naming of the 
SCF complex. SKP I in tum recruits the specificity module, known as Fbox 
proteins to the SCF complex (Jin et at. 2004). 
F"-b= potein 
Figure 1.3. Schematic of the SCF complex. The schematic shows the Rbx 1 
protein interacting with the E2 enzyme (in the case of SCF complexes UbcHS), 
and the Cullin I scaffold, which interacts with the specificity module SKP l-Fbox. 
The Fbox protein makes protein-protein interactions with the substrate, bringing it 
into contact with the E2 enzyme and allowing transfer of ubi quit in. From Welcker 
and Clurman 2007. 
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The Fbox proteins interact with SKP1 through their Fbox domains. The Fbox 
domain is a 40 amino acid sequence first identified in Cyclin F (Bai et at. 1996). 
There are currently 68 known Fbox proteins in mammals, with other Fbox 
proteins being found in yeast and plants (Jin et al. 2004). The Fbox proteins 
contain other domains, which make contact with the SCF substrates. The presence 
of these domains is used to subdivide the Fbox family into three classes, Fbxw 
contain WD40 motifs, Fbxl contain LRR motifs (Leucine Rich Repeats) while the 
third group Fbxo contain various other motifs and domains (Jin et al. 2004). Most 
Fbox proteins recognise phosphorylated substrates, although some recognise 
carbohydrate side chains (Glenn et al. 2008). Consensus motifs have been mapped 
for Fbxw7 and PTRCP1 interaction with substrates. These motifs are called 
phospho-degrons, as they signal phosphorylation dependent degradation. 
PTRCPI/ Fbxwl Fbxw7 
Substrate Phospho degron Substrate Phospho degron 
IKBP D ~ G L D ~ ~ c-Myc L P I P P L ~ P S S
plOS D ~ G V E T ~ ~ c-Jun G E I P P L ~ P I I
eatenin D ~ G I H ~ ~ SREBPI T L I P P P ~ D A A
POC04 D ~ G R G D ~ ~ Cyelin E L L I P P ~ G K K
I P I P D K ~ D D D
Claspin D ~ G Q G ~ ~ PGCla P L I P E ~ P N N
GLIPPTIP 
ATF4 D ~ G K G ~ ~ SRC-3 V H ~ P M A ~ ~
SNAil D ~ G K G ~ ~ SV40 T antigen F L I P S P ~ S P P
Perl T ~ G C S ~ ~
Consensus OSGXX(x)S lLIPxxoLIlS 
Table 1.3 Phospho-degrons. The phospho-degrons of PTRCPI (p-Transducin 
repeats containing protein 1 IFbxwl) and Fbxw7 (Fbox and WD40 containing 7). 
Data is adapted from Frescas & Pagano 2007 and Hunter 2007. Abbreviations 
IKBP (Inhibitor of NFKB-P), PDCD4 (Programmed Cell Death 4), ATF4 
(Activating Transcription Factor 4), Per (Period), SREBP (Sterol Regulatory 
Element Binding Protein), PGCla (PPARy Coactivator a), SRC-3 (Steroid 
Receptor Coactivator 3). 
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1.1.9. Fbxw7 
Fbxw7 (FBox WD40 containing 7) is one of the most studied Fbox 
proteins (after Skp2 and PTRCP I) and is proving to be a key node in several 
oncogenic signalling pathways. Fbxw7 was first identified in a yeast screen for 
proteins involved in cell cycle control. The yeast homolog of Fbxw7 was named 
Cdc4 (Cell Division 4) (Hartwell I 973).Various orthologues of Fbxw7 protein are 
found throughout the animal kingdom, in nematodes it is known as SEL-IO and 
in fruit flies as archipelago (Welcker and Clurman 2008). The Fbxw7 gene 
encodes three protein coding transcripts which are produced from .altemative 
splicing. Each isoform has its own first exon, while the other ten exons are shared 
between all three. The a. isoform is the largest and most highly expressed of the 
three isoforms. The P and y isoforms exhibit some tissue specific expression 
patterns (Sprock et al. 2002). Each of the three isoforms localises to a different 
subcellular location, with the a. isoform being nuclear, p cytoplasmic and y 
nucleolar, see figure l.4A (Welcker and Clurman 2007). 
Fbxw7 contains three major domains, an N terminal Fbox, eight C 
terminal WD40 repeats which are required for the interaction with phosphorylated 
substrates and a D (dimerisation) domain (Orlicky et al. 2003). The D domain is 
required for Fbxw7 dimers to form (see figure l.4B). Although not yet well 
understood, it is thought that dimerised Fbxw7 proteins are able to make contacts 
with more than one degron in a substrate. This allows Fbxw7 to promote 
degradation of its target substrates even if they do not carry the· required 
phosphorylation mark (Tang et al. 2007). 
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Figure 1.4 Structure of Fbxw7 A) Genomic organisation of the human Fbxw7 
gene, showing the three alternative transcripts caused by differential use of the 
first exon. Cartoon of the domain organisation of Fbxw7 and localisation of the 
threeisofonlls of Fbxw7 (We\Cker & Clunnan 2007). B) Cartoon structure of 
Fbxw7, the blue protein is SKPI , while the red protein is Fbxw7a. The eight 
bladed beta propeller WD40 domain of Fbxw7 is shown bound to the pho pho-
degron ofCyC\in E (cyan). From Welcker and Clunnan 2007. 
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One of the best studied Fbxw7 substrates is c-Myc. Phosphorylation of c-Myc at 
Ser62 by ERK (Extracellular Regulated Kinase) kinases produces a priming site, 
which allows for phosphorylation at Thr58 by GSK3J3. This phosphorylation 
produces a phospho-degron which is recognised by the WD40 repeats of Fbxw7 
(Welcker et al. 2004). This recognition in tum promotes ubiquitination and 
reduction in c-Myc transcriptional activity. Another oncogenic transcription 
factor; c-Jun is also targeted by Fbxw7 following GSK3J3 dependent 
phosphorylation (Wei et al. 2005). As such two of the most potent oncogenes are 
down-regulated by the activity of GSK3J3 and Fbxw7 working in unison. Studies 
in FbxwT1- mice have shed further light on the roles of Fbxw7 in development. 
Mice that are deficient for Fbxw7 die in utero at day 11. This is due to defects in 
haematopoietic and cardiovascular function (Tsunematsu et al. 2004 and 
Tetzlaff et al. 2004). When conditional knockouts of Fbxw7 were created, it was 
found that the mice developed severe pancytopenia due to loss of haematopoietic 
stem cells (HSC). As such Fbxw7 plays a role in the maintenance of the HSC 
population. It is not yet known which deregulated Fbxw7 substrates are 
responsible for this defect (Matsuoka et al. 2008). 
Fbxw7 is located in the 4q32 chromosomal region which is commonly 
deleted in cancers. It has been reported that in some cancers 30% of samples 
harbour mutations in the Fbxw7 gene (Maser et al. 2007). The Fbxw7 gene is 
prone to truncating mutations, but more commonly point mutations within the 
WD40 motifs are found. Three arginine residues that are essential for substrate 
recognition are highly prone to mutation (Calhoun et al. 2003). In addition to 
mutations in the Fbxw7 gene, mutations in substrates can prevent Fbxw7 binding. 
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For example the T58A mutation of c-Myc found in Burkitts Lymphoma samples 
prevents Fbxw7 dependent ubiquitination (Bahram et al. 2000). 
1.1.10 UPS and transcription. 
Although long thought to be entirely separate biological processes, 
growing evidence suggests that the ubiquitin-proteasome system (UPS) is 
intimately involved in transcription. Quantitative, temporal and spatial regulation 
of TFs is essential for fine tuning of transcriptional responses and all of these 
processes can be controlled by the UPS. The first ubiquitinated protein described 
was the histone H2A. Other histones including H2B, HI and H3 have also been 
shown to be ubiquitinated (Weake and Workman 2008). It is not fully understood 
how ubiquitination of histones affects transcription, although it has been 
suggested to act in both transcriptional activation and repression. It is possibly, 
that addition of bulky ubiquitin groups has an allosteric effect on chromatin 
structure, or that ubiquitin acts as a protein-protein interface with HDAC6, which 
posses an ubiquitin interacting domain (Hook et al. 2002). Mono-ubiquitination of 
histone 2B (ub-H2B) has been extensively studied in the context of transcription. 
Addition of ubiquitin to H2B occurs via the E3 ligases RNF20/40 in mammals. 
Ub-H2B is found to be enriched on chromatin of actively transcribed genes in 
both the 5' region and throughout the coding sequence, indeed there is evidence 
that ub-H2B plays a role in transcriptional elongation. Two histone marks 
associated with activate transcription (H3K4me and H3K79me) are also increased 
by ub-H2B suggesting complex PTM crosstalk is occurring. Conversely; in 
addition to acting as a mark for transcriptional activation, ub-H2B may also playa 
role in transcriptional silencing (Shema et al. 2008). 
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The UPS system also serves to keep TFs away from the nucleus. In the 
case of NFKB proteins, interaction with IKB (Inhibitor of NFKB) prevents 
translocation to the nucleus. Destruction of IKB liberates NFKB and allows its 
entry to the nucleus and the DNA within (Palombella et al. 1994). The UPS can 
also affect the abundance of a TF by targeting it for destruction. In the case of 
several TFs including p53, HIFla (Hypoxia Inducible Protein la) and p-Catenin, 
constitutive turnover occurs in the absence of signal. The Wnt signalling TF P-
Catenin is targeted for destruction through GSK3p dependent phosphorylation. 
Wnt signals lead to the inhibition ofGSK3p which prevents p-Catenin destruction 
and allows it to bring about transcription of Wnt target genes (Yost et al. 1996). 
This enables the cell to keep a low amount of TF available, but if needed can 
rapidly increase the amount of TF and allow a transcriptional response. The UPS 
can re-programme transcriptional responses by regulating the availability of 
transcriptional coactivators. The ubiquitin ligase RLIM (RING finger LIM 
domain) recognises DNA bound TF LIM and its coactivator CLIM (Coactivator 
LIM). RLIM destroys CLIM, which allows LIM to interact with a different set of 
coactivators (Ostendorff et af. 2002). 
Intriguingly transcriptional activation and destruction appear to be 
entwined. There is a significant overlap between T ADs (the minimal region of a 
protein required for transcriptional activation) and degrons in unstable 
transcription factors (see figure 1.5), suggesting that the transcriptional activity of 
a TF is linked to its ability to be ubiquitinated and destroyed (Salghetti et al. 
2000). It is possible that the UPS can mark active TFs for destruction during the 
process of transcriptional activation. In yeast the TF GCN4 (General Control 
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ondepre s ible 4) is pho phorylated by SrblO, leading to UPS dependent 
destruction . The Srb I 0 kinase is a component of the Pol II holoenzyme uggesting 
that Pol II can eliminate the coactivators that recruited it, and prevent 
inappropriate transcriptional re-initiation. TFs regulated in this fa hion have been 
dubbed Blackwidow (Tansey 200 1) or Kamikaze factors (Thomas and Tyers 
2000). 
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Figure 1.5. Overlap between the T ADs and degrons of several unstable 
transcription factors. Here degrons are de ignated the regions which regulate 
ubiquitination rather than the regions containing ubiquitinated Iy ines. The blue 
box highlights the overlap between the degrons and the TADs. From Muratani & 
Tan ey 2003. 
The role of the UPS in regulating TF activity may differ from protein to prot in. 
Not all TFs respond in the same fashion to the UPS system. While orne TF are 
simply degraded by the UPS, which enables a dosage response, others require it 
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for activity. The UPS system is able to destroy some TFs that are bound to DNA. 
This could be a possible mechanism for PIC quality control. If a TF is able to bind 
a promoter, but does not recruit other proteins which shield it from the UPS, it is 
destroyed preventing aberrant transcription. This also allows for the one shot 
Blackwidow / Kamikaze response in which a TF can only initiate one round of 
transcription before being destroyed and new factors being needed for further 
rounds (Lipford and Deshaies 2003). TFs may also be activated by the UPS 
system, for example the nuclear receptor coactivator SRC-3 (Steroid Receptor Co 
activator 3) is phosphorylated by GSK3p, which in tum causes recruitment of the 
E3 SCFFbxw7• This promotes multi-mono ubiquitination of SRC-3. The multi-
monoubiquitination enables interactions with nuclear receptors and as such 
increases transcriptional activity. However, eventually the mono-ubiquitin is 
extended into poly-ubiquitin chains, which in tum promotes destruction. This 
highlights the diversity of events ubiquitination can bring about, and reminds us 
that this multi-step process can promote protein-protein interactions in a short 
window of time before signalling proteins destruction (Wu et al. 2007). 
One model of the role of the UPS in transcription is that DNA bound TFs recruit 
E3 ligases, which promotes ubiquitination of not just the TF, but of other co 
activators, Pol II and histones. This in tum recruits the proteasome, which 
destroys the proteins involved in assembly of the PIC (and thus prevents it 
spontaneously reforming), but also aids Pol II in elongation and promotes 
modification ofthe chromatin during transcription (Muratani and Tansey 2003). 
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1.2.1. The Interferon Regulatory Factor (lRF) family. 
Currently the IRF family consists of nine members with the first members; 
IRF-I and IRF-2 being identified in the 1980s (Miyamoto et al. 1988). All IRF 
family members contain a well conserved DNA binding domain, sometimes 
referred to as an IRF domain (see figure 1.6). This domain contains a pentad of 
tryptophan residues that are distinctive for the IRF family of transcription factors. 
Surprisingly, although IRF family members contain similar DBDs they act on 
disparate genes. This is likely due to the lack of conservation between IRF's C 
terminal regions. Consequently each IRF occupies its own transcriptional niche 
(Takaoka et al. 2008). The roles of IRF -1 are discussed in detail in sections 1.2.2-
1.3. IRF-l's closest relative in the IRF family is IRF-2 (see figure 1.6). IRF-2 was 
originally described as an antagonistic repressor of IRF-l activity (Harada et al. 
1989) and an oncoprotein (Harada et al. 1993). IRF-2 also acts as a transcriptional 
activator (Vaughan et al. 1995). IRF-3, like IRF-l and IRF-2 is constitutively 
expressed; however it is found predominantly in the cytoplasm (Au et al. 1995). 
Viral signalling leads to phosphorylation of IRF-3 promoting nuclear 
translocation and transcriptional activity. IRF-3 can homodimerise and 
heterodimerise with IRF -7. Both of these proteins are essential for type I 
interferon signalling (Au and Pitha 2001). 
IRF-4 is predominantly expressed haematopoetically, and possesses little 
DNA binding affinity of its own. Partner factors, including other transcription 
factors such as Pu.l or other IRFs such as IRF-8 are essential for IRF-4 DNA 
binding. IRF -4 is important in B cell development, and is found to be translocated 
in multiple myeloma samples (Shaffer et al. 2009). IRF-4 can act as a 
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transcriptional repressor, and is able to prevent IRF-l transactivation of the 
TRAIL promoter (Yoshida et al. 2005). IRF -5 is up-regulated in response to 
interferons, viral infection and DNA damaging agents and is critical in innate 
immune signalling and may have tumour suppressor activities (Takaoka et al. 
2005). IRF-5 plays a role in the pathology of Systemic Lupus Erthyromatosis 
(Graham et al. 2006). 
IRF-6 is unique among the IRF family as it is the only member whose knockout 
mice are not viable. IRF-6-1- mice have severe defects in craniofacial, skin and 
limb development (Kondo et al. 2002). Mutations in the IRF-6 gene are associated 
with van der Woude syndrome, which is characterised by cleft palate (Ingraham et 
al. 2006). IRF-7 is required for type I IFN signalling in partnership with IRF-3. 
Levels of IRF-7 are lower than IRF-3 in most cell types (Sato et al. 2000). IRF-8 
- also known as ICSBP (Interferon Consensus Sequence Binding Protein) is 
similar to IRF-4 in its DNA binding and tissue distribution. IRF-8 may act as a 
tumour suppressor, as knockout IRF-8 mice develop a CML (Chronic Myeloid 
Leukaemia) like syndrome (Holtschke et al. 1996). IRF-9 is a component of the 
trimeric ISGF3 (Interferon Stimulated Gene Factor 3) complex, which also 
contains STAT -1 (Signal Transducer and Activator of Transcription) and STAT-
2. As such IRF-9 is best known for its role in directing the transcription of ISGs 
(Interferon Stimulated Genes) (Majumder et al. 1998). 
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Figure 1.6. Alignment of human IRF family members, The amino acid 
sequences of human IRF-l through IRF-9 where aligned against each other u ing 
the T -Coffee multiple alignment programme (http://www.ebi.ac. ukJTools/t-
coffeelindex.html). The score of the amino acid alignment is represented as a heat 
map were red is the trongest alignment and blue the weakest. Con ervation 
among the DNA binding domain is strong among IRF family member while the 
C terminal regions are poorly con erved. The IADI region (JRF As ociation 
Domain I) is only cons rved between IRF-3 through IRF-9, with IRF-I and IRF-2 
pos e ing a variant of this domain. 
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1.2.2. IRF-l discovery 
IRF-J (lnterferon Regulatory f actor 1) was originally identified in mice as a 
factor that transacti vate the promoters of I nterferon a and P (M i yamoto el al. 
1988). The human IRF-I gene was cloned shortly after from HeLa cells treated 
with IFNa (Interferon a). This factor was briefly known as ISGF2 (Interferon 
Stimulated Gene Factor 2) but is now referred to as IRF-I (Pine and Darnell 
1989). IRF-I has also been identified as Myd32 (Myeloid Differentiation gene 32) 
due to its role in development of myeloid cells (Abdollahi el al. 1991). 
1.2.3. The IRF-l gene 
The human IRF-I gene is located on chromosome five at position q.31.1 -
the long arm of chromosome five (Harada el al. 1993). In humans, the TRF -I gene 
consists of ten exons and nine introns and spans 9. 16kb. Exons two, three and four 
are the most conserved among different species of IRF-I (Shi et at. 2008 and Jia 
and Guo 2008). 
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Figure 1.7 Exon distribution of human IRF-t. Protein coding exons are hown 
as filled bars, while exons that encode 5' and 3' UTR are shown unfilled. Source: 
http://www .ensem bl.org/Homo _ sapiens/TranscriptlS ummary? db=core;g= ENSGO 
0000125347;r=5: 131817302-13l826469;t= ENST00000245414 
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1.2.4.59 Syndrome and loss of heterozygosisty (LOU) 
The localisation of IRF-l on chromosome five led to the hypothesis that it 
may be involved in cancer, as this region is deleted in certain solid tumours, 
myelodysplastic syndrome (MDS) and is the sole karyotypic feature of 5q 
syndrome. 5q syndrome (also known as monosomy five) is characterised by 
refractory anaemia and megakaryocytic abnormalities. IRF-l is one of the most 
commonly lost genes in this chromosomal deletion (Boultwood et al. 1993 and 
Willman et al. 1993). Loss of the IRF-l gene as a feature of the 5q deletion has 
been reported in bladder cancer, colorectal carcinomas, esophageal cancer and 
pulmonary large cell neuroendocrine carcinomas (Ogasawara et at. 1996, Tamura 
et al. 1996a, Peralta et al. 1998, Kram et al. 2001 and Shin et al. 2005). Some 
studies on the 5q deletion have identified patients that retain the IRF-l locus, 
suggesting that IRF-l is not entirely responsible for the clinical manifestations of 
this deletion (Boultwood et al. 1993 and Kroef et al. 1994). 
LOH (Loss of heterozygosity) of the IRF-l locus has been observed in 
AML, MOS, gastric and esophageal tumours (Green et at. 1999, Willman et al. 
1993, Ogasawara et al. 1996 and Tamura 1996a). Most commonly the loss of the 
first allele is caused by 5q interstitial deletion, although there may be other 
mechanisms by which one IRF -I allele is lost. It is not yet clear if germ line 
mutations in the IRF-l locus are involved in IRF-l LOH. The remaining IRF-l 
allele undergoes accelerated exon skipping leading to a complete loss of proper 
IRF-l expression and LOH. In one case of gastric cancer the remaining IRF-l 
allele contained a point mutation which severely reduced its transcriptional 
activity (Ogasawara et al. 1996). 
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1.2.5. IRF-I Splicing. 
Several splicing variants of IRF-l have been identified. Most splicing 
variants occur in exons two and three which code for the DNA binding domain 
(OBD) (Harada et al. 1994). As expected these mutants have no transcriptional 
activity. These mutations have been found in patients with MOS, APL, AML and 
CML (Maratheftis et at. 2006, Green et al. 1999 and Tzoanopoulos et al. 2002). 
Five splice variants have been reported in cervical cancers. These splice variants 
involve exons seven, eight and nine (Lee et al. 2006). 
1.2.6. IRF -I mutations and polymorphisms 
The protein coding region of human IRF-l gene exhibits relatively few 
point mutations, with mechanisms of inactivation primarily occurring from 
deletions and ex on skipping. Only two missense mutations in the IRF-l coding 
sequence have been reported to date. M8L ( M e t 8 ~ L e u ) ) was identified in a gastric 
adenocarcinoma sample, and is reported to be less effective at inducing cell cycle 
arrest compared to wild type IRF -1 (wild type IRF -I) (Nozawa et al. 1998). A 
mutation producing IRF-l WIIR ( T r p l l ~ A r g ) ) was found in non small cell lung 
carcinoma cell lines. This mutation abolished DNA binding, as structural analysis 
of the IRF-l OBD had previously shown that the Trpll residue is important in 
making contact with DNA (Eason et al. 1999). 
Some IRF-l polymorphisms are associated with human diseases. Most of 
the polymorphisms are located in the untranslated or intronic regions of the IRF-I 
gene. Among eleven promoter polymorphisms identified by Ji and coworkers 
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three modified a Sp 1 binding site, suggesting a mechanism by which these 
polymorphism may affect IRF-I induction (Ji et al. 2004). The A4396G 
polymorphism may alter the binding of certain transcription factors to the IRF-l 
promoter. This polymorphism has been found to be associated with breast cancer 
and is more frequent in African Americans than in European populations (Bouker 
et al. 2007). IRF -I promoter polymorphisms have also been correlated to clinical 
outcome in Hepatitis C and Bechets disease (Saito et at. 2002 and Lee et al. 
2007). 
1.3.1. DNA binding domain (DBD) 
The IRF -1 DBD is located within the first 115 amino acids and constitutes 
the most conserved region of IRF -1 between different species (see figure 1.9). The 
DNA binding domain of IRF-l is the only part of IRF-l which has been 
crystallised and structurally studied (Escalante et al. 1998). Residues 1-113 of 
mouse IRF-l were co-crystallised with 13bp of DNA corresponding to the IRF-E 
(lRF Element) found in the IFNJ3 promoter. The DBD consists of three a-helices 
flanked by mixed four stranded J3 sheets. In addition, three characteristic large 
loops emanate from the J3-sheets and a-helices. The IRF-I DBD has a unique 
helix-turn-helix structure (see figures 1.8 and 1.9). 
IRF-I recognises DNA via the major groove. Residues projecting from 
the last two turns of the recognition helix are responsible for interacting with the 
IRF-E. The DBD of IRF-l also forms extensive contacts with residues outside of 
the core GAAA sequence. Residues within all of the a helices and loops one and 
three make contact with phosphate groups up to 6 bp away from GAAA. 
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IRF-I is characterised by its tryptophan (Trp) pentad or tryptophan cluster, 
which is highly conserved in all members of the IRF family. Only three of the five 
residues interact with the DNA (Trpl I, Trp38 and Trp58). These residues straddle 
the major groove and make hydrogen and van der-Waals interactions with the 
sugar phosphate backbone. The Trp residues are held in place by the hydrophobic 
core of the DBD including two absolutely conserved residues (Phe55 and Phe81) 
found in a-helix two and a-helix three (Escalante et at. 1998). 
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Figure 1.8 Schematic of residues involved in IRF-l : DNA interactions. The 
core GAAA motif is shaded. The three loops are designated Ll-L3 and the a 
helices as al-a3. Hydrogen bonds to bases are drawn as dotted lines, while 
hydrogen bonds to the DNA backbone are shown as dashes. Diagram from 
Escalante et at. 1998. 
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Figure 1.9 Alignment of the DBD of murine IRF-I and IRF-2. Residues that 
make contacts with the phosphate backbone are indicated with circled pink P. 
Criti cal residue involved in binding the GAAA consensus are highlighted in 
yellow and the conserved tryptophan residues are highli ghted in blue. From Fuji 
el at. 1999. 
Crystal structures of other members of the IR F fa mil y have helped to under tand 
the DBD of IRF- I furth er. The crystal structure of IRF-2 was obtained at higher 
resolution, so provide insight to IRF-I 0 A binding. The tructure of IRF-2 
identifi ed interaction with two adenine residues up stream of the core GAAA 
sequence; this is in agreement with the AA (NI-4) GAAA JRF-E consensus ite. 
Thi s interaction involves the completely conserved His40 residue making contact 
with the minor groove. Although thi s wa not as clearl y demon trated in the first 
tudy, it is likely that thi interaction occur in IR F- J (Fujii et at. 1999) . 
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1.3.2. DNA recognition 
Prior to the crystal structure of the IRF-I OBD being solved, an IRF 
consensus site had already been identified. IRF -1 was first shown to be able to 
bind Interferon Stimulated Response Element (lSRE) sequences in the promoters 
of the interferon stimulated gene ISG 15 (Pine and Darnell 1989). The exact 
sequence to which IRF-l binds was first found by Tanaka and co-workers. It was 
noted that since IRF-l and IRF-2 have similar N terminal regions (OBO) they 
might bind similar sites. This was confirmed, and it was found that both IRF-1 
and IRF-2 bind essentially the same sites. Using peR assisted DNA binding site 
selection method a consensus site was determined to be (G)AAA(N2_ 
3)GAAA(G/C)(T/C). This motif is located in several interferon stimulated genes and 
was named IRF-E (Interferon regulatory factor - element) (Tanaka et al. 1993). 
A selection ofIRF-l binding sites is given in table 1.4. 
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GENE 
Single site IRF-E 
IFNJ3 
ODC 
FoxP3 
IL-12RIH 
TLR9 
IL-IO 
RIG-l 
ISRE or single site IRF-E 
OAS 
XAFl 
VCAMl 
RANTES 
iNOS 
Caspase-l 
FasL 
IL27p28 
Multiple sites (lSRE/IRF-E) 
ISG54 
CIITA 
MECLl 
IL-7 
IL-6 
INDO 
ISG15 
IL-15 
SEQUENCE 
AA GAAA 
AA GAAA 
AA GAAA 
AA GAAA 
AA GAAA f 
AA I GAAA 
AA GAAA C 
GAAA GAAA 
~ ~ GAAA C GAAA 
GAAA ' GAAA 
f T GAAA A GAAA AC 
A GAAA 1 GAAA GA 
GAAA GAAA 
GAAA GAAA ' 
C GAAA GAAA 
AA GAAA C GAAA 
GAA GAAA ( GAAA GG 
AAA GAAA J GAAA Gc 
AAAGT A GAAA CT GAAA G I 
T AAAA GAAA AAA GAAA G T 
GTAAG GAAA ACT GAAA CC 
G GAAA GG GAAA CC GAAA CT 
A GAAA AGT GAAA GA GAAA GA 
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Foss and Prydz 1999 
Oshima et 01. 2004 
Sanceau et 01. 1995 
Konan and Taylor 1996 
Tanaka et 01. 1993 
Azimi et 01. 2000 
Table 1.4 IRF-I binding sites. List of IR F-E and [SRE elements known to be 
bound by IRF-I in target promoters. The IRF-E motif overlaps with ISRE motifs. 
The core GAAA motif is highlighted. Some gene contain multiple IRF- I binding 
si tes, which are not all described here. Abbreviations, ODC (Ornithine 
Decarboxylase), FoxP3 (Forkhead P3), IL-12RPl (IL-12 receptor P1), 1 LR9 
(Toll Like Receptor 9), OAS (Oligoadenylates Synthetase), XAFl (XIAP 
As ociated Factor I), RANT ES (Regulated upon Activation olmally T cell 
ex pres ed and pre umably secreted) VCAM-l (Va cular Cell Adhe ion 
Molecule-I) FasL (Fa Ligand) , CIITA (Ia II Tran activator) LMP2 (Low 
Molecular Weight Protein 2), INDO (lndoamine-2-3 dioxygena e), H4 (histone 
4), RIG-l (Retinoid Inducible Gene-I). Adapted from (Fuji i eta/. 1999). 
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1.3.3 Transactivation and repressor domains 
The transactivation domain (TAD) resides within the central C terminal region of 
the IRF -1 protein. In mouse IRF -1, the TAD is mapped to amino acids 185-260 
(Schaper et al. 1998 and Kirchhoff et at. 2000). while in humans it is located 
between amino acids 217-260 (Kim et al. 2003a). The IRF-l TAD overlaps with 
the heterodimerisation domain (aa 124-219) used for interaction between IRF-l 
and IRF -8 (Schaper et at. 1998). 
Several short stretches of IRF-l have been suggested as repressor domains. The 
region from amino acid 170-200 has a repressive effect on the IFNI3 promoter 
reporter (Lin et al. 1994). Residues between amino acid 197 and 202 (lPVEVV) 
have a repressive effect on IRF-l activity (Upreti et al. 2004). IRF-l also contains 
an LxxLL motif in its C terminus e06LDSLL310). The LxxLL motif is a short a-
helix domain involved in protein - protein interactions. This region has been 
implicated in recruitment of coactivators to nuclear receptors (Heery et al. 1997). 
This region is required for IRF-l repression of the Cdk2 (Cyclin Dependent 
Kinase 2) promoter, and mutation of LxxLL residues reduces IRF-l's growth 
suppressor activities. This LxxLL motif does not modify IRF-l protein-DNA 
interactions (Eckert et al. 2006). The chaperone protein Hsp70 (Heat Shock 
Protein 70) interacts through the IRF-l LxxLL motif and is involved in the 
proteasome dependent turnover oflRF-l (Narayan et al. 2009). 
44 
E \ I I I I ~ ~
Prott'in 
F U I l l · t i o o ~ ~
Post Translational Regulation of the Tumour Suppressor IRF-l 
2 3 I ~ ~ 5 I 6 7 
II" ' lUll 
I 50 IIHI 1511 20U 251) 
11111111111111 
I I 1 I 
I 
1I11111( 
h.rdroplwbic basic acidic 
DNA·bindill!: 
1 · J : ! ~ ~ . a . .
I PIUJ "n arbunJry C·/UIflInUl ttlfllJltm) /iiI 
1ifi.TIij"ij.a. 
IJolllodilllt'ri!iofinll Ilelerodilllerisnfioll 
11>.1·219 a.a. 
Repr s iOIl 
I-Ml a.a. 
Acfimfioll 
1l!5·25" a.u. 
8 I 9 I 
.\1"1 32'/ .. ~ ' 1 1
311U 3 2 ~ ~
I I 111111111: 
hydrophobic 
Ellhallcemel/t 
257·329 a.n. 
II/stability 
21i9.J2'/ u.a. 
Figure 1.10 Domains of IRF-l. Schematic of murine IRF- l , with the locations of 
the variously described domains and motifs. Top (exons) illustrates the location of 
the exons in relation to the protein. The Activation domain is referred to as the 
TAD domain in the text. From Upreti and Rath 2005. 
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1.3.4. Nuclear localisation signal 
IRF-I is almost exclusively retained in the nucleoplasm. The nuclear localisation 
signals of IRF-I have been mapped. Two distinct sequences (120RKERKSK and 
I 32KSKTKRK) are both required for proper localisation. Epitope mapping 
suggests this region is exposed to the surface (Schaper et al. 1998). IRF -I has 
been shown to physically interact with the nuclear import protein Karyopherin 2 
(KPNA2) in normal human epidermal keratinocytes. Knockdown of KPNA2 
causes IRF -I to be exclusively localised in the cytosol (Umegaki et al. 2007). 
Nuclear translocation of IRF-I may also be brought about by interactions with the 
TLR (Toll Like Receptor) adaptor protein MyD88 (Myeloid Differentiation Gene 
88) this "licensing" of IRF-I by MyD88 into the nucleus is involved in 
transcription of a distinct set of IRF-I targets involved in the immune response 
(Negishi et al. 2006 and Schmitz et al. 2007). 
Cytosolic localisation of IRF-l has been noted by immunohistochemistry in a 
number of tumours, including breast, melanoma, colon and endometrial tumours 
(Lowney et al. 1999, Kuroboshi et al. 2003, Zhu et al. 2006, Coppola et al. 
2009 and Giatromanolaki et al. 2004). 
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1.3.5 IRF-l protein turnover 
IRF-l is a relatively unstable protein with a half life of around 30 minutes 
(Watanabe et al. 1991 and Pion et al. 2009). IRF-l is degraded by the ubiquitin-
26S proteasome system. Evidence for this degradation comes from the 
stabilisation of IRF-l by proteasome inhibitors (MG-132 and MG-115) and the 
presence of poly-ubiquitinated IRF-I detected by immunoblot (Nakagawa and 
Y okosawa 2000 and Pion et al. 2009). Truncation studies suggested that the 
extreme C terminus of IRF-l (aa 291-329) regulates IRF-I stability (Nakagawa 
and Yokosawa 2000). 
The cysteine protease inhibitor E64d (which blocks the activity of Calpains and 
lysosomal proteases) does not lead to accumulation of IRF-l protein in HeLa 
cells, suggesting that neither of these enzyme classes are involved in IRF-l 
degradation (Nakagawa and Yokosawa 2000). IRF-I is primarily poly-
ubiquitinated by K48 linked ubiquitin which is involved in degradation. The far C 
terminus of IRF-I was found to be important for IRF-I stability. Deletion of the 
last 25 amino acids of IRF-I induced a stabilisation of the protein, although it did 
not affect the ubiquitination. Substitutions between lysine and arginine on 
residues 275 and 299 (singly and in combination) did not lead to a significant 
change in half life, or ubiquitination suggesting that these two residues are not 
involved in IRF-l turnover. Rather the conclusion is that, the far C terminus of 
IRF -I regulates protein interactions that regulate IRF -1 turnover instead of 
harbouring the lysines which are targeted by ubiquitin (Pion et al. 2009). 
The same group identified an interaction between the LxxLL motif in the far C 
terminus of IRF-I and Hsp70. This chaperone in tum interacts with Hsp90 which 
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is involved in protein stability. Inhibition of Hsp90 caused a de-stabilisation of 
IRF -I, while over-expression of Hsp90a/p increases the stability of IRF -1. It is 
suggested that IRF-I is a "client" of the Hsp70/90 chaperone complex, which is 
required to prevent degradation of IRF -1 (Narayan et al. 2009). 
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1.3.6. IRF -1 protein-protein interactions 
Approximately 35 proteins have been documented to interact with IRF-l. The 
majority of these interactions have not been extensively studied and the 
consequences of the interactions are not well understood. The largest group of 
interacting partners are those involved in transcription. IRF -I can heterodimerise 
with two other members of the IRF family (lRF-8 and IRF-5). The interaction 
with IRF-5 has not been studied in detail (Barnes et al. 2003 and Meraro et al. 
1999) although the importance of the interaction between IRF -1 and IRF -8 is well 
understood. IRF -8 requires other transcription factors in order to bind to 
promoters, and together IRF-l and IRF-8 co-regulate a significant cohort of genes 
(Dror et al. 2007). Several TFs interact with IRF-l, many of these TFs occupy 
binding sites adjacent to IRF-I binding sites (Hurgin et al. 2002, Tendler et al. 
2001 and Drew et al. 1995a). IRF-I also makes contact with several coactivators 
including KAT (lysine acetyltransferases) enzymes p300 and CBP, as well as 
components of the basal transcriptional machinery such as TFIIB and RNA Pol II 
(Merika et al. 1998 Ramsauer et al. 2007 and Kadam and Emerson 2003). The 
next largest group of interacting partners contains those that are related to IRF-l 
post translational modifications, including the kinases CK2 and PKCa, as well as 
components of the SUMOylation machinery (Lin and Hiscott 1999, Giroux et al. 
2003 and Kim et al. 2008). A number of viral proteins have been identified as 
interacting partners of IRF -1. Most of these proteins inhibit IRF -1 transcriptional 
activity through as yet unknown mechanisms. All of the published IRF-I 
interacting partners are listed in table 1.5. 
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Protein Interaction Outcome Reference 
domain 
IRF-S Unknown Unknown Barnes et al. 2003 
IRF-8 lAD Transactivation of promoters Meraro et al. 1999 and Dror et al. 
2007 
pSO, p6S, Unknown Transactivation of iNOS and other Saura et 01. 1999, Drew et 01. 
RelA promoters. 1995b and Liu and Khachigian 
2009 
C / E B P ~ ~ Unknown Transactivation of IL18BP promoter Hurgin et 01. 2002 
HIFla. Unknown Hypoxic activation of iNOS promoter Tendler et 01. 2001 
GRa Unknown Increased activity of IRF-1 in reporter assays. Jiang et 01. 2004 
pS3 Unknown Transactivation of p21 and GBP promoters Dornan et 01. 2004 and 
Guimaraes et 01. 2009 
STAT-l 200-300 Transactivation of LMP2 promoter Chatterjee-Kishore et 01. 2000a 
CBP C terminus Interacts on I F N ~ ~ enhancesome Merika et 01. 1998 
p300 271-290 Interaction enhances acetylation of pS3 Dornan et 01. 2004 
hGCNS DBD Unknown Masumi et 01. 1999 
PCAF DBD Increases IRF-1 reporter activity Masumi et 01. 1999 
SRC-2 Unknown Increases IRF-1 reporter activity Bhandare et 01. 2009 
TFIIB N terminus Transcription Wang et 01. 1996 
RNA Pol II Unknown Transcription Ramsauer et 01. 2007 
HMGl Unknown Interacts on I F N ~ ~ enhancesome Vie et 01. 1999 
NPM Unknown Prevents DNA binding Kondo et 01. 1997 
HDACl Unknown Repression of PDGF-D promoter Liu and Khachigian 2009 
CK2 Unknown Phosphorylation, increases IRF-1 activity Lin and Hiscott 1999 
PKCa. Unknown In vitro phosphorylation Giroux et 01. 2003 
ULK2 Unknown Unknown Ewing et 01. 2007 
SUMO-l 233-2SS Decreases transcriptional activity Kim et 01. 2008 
PIASy 1-190 SUMO-1ylation of IRF-1 Nakagawa and Yokosawa 2002 
Ubc9 1-190 SUMO-1ylation of IRF-1 Nakagawa and Yokosawa 2002, 
Kim et 01. 2008 
E6 Unknown Unknown Ronco et 01. 1998 
E7 167-325 Decreases IRF-1 activity in reporter assay. Park et 01. 2000 
vlRF-l C terminus Decreases IRF-1 activity Burysek et 01. 1999 
Tat C terminus Promotes transcription of the HIV genome. 5garbanti et al. 2002 
MyD88 Unknown Increases shuttling into nucleus, increasing Negishi et 01. 2006 and Schmitz et 
transcriptional activity 01.2007 
VEGFR 2 Unknown Unknown Lee et 01. 2008 
KPNA2 Unknown Nuclear translocation of IRF-1 Umegaki et 01. 2007 
GAGE Unknown Reduces IRF-1 transcriptional activity Kular et 01. 2009 
Hsp70/90 301-325 Regulates IRF-1 stability Narayan et 01. 2009 
Table 1.5 Interacting partners of IRF-l. Table summarising the known interacting partners of 
human and mouse IRF-I and the site of interaction on IRF-l. Abbreviations C / E B P ~ ~ (CCAAT 
Enhancer Binding Protein P), HIFln (Hypoxia Inducible Factor In), CBP (CREB Binding 
Protein), PCAF (P300/CBP Associated Factor), hGCN5 (General Control Amino Acid Synthesis 
5), HDAC-t (Histone De acetylase-I) TFIIB (Transcription Factor 2b), RNA Pol II (RNA 
Polymerase 2), HMGt (High Mobility Group Box }), NPM (Nuc1eophosmin), CIa (Casein 
Kinase 2), PKCn (Protein Kinase Cn), ULIa (Unc5} Like Kinase 2) PIASy (Protein Inhibitor of 
Activated STAT y), Ubc9 (Ubiquitin Conjugating Enzyme 9), MyD88 (Myeloid Differentiation 
Gene 88), VEGFR2 (Vascular Epithelial Growth Factor Receptor 2), KNPA2 (Karyopherin A2), 
GAGE (G Antigen}), Hsp70/90 (Heat Shock Protein 70/90). 
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1.3.7. Phosphorylation 
IRF-l has been referred to as a phospho-protein in several reports. During 
the original cloning of human IRF-l (then designated ISGF2) isoelectric focusing 
produced three distinct species with a pI range between 5.3 and 4.7. Treatment of 
extracts with potato acid phosphatase eliminated two of these bands, only leaving 
the most basic. This also reduced the DNA binding ability of IRF-l by EMSA 
analysis. Addition of phosphatase inhibitors rescued this loss (Pine and Darnell 
1989). The serine/threonine kinase inhibitor staurosporine has been shown to 
prevent Newcastle Disease Virus (NDV) dependent transactivation ofIRF-l on an 
I F N ~ ~ promoter reporter, suggesting that NDV activates IRF-l by phosphorylation 
(Watanabe et al. 1991). 
PKCa phosphorylates IRF-I, and can physically interacting with it (table 
1.5). This phosphorylation is required for IRF -1 to transactivate the CTIIA (MHC 
Class II Transactivator) promoter (Giroux et al. 2003). Phorbol ester treatment of 
the mouse macrophage cell lines RAW264.7 increases iNOS expression and IRF-
1 activity, while the PKC inhibitor Ro 31-8220 decreases IRF-l dependent 
transcriptional activity on the iNOS promoter suggesting that PKC may be 
required for IRF -I activity (Momose et al. 2000). 
IRF-I has been shown to interact with CK2, and these interactions result 
in phosphorylation in vitro. Mapping and in vitro kinase assays of IRF -I showed 
that phosphorylation occurs at S e ~ 1 9 , , S ~ 2 1 , , T h ~ 2 4 4 or ~ 2 5 . . Substitution of these 
residues with alanine resulted in decreased reporter activity (Lin and Hiscott 
1999). 
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IRF-l is phosphorylated on tyrosine residues during IFNy induced differentiation 
of U937 cells. Substitution mutants showed that y I09 was the sole phospho-
tyrosine residue. This modification is needed for interaction with IRF-8 and 
transactivation of promoters (Kautz et al. 2001 and la Sala et al. 2009). 
1.3.8. SUMOylation 
Yeast two hybrid screens with IRF-l pulled out PIAS3 and Ubc9 as IRF-l 
interacting proteins. This led to the finding that IRF-I is SUMOylated by PIAS3. 
SUMO-l is an ubiquitin like protein that is conjugated to lysine residues using a 
similar enzymatic cascade to ubiquitination (see section 1.1.6). Assays using a 
ISRE-Luc reporter showed that SUMOylation of IRF-1 repressed reporter 
activity, as co-transfection of wild type, but not mutant PIAS3 reduced reporter 
activity (Nakagawa and Yokosawa 2002). The SUMO-I binding sites were then 
identified to be Lys275 and Lys299; this was reported using K-R mutants with in 
vitro SUMO assays and immunoprecipitations with SUMO-l and IRF-l. The 
SUMO isopeptidsase SENP1 (Sentrin specific protease 1) de-SUMOylates IRF-l. 
This study also showed that SUMOylated IRF-1 is commonly found in ovarian 
cancer samples. Functionally SUMOylated IRF-l does not induce p21 dependent 
reporter activity, as SUMO-l conjugation mutants K275R and K299R have higher 
reporter activity than wild type. These SUMO-l conjugation mutants also showed 
enhanced apoptotic activity compared to wild type (Park et al. 2007). 
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The interaction between IRF-I and SUMO-I was mapped to amino acids 
233-255 in a separate study, this region resides within the TAD of IRF-I. 
Therefore IRF-I is able to interact with SUMO-I as well as become SUMO-
I ylated. This group was also able to demonstrate in vivo and in vitro S UMO-
1 ylation of IRF-I and confirmed that IRF-I interacts with Ubc9 through its DBD 
(Kim et al. 2008). 
1.3.9. Ubiguitination 
Following treatment with the proteasome inhibitor MG 132 multi-ubiquitin 
conjugated IRF-I can be detected (Nakagawa and Yokosawa 2000). Splice 
variants lacking exon nine or seven and eight were found to be more stable than 
wild type IRF-I. This suggests that the degradation signal or ubiquitination sites 
may reside in protein corresponding to these exons (Lee et al. 2006). The majority 
of IRF -I is ubiquitinated by K48 linked ubiquitin. This form of branching is 
predominantly involved in proteasomal degradation (Pion et al. 2009). SUMO-
Iylation of IRF-I at Lys275 and Lys299 prevents ubiquitination and increases 
protein stability. It is likely that SUMO-I and ubiquitin compete for Lys residues 
on the IRF -1 protein (Park et al. 2007). 
1.3.10. Acetylation 
IRF-I may be acetylated by the KAT (lysine acetyltransferases) proteins 
with which it interacts including PCAF, GCNS, p300, SRC-2 or CBP (Masumi et 
al. 1999, Deng and Wu 2003, Bhandare et al. 2009 and Doman et al. 2004). Co-
transfection of PCAF with IRF-I increased reporter activity on an ISRE driven 
promoter suggesting this interaction, and possibly acetylation increases activity of 
IRF-I (Masumi et al. 1999). 
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1.3.11 IRF-l transgenic mice. 
IRF-l and IRF-2 mice were first generated by Matsuyama et al. 1993. The 
IRF_ltmlMak mice strain has a neomycin cassette inserted into the IRF-l gene 
which leads to removal of amino acids 63-223. Early studies on this mouse strain 
identified a role for IRF-l in T cell development (see section 1.5.8) (Matsuyama 
et al. 1993). 
A separate strain of IRF -1-1- mice was generated by Reis and co-workers in 
1994. IRF-l tmlcew mice were generated by adding a disrupting neomycin cassette 
into the IRF-l gene between exon four and six. This region was chosen because it 
was thought to contain part of the DBD. This mutation removes amino acids 63-
182 from the protein. EMSA studies show that this disrupted species does not 
bind DNA. Many of the original phenotypic characteristics of this knockout are 
similar to the strain produced by Matsuyama et al. These similarities include a 
reduction in iNOS expression following IFNy or LPS treatment in macrophages, a 
reduction in the amount of CD8+ T cells and a decrease in MHC I expression in 
thymocytes and splenocytes (Reis et al. 1994). 
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1.4.1. IRF -1 expression 
IRF-l is ubiquitously expressed. IRF-l levels are particularly high in cells of the 
immune system (Harada et al. 1990). It is not yet known what roles basal (not 
induced by exogenous agents) IRF-l plays in cells. Levels of IRF-l protein and 
mRNA change during the cell cycle, suggesting that IRF -1 expression is cell cycle 
regulated. It was found that the first wave of expression occurred in the G 1 stage 
between fithteen minutes and two hours and was highly transient. The second 
wave of expression in the G liS phase was broader, occurring at eight hours. Both 
phases of expression required de novo synthesis of IRF-l protein and the two 
pools of IRF-l exhibited distinct half lives, with the first having a half-life of 
twenty minutes and the second, a half-life of sixty minutes (Stevens and Yu-Lee 
1992). 
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1.4.2. Regulation by STAT family members 
Several members of the STAT family of transcription factors have been found to 
occupy the GAS element in the IRF-l promoter (see figure 1.11). IFNa causes 
IRF-l induction in cells via STAT-l I STAT-2 complexes (Li et al. 1996). IFNa 
treatment also promotes the binding ofSTAT-3 and STAT-4 to the GAS element 
(Matikainen et al. 1999). IRF-l is inducible by I F N ~ ~ (Fujita et al. 1989). 
Tyrosine phosphorylated STAT -1 binds the GAS element on the IRF -1 promoter. 
Several interleukins and growth factors that signal to the ST AT family of 
transcription factors modulate IRF-l expression including IL-12 (STAT-3), IL-4 
(STAT-6) Epidermal Growth Factor (STAT-1I3) Prolactin (STAT-I) and Growth 
Hormone (STAT-1/3) (Galon et al. 1999, Goenka et al. 1999, Book McAlexander 
and Yu-Lee 2001a, Book McAlexander and Yu-Lee 2001b, Andersen et al. 
2008 and Le Stunff and Rotwein 1998). STAT -1 binding has been identified on 
the IRF-l promoter by ChIP on Chip profiling of tiling arrays within the 
ENCODE regions. Three STAT-l binding sites were found at -160, -4786 and -
5997. RNA Pol II binding closely matched STAT-I binding confirming earlier 
findings that IRF-l transcription is regulated by STAT transcription factors 
(Wormald et al. 2006). 
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Figure 1.11 The IRF-l promoter and agents that regulate its expression. 
Cartoon illustrating the major pathways that regulate IRF-l expression. Type I 
IFN receptors (IF a, IFNP etc) when bound promote phosphorylation of STAT-I 
and STAT-2 by the tyrosine kina e TYK2 (Tyrosine Kina e 2) and JAKI (Janu 
Activated Kinase \) . Thi promotes heterodimerisation and binding to GAS 
elements in ISGs. The STA T-\ /2 heterodimer can also interact with IRF-9 to 
promote the fonnation of TSGF3 (Interferon timulated Gene Factor 3) 
complexe , which interact with I RE equences through the DBD of IRF-9. Type 
II IF receptor are bound by IFNy, which promote pho phorylation of STAT-I 
homodimers, which can also bind the GAS element . Several other cytokine are 
able to promote STAT binding to the GAS element in the IRF-l promoter 
including lnterleukins and EGF (Epidermal Growth Factor). The K8 element is 
activated by NFlCB p50-p65 heterodimers which can be activated by TNFa 
ignalling, but also through the CD40 and TLR pathways. A number of other 
agent also regulate IRF-l expression through unknown mechanism including 
PPARy (Peroxi ome Proliferator Activated Receptor y) agonists, and PMA 
(Phorbol- 12-myri tate-I 3 acetate). 
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1.4.3. Tumour necrosis factor (TN Fa) 
TNFa induces IRF-l mRNA and protein in humans and mice (Fujita et al. 1989). 
In addition, IRF-l is able to transactivate the TNFa promoter, causing an up-
regulation of its own inducer (Vila-del Sol et al. 2008). CD40 is structurally 
related to the TNF family and is important in the development of B cells. CD40 
ligation induces members of the NFKB family to bind the IRF -1 promoter leading 
to IRF-l mRNA and protein induction (Gupta et al. 1998 and Moschonas et al. 
2008). 
1.4.4. Retinoids 
IRF -I expression is inducible by the RARa ligand A TRA (All-trans Retinoic 
Acid) (Matikainen et al. 1996). The IRF-I promoter does not contain any RAR 
binding elements within 3kb of the transcription start site (Clarke et al. 2004). 
RARP, R A R ~ ~ and RXR ligands also induce IRF-I expression, but are less 
effective than RARa (Luo and Ross 2006). It has been suggested that some of the 
cellular activities of retinoids (cell cycle arrest, apoptosis and differentiation) may 
be achieved (at least partially) through the activation of IRF-l. Several important 
IRF-I target genes have been identified to be strongly induced by synergistic 
action of retinoids and IFNy, including TRAIL (TNF Related Apoptosis Inducing 
Ligand), OAS 2 (2'-5' Oligoadenylate Synthase 2), p21, CIITA and XAF 1 
(XIAP Associated Factor 1) (Clarke et al. 2004, Arany et al. 2003b, Sanda et al. 
2007 and Wang et al. 2006). 
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1.4.5. Bacterial and viral induction 
IRF- I mRNA and protein is inducible by a number of ligands for the Toll Like 
Receptors (TLR). These ligands are components of bacteria or viruses which 
activate transcription via signalling to NFKB family members. Each TLR 
responds to a different bacterial or viral ligand, conferring a high degree of 
specificity to the transcriptional response. TLR ligands which activate IRF-l 
expression include messenger RNA (TLR3), oligodeoxyribonucleotides (TLR9) 
and LPS (TLR4) (Fujita et at. 1989, Kariko et al. 2004, Uchijima et al. 2001 
and Schmitz et at. 2007). 
1.4.6. Genotoxic stress 
Ionising radiation OR) and etoposide cause an induction of IRF-l protein (Tanaka 
et al. 1996 and Pamment et al. 2002). Genotoxic induction of IRF-l occurs at the 
transcriptional rather than post translational level (in contrast to p53). IR and 
etoposide also caused an increase in IRF-l t ~ ~ (half life) from thirty minutes to 
two hours, suggesting genotoxic stress effects the degradation of IRF-l. The 
induction of IRF-l by genotoxins is dependent on the ATM (Ataxia telangiectasia 
mutated) pathway, although it is not thought that A TM directly phosphorylates 
IRF-l, as it does not contain any ATM consensus phosphorylation sites (Pamment 
et al. 2002). The DNA damaging agent MNU (N-methyl-N-nitrosourea) 
promotes an increased expression ofIRF-l mRNA in mice (Liu et al. 2004). 
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1.5.1. IRF -1 and transcription 
Like most TFs, IRF -1 co-operates with a number of other transcription factors 
including STAT-I, NFKB, p53 and ORa (see table 1.5). IRF-I also co-operates 
with other members of the IRF family including IRF-2 and IRF-8 (Meraro et al. 
1999). Additionally, anti-cooperative interactions with IRF family members have 
also been reported (Brass et al. 1999) with IRF-4 preventing the IRF-I dependent 
activation on the TRAIL promoter (Yoshida et al. 2005). The mechanism by 
which IRF -1 brings about transcriptional activation includes recruitment of other 
TFs and coactivator proteins. IRF-1 has been shown to interact with the 
coactivators CBP, p300, PCAF and TIF2 in addition to making direct contacts 
with RNA Pol II (see table 1.5). Detailed studies on the GBP promoter in mice 
shows that following IFN treatment STAT-1 is recruited to the promoter along 
with CBP, with IRF-l binding occurring much later. IRF-l recruitment was 
closely matched by Pol II recruitment, STAT-I-Pol II protein interaction could 
not be detected, while an IRF-I-Pol II interaction was detected. Consequently 
IRF -1 serves to initiate transcription of GBP mRNA on a promoter that has been 
made available by previous STAT and C.BP binding (Ramsauer et al. 2007). The 
ability of IRF-l to bring about transcription is likely regulated by the agents that 
induce IRF-I expression. Low levels of IRF-I are present in most cells, but may 
not be high enough to promote transcription of some target genes. The quick 
increase in IRF-l expression is usually driven by external stimuli such as IFNs, 
retinoids, LPS or TNFa. Some examples of differential regulation of IRF-l by 
external induction have been reported, for example, IRF-I regulates the 
expression of IL-I 0 following IFNa treatment, but not LPS. Activation of other 
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TFs that interact with IRF-I or PTMs initiated by external agents may explain the 
differences in response (Ziegler-Heitbrock et at. 2003). 
IRF -I has been shown to up-regulate the expression of numerous genes in several 
reported cDNA microarray experiments (Erickson et al. 2004, Liu et al. 2004 
Kroger et al. 2007, Dror et al. 2007, Schmitz et al. 2007 and Aly et at. 2008). 
Many of these genes are involved in immune regulation, although genes involved 
in metabolism, cell cycle and apoptosis are also regulated by IRF -I con tinning its 
role in diverse processes. ChIP-chip analysis of IFNy treated breast cancer cells 
also suggests that IRF -I regulates genes involved in numerous processes, with 
DNA damage and repair being a major functional group of regulated genes. IRF-I 
protein was also chromatin immunoprecipitated at a number of promoters of other 
TFs suggesting IRF-I may regulate transcriptional cascades (Frontini et al. 2009). 
Traditionally thought of as a transcriptional activator, IRF-I has been shown to 
repress the expression of a number of genes including IL-4, Survivin, CDK2 
(Cyclin Dependent Kinase 2), Cyclin DI, and Foxp3 (Forkhead Box P3) (Elser et 
al. 2002, Pizzoferrato et al. 2004, Xie et al. 2003, Kroger et al. 2007 and 
Fragale et al. 2008). Micro-array analysis in IRF-I+1+ and IRF-l"/- mice found 55 
genes down-regulated and 17 up-regulated genes in mice with experimentally 
induced colitis (Mannick et al. 2005). Similarly IRF-l was shown to both up-
regulate and down-regulate gene expression in other micro-array studied (Liu et 
al. 2004a, Kroger et al. 2007, Schmitz et al. 2007 and Aly et al. 2008). 
Mechanistically, little is known about how IRF-I brings about transcriptional 
repression, although one study showed that IRF-I was able to fonn a complex 
with HDACI (Histone de-acetylase I) and NFKB-p65 on the PDGF-D (Platelet 
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Derived Growth Factor-D) promoter (Liu and Khachigian 2009). The LxxLL 
motif of IRF-l is needed for transcriptional repression of the CDK2 promoter 
(Eckert ct al. 2006). 
The oncoviral E7 protein interacts with IRF -1 and promotes a switch from 
activator to repressor on the I F N ~ ~ promoter. It is possible that the ability of E7 to 
recruit the NuRD (Nuclear Remodelling and De-acetylation complex) repressor 
complex is responsible for this switch (Park et al. 2000). 
IRF-l may be able to regulate transcription without direct DNA binding. The cell 
cycle inhibitor p21 was one of the earliest IRF -1 target genes identified, although 
the p2l promoter does not contain any functional IRF -I binding sites (Tanaka et 
al. 1996). Rather than directly binding the p21 promoter, IRF-I interacts with p53 
and stimulates its transcriptional activity (Doman et al. 2004). It is not yet known 
if IRF -I has any roles not directly related to transcription, although IRF-l has 
been shown to interact with VEGFR2 (Vascular Epidermal Growth Factor 
Receptor 2), this interaction may be important for the anti-angiogenic activity of 
IRF -1 (Lee et al. 2008). 
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1.5.2. Apoptosis 
IRF-I regulates apoptosis at several levels, including transcriptional up-regulation 
of death ligands and death receptors, caspases and pro-apoptotic factors. 
Additionally IRF-I can down regulate the expression of anti-apoptotic factors. 
IRF-I is capable of promoting both extrinsic death receptor mediated apoptosis 
and intrinsic mitochondrial apoptosis (Clarke et al. 2004 and Gao et al. 2009). 
IRF-l regulates the expression of C09S (FasL) in a number of cell types 
including, monocytes, esophageal cancer cells, breast cancer cells and renal 
cancer cells (Conte et al. 2003, Porta et al. 2005, Watson et al. 2006 and 
Tomita et al. 2003). Additionally, the ligand for C09S, has been shown to be 
transcriptionally up-regulated by IRF-I (Chow et al. 2000 and Kirchhoff et al. 
2002). 
TRAIL, (TNFa Related Apoptosis Inducing Ligand) is a member of the 
TNFa super family, but unlike TNFa and Fas, its receptors are more widely 
expressed, suggesting that TRAIL can act on many cell types. TRAIL brings 
about apoptosis via two receptors DR4 and DRS (Death Receptor 4/5) which 
signals via caspases to bring about apoptosis. TRAIL is induced in APL and 
breast cancer cell lines by co-treatment with IFNy and retinoids. Recruitment of 
IRF-l to the TRAIL promoter was identified by EMSA (Electrophoretic Mobility 
Shift Assays) and ChIP (Chromatin Immunoprecipitation). In co-culture 
experiments using the breast cancer cell line SK-BR3 and the T cell line Jurkat, 
treatment with IFNy and RA (retinoic acid) caused TRAIL dependent cell death in 
both cell lines. Using normal T cells in place of Jurkat cells caused a marked 
decrease in apoptosis in these cells, suggesting that TRAIL is selective for cancer 
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cells (Clarke el at. 2004). IRF-l also up-regulates TRAIL expression in A549, 
H 1299 and UM-UC-12 cells (Park et al. 2004, Eckert et al. 
2006 and Papageorgiou et al. 2007). 
Many groups have reported caspase 1 dependent apoptosis following IRF-I 
induction. caspase 1 levels are up-regulated by IRF-I and down-regulated by IRF-
2 in vascular smooth muscle cells, rat and mouse islet cells, ovarian cancer cell 
lines, monocytic cells, pancreatic cancer cell lines, gastrointestinal 
neuroendocrine tumours and the Daudi cell line (Tamura et al. 1996b, Horiuchi et 
al. 1999, Karlsen et al. 2000, Detjen et al. 2001, Kim et al. 2002 and Iwase et al. 
1999). Caspase 8 is an important initiator caspase which is involved in signalling 
via the TNFa, Fas and TRAIL death receptors. IRF-I transcriptionally increases 
caspase 8 in neuroblastoma cells, and breast cancer cells (Casciano et al. 2004, 
Ruiz-Ruiz et al. 2004, De Ambrosis et al. 2007). A number of other caspases have 
been suggested to be regulated by IRF-I including caspase 7 (Kim et al. 2004, 
Sanceau et al. 2000 and Bouker et al. 2005) and caspase 3 (Sun et al. 2006). 
Several other pro-apoptotic factors including GADDl53 (Growth Arrest and 
DNA damage inducible 153), BclG, (B Cell Lymphoma G) NOXA (Latin for 
damage) and XAFI are regulated by IRF-l (Watanabe ct al. 2003, Zhang et al. 
2006, Lallemand et al. 2007 and Wang et al. 2006). IRF -I promotes 
mitochondrial intrinsic apoptosis in gastric cancer cell lines. IRF-I 
transcriptionally up-regulates the apoptotic protein PUMA (p53 Up-regulated 
Modulator of Apoptosis) although it does not effect the expression of other BH3 
proteins such as Bid, Bad or Bim. IRF-I is capable of up-regulating PUMA 
independently ofp53 (Gao et al. 2009). 
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In addition to inducing expression of pro-apoptotic factors IRF-I also down 
regulates anti-apoptotic factors. Microarray analysis of breast cancer cell lines 
(MDA-MB-468 and SK-BR3) that over express Ad-IRF-l (adenovirally 
transduced IRF-l) show a 15 fold down regulation of survivin. This down-
regulation was confirmed, and shown to be independent ofp53. The authors noted 
that cells that express Ad-IRF-I show increased rates of apoptosis. Xenograph 
models of breast cancer in which Ad-IRF-I was injected into tumours show that 
IRF-I was able to cause growth inhibition in vivo. cancer cells removed from 
these tumours show high expression of IRF -1 and no expression of survivin 
(Pizzoferrato et al. 2004). Survivin levels were also decreased in esophageal cell 
lines that have been transfected with IRF-I (Watson et al. 2006). 
1.5.3. IRF -1 and cell cycle 
In normal cells, genotoxic stress such as IR or adriamycin causes cell growth 
arrest. Embryonic fibroblasts from IRF-l·l- mice do not undergo cell cycle arrest -
in a similar fashion to p53-1- embryonic fibroblasts (EFs). In wild type EFs a 90% 
decrease in S phase cells occurs following y irradiation, however in IRF -1-1. EF 
only a 10% decrease occurs. This is a similar level to p53·1- EFs (Tanaka et al. 
1996). Since CDK2 and CDK4 are involved in this process, they were assayed for 
their phosphorylation by in vitro kinase assays. In IRF -1 +1+ cells a strong decrease 
in phosphorylation was seen in both CDK2 and CDK4 following y irradiation, this 
did not occur in IRF-rl- cells. This suggested a defect in CDK inhibitors (CKI). 
The levels of these proteins were tested in IRF - .-/- cells. Of the CKIs tested only 
p21 was found to be down regulated in IRF -1-/- cells, while p27, pIS, P 16, P 18 
and p 19 were unchanged (Tanaka et al. 1996). 
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The G liS related cyclin dependent kinase 2 (COK2) is repressed by IRF-l, but 
not by IRF-2, IRF-3 or IRF-7. This repression is independent of p53 and 
COP/Cut/Cux 1 homeodomain protein, which all repress CDK2 by acting on 
different regions of the promoter. The promoter region found to be responsive to 
IRF -1 was found not to contain any binding elements for IRF -1, suggesting that 
IRF -1 does not directly bind this region. Rather a Sp 1 site is located in this area. It 
was found that Sp 1 positively regulates this portion of the promoter, while 
transfection of IRF-l causes repression. Biochemical analysis suggests that IRF-l 
indirectly represses CDK2 by interfering with Spl expression (Xie et al. 2003). 
IRF -1 has been shown to revert an oncogenic gene signature in NIH3T3 cells that 
express ectopic c-Myc and c-Ha-Ras. Microarray analysis identified 1,347 genes 
that were de-regulated by the expression of these oncogenes. Activation (by 
addition of extradiol) of the hER-IRF-l chimeric protein caused 60% of these 
genes to revert back to untransformed levels (cells not expressing c-Myc and c-
Ha-Ras). Cyclin D 1 was among the transcripts regulated by IRF -1. The cyclin D 1 
protein is involved in the GI/S phase of the cell cycle. In untransformed cells 
IRF -1 had little effect on cyclin D 1 expression, with transformation being 
required for IRF-I dependent cyclin 01 repression. The DBO of IRF-I was 
required for IRF-I to repress cyclin D I expression, although no IRF binding sites 
could be found up to 3kb from the TSS (transcription start site). The repression of 
cyclin D I also occurred twenty four to forty eight hours after IRF -I activation. It 
is possible that IRF-I has an indirect activity towards cyclin D1. Experiments in 
mice show that cyclin D 1 repression decreases tumour formation, as such this 
may be one mechanism by which IRF-I acts as a tumour suppressor (see section 
2.1.5) (Kroger et al. 2007). Mouse breast cancer cell lines undergo cell cycle 
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arrest when infected with Ad-IRF -1, however when two non-malignant breast 
cancer cell lines (C 1271 and NMuMG) were infected the cell cycle profile 
remained unchanged (Kim ct al. 2004). 
1.5.4. DNA damage and repair 
Splenocytes from IRF -1-1- mice are not able to undergo apoptosis following y 
irradiation, Adriamycin or Etoposide treatment unlike splenocytes from wild type 
mice (Tamura et al. 1995). In addition, MEFs from IRF-I-I- mice do not undergo 
cell cycle arrest when treated with y radiation or adriamycin (Tanaka et al. 1996). 
Consequently IRF-I is needed for cells to respond appropriately to DNA damage. 
IRF-I-1- hepatocytes are significantly less able to repair a UVC damage reporter 
construct that hepatocytes from IRF -1 +1+ mice (Prost et al. 1998). IFNy treatment 
in the breast cancer cell line H3396 promotes IRF-l recruitment to a number of 
genes that are involved in DNA damage and repair responses. Some of these 
genes include BARDI (BRCA Associated RING Domain I), BRIPI (BRCA 
Interacting Partner 1), PMS2L4 (Post Meiotic Segregation Increased 2 Like 4), 
LIG4 (DNA Ligase 4), UNG (Uracil DNA Glycosylase) and PCNA (Proliferating 
Cell Nuclear Antigen). IFNy treatments and IRF-l over-expression also leads to 
an increase in mRNA level for these genes. BRIPI (a member of the Fanconi 
Anaemia family of proteins) is involved in repair of intra-strand crosslinks (lCL). 
BRIPI does not localise to ICL foci following melphalan (an ICL inducing agent) 
treatment in IRF -I depleted cells. In addition, the characteristic G2/M 
accumulation that occurs in patients deficient in BRIP-l is evident when IRF-l 
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protein is depleted. This suggests that IRF -I, via its transcriptional regulation of 
BRIPI is involved in ICL repair (Frontini et al. 2009). 
1.5.5. IRF -1 and cancer 
Strong evidence suggests that IRF-I has tumour suppressor activities. IRF-l can 
act as a tumour suppressor intrinsically via its ability to regulate the expression of 
genes involved in cell cycle regulation, apoptosis and DNA damage/repair. IRF-I 
also has an extrinsic activity in tumour suppression, as it is required for antigen 
presentation and the proper differentiation of immune cells required for immune 
surveillance and thus destruction of damaged cells. Four main arguments can be 
made in support of IRF -1 s role in tumour suppression. 
1. IRF-I levels (mRNA and protein) are decreased in several cancers. There 
is often an inverse relationship between IRF-l expression and patient 
survival (see table 1.6). 
2. IRF-I is able to antagonise the transforming abilities of oncogenes. 
3. Animals models of tumour growth support cell culture data suggesting 
IRF-I is involved in apoptosis and cell growth/proliferation. 
4. IRF-l·1- mice have increased susceptibility to spontaneous tumour 
development when crossed with p53-1- mice. 
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Cytosolic 
localisation 
Breast2 
Colorectal4 
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Skin13 
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Cervical3 
Leukaemia7 
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Mutations defects 
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expression 
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Table 1.6 Abnormal expression of IRF-l in human cancers. As discussed in 
section 1.2.2, 1.2.3 and 1.2.4 the IRF-l gene is prone to exon skipping, deletions 
and LOH. Immunohistochemical analysis has identified a correlation between 
IRF-l expression and clinical outcome for a number of malignancies including 
breast, skin and colorectal cancers. In addition excess SUMO-ylation and nuclear 
exclusion have also been noted in some cancer biopsies. Above is a summary of 
the types of deregulation that occur on the IRF-l protein, and the cancers in which 
they occur. The reduced expression is either due to the 5q abnormality or an 
unknown loss of IRF-l expression. So far the only PTM defect of IRF-l was 
enhanced SUMO-lylation. Leukaemia includes MDS, AML and CML. 
References: 1) Kram et at. 2001 2) Yoshino et al. 2005. 3) Doherty et al. 
2001 Connett et at. 2005 Cavalli et al. 2009 4) Lee et al. 2006 5). Camus et 
at. 2009, Coppola et al. 2009. 6) Kuroboshi et al. 2003 Giatromanolaki et al. 
2004 7) Watson et al. 2006 Wang et al. 2007, Ogasawara et al. 1996 and 
Peralta et at. 1998 8). Tzoanopoulos et at. 2002, Maratheftis et al. 2006 
Harada et al. 1993, Green et al. 1999 Hochhaus et al. 1997 and Mild et al. 
1999 Preisler et at. 2001 9). Moriyama et al. 2001 and Tnani and Bayard 
1999 . 10). Mendes-da-Silva et al. 2000 and (Eason et al. 2003) 11). Zhou et al. 
2000 12). 13). Lowney et al. 1999. 14). Nozawa et al. 1998 , 15). Shen et al. 
2009 . 16). Nozawa et al. 1998 . 
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Several studies have shown that IRF-I can antagonise the activities of a number 
of oncogenes. The first study to show that IRF-I is involved in cancer used the 
oncogene c-Ha-Ras (Rous sarcoma oncogene). Normally, when transfected in 
MEFs ras can only induce transformation when another oncogene such as c-Myc 
is introduced. IRF-rl- MEFs infected with c-Ha-ras undergo transformation, 
suggesting that loss of IRF -I has a similar effect as gain of an oncogene. 
The IRF-I-I- c-Ha-Ras expressing MEFs show increased rates of growth in soft 
agar assays. Introduction of either mouse or human IRF -I into the IRF -r l - ras 
expressing MEFs prevented transformation (Tanaka et al. 1994). To detennine if 
loss of IRF-l or the dominance of IRF-2 was the cause of this transfonnation, 
double IRF-l / IRF-2 knockouts were generated. The transfonned phenotype was 
the same as the IRF-I-I- singe knockout. As such it is the loss of IRF-l rather than 
the predominance of IRF-2 activity that allows ras transformation. Apoptosis was 
promoted by ras transformation in wild type MEFs, but not in p53-1- or IRF-I-I-
mice when treated with the DNA damaging agents adriamycin, 5-flouro-uracil or 
ionising radiation. Therefore IRF-I is important in c-Ha-Ras dependent apoptosis 
(Tanaka et al. 1994). IRF-I can also revert the transfonned phenotype of cells 
expressing the oncogenes c-Myc, c-Fos, Elaib and HER-I (Tanaka et al. 1994, 
Kirchhoff and Hauser 1999 and Kroger et al. 2003). 
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NIH 3T3 cells stably expressing the estradiol activatable hER-IRF-1 (estrogen 
receptor ligand binding domain fused to IRF-I protein) chimera with a bi-
directional c-Mycl c-Ha-Ras Tet off system were used to further probe the role of 
IRF-I following oncogene transformation. Expression of tetracycline inducible 
c-Myc/Ras (by addition of doxycycline) causes an increase in S phase and a 
decrease in G I phase of the cell cycle - consistent with the transforming 
properties of these oncogenes. Activation of IRF-I reverses this pattern back to 
non transformed levels (Kroger et al. 2003). 
The hER-IRF-I c-Mycl c-Ha-Ras cells were implanted in nude mice (without B 
and T cells). Transformation (by dox treatment) of these cells led to tumour 
formation in all mice within three weeks with a mean tumour size of 2 cm3• In the 
non transformed (untreated) cells no mice developed tumours. Cells that were 
transformed by c-Mycl c-Ha-Ras induction, but had activated IRF-I (estradiol 
treatment) delayed tumour formation by three weeks; the mean tumour volume 
was 1.5cm3 and 40% of the mice did not develop tumours at all. This suggests that 
IRF-I is able to bring about repression of transformation independently of IFNs 
and lymphocytes. To address the delay in the tumour formation, tumours were 
removed from the mice. It was found that in the delayed tumours only 10% of the 
IRF-l -hER remained. This suggests that the delay in tumour formation is caused 
by clearance of the IRF-I expressing cells, rather than an inability of IRF-I to 
revert the transformation (Kroger et al. 2003). 
Hepa 1-6 cells which stably express hER-IRF-Ichimera demonstrate a decrease in 
anchorage dependent cell growth via soft agar colony forming assays. 
Implantation of control Hepa 1-6 cells into mice resulted in a high incidence of 
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tumour formation. Treatment of the mice with estradiol (and therefore activation 
of IRF -I) caused complete protection of the mice on six out of eight cases, with 
the other two mice having small, slow growing tumours. Re-challenge 
experiments suggest that T memory cell immunity occurs following IRF-I 
activation, an increase in cytotoxic T lymphocyte immunity and recognition of 
tumour specific antigens was also found. Mice injected with Hepa 1-6 hER-IRF-I 
which had undergone CD4+ or CD8+ T cell depletion did form tumours, but the 
growth rate was delayed, suggesting that the host immune system is not entirely 
responsible for the reduction in tumour formation. Estradiol treatment of mice 
infected with Hepa 1-6 hER-IRF -1 cells 19 days later (when the tumours have 
grown to around 200 mm3) caused a permanent growth arrest in these tumours 4 
days later (Kroger et al. 2001). 
The MCA-IOI cell line is a highly aggressive methyl cholanthrene induced 
sarcoma which expresses little or no MHC I molecules on its surface. Injection of 
these cells into mice caused rapid tumour formation and death. Stable transfection 
of murine IRF-l under the control of the CMV promoter into these cells leads to 
an induction of MHC I molecules. Additionally cell growth was decreased and 
anchorage independent cell growth in soft agar assays was reduced. Transplanting 
these cells into mice increased the tumour latency and slowed tumour growth, 
while MCA-IOI cells carrying empty vector displayed their characteristic 
oncogenicity. Mice infected with IRF-I expressing MCA-IOI cells were immune 
to subsequent re-challenge with these cells, suggesting immunity is developed. 
Gamma irradiation of mice infected with the IRF-I expressing sarcoma cells 
caused a shorter tumour latency and faster tumour growth. This suggests that an 
72 
Post Translational Regulation of the Tumour Suppressor IRF-l 
intrinsic reversion of phenotype and an immune recognition playa role in IRF -1' s 
ability to regulate oncogenesis (Yim et al. 1997). 
Although there is considerable evidence for IRF-l 's role in cancer, IRF-l null 
mice develop a surprisingly low incidence of spontaneous tumours. Up to two 
hundred days after birth only 2 % (6 1 315) of IRF- .-/- mice developed tumours (a 
malignant fibrous histiocytoma like sarcoma). No wild type mice (0/625) 
developed spontaneous tumours. However the incidence of spontaneous tumour 
formation in the IRF-1-1- mice was not considered statistically significant. 
A possible explanation for this low incidence of tumour formation is that IRF-1 
co-operates down stream of another tumour suppressor. IRF-1 has been shown to 
co-operate with the prototypical tumour suppressor p53 (Tanaka et al. 1996). 
Experiments were conducted in which IRF-1-1- mice were crossed with p53-I-mice. 
If IRF -1 was a downstream mediator of the p53 pathway the incidence and 
spectrum of tumour incidence in the double knockout mice would be expected to 
remain the same (Nozawa et al. 1999). 
Within two hundred days, 56% (137 1 254) of p53-1- developed tumours, while 
96% (3221 355) of the p53/IRF-1-1- developed tumours, with a seven fold increase 
in the number of mice carrying multiple tumours compared to the p53-1- single 
mutants. In addition, the spectrum of tumour incidence was drastically different, 
with some types of tumour only occurring in the double knockout mice 
(ganglioneuroblastomas and medulloblastomas). Therefore IRF-l is not hypostatic 
to p53 in tumour predisposition. One possibility for the massive increase in 
tumour incidence in the double knockout mice was suggested to be caused by a 
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fault in tumour immune-surveillance, as IRF-l is important in the functioning of 
the immune system. 
To determine if this was the case, chimeric mice were generated to the point at 
which the immunological defects associated with loss of IRF -1 were not 
detectable. In these mice, 9112 tumours originated from the double-I- cells while 
three originated from the p53 -1- cells. This suggests that there is an intrinsic 
increased susceptibility to tumorigenesis in cells that have lost both p53 and IRF-
1. In support of their increased tumour formation, cells from the double -1- mice 
were less able to undergo apoptosis in response to DNA damage and showed 
impaired growth characteristics (Nozawa et al. 1999). 
IRF-I-1- mice were also crossed with mice that contain five to six copies of the 
oncogenic c-Ha-Ras oncogene (RasH2 mice). Six months after birth, the mice 
were sacrificed. 7% (2/30) of RasH2 heterozygous IRF-rl+ developed tumours, 
while 44% of IRF-I-I- RasH2 mice developed tumours - mostly angiosarcomas 
(Nozawa et al. 1999). This suggests that loss of IRF-l and gain of an oncogene 
increases the incidence of tumours. 
A contrasting study by Eason et al. showed that IRF-I-1- mice are prone to 
developing an anaplastic large cell lymphoma like condition. The Nowaza study 
showed that IRF-I-I- mice are not significantly prone to developing spontaneous 
neoplasia. The key difference between these studies was the age of mice used. 
The Nowaza study used two hundred days mice and the Eason study used three 
hundred days old mice. To address the discrepancy the latter group tested two 
hundred daya IRF-I-1- mice for lymphoma and found no abnormalities in the 
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lymph nodes. This suggests that IRF-l alone may be important in the 
development of neoplasia, but the development is delayed compared to other 
tumour suppressors such as p53 (Eason et al. 2003). 
IRF-l may also be involved in the development of lymphomas following HCV 
(Hepatitis C virus) infection. IRF-l null mice which express HCV core proteins 
are significantly more prone to T and B cell lymphomas, lymph node and thymic 
hyperplasia, splenomegaly and abdominal adenocarcinomas (Machida et al. 
2009). The number and onset of tumour formation is higher in IRF-I-1- HCV mice 
than the HCV IRF-l +1+ mice 500 days post infection. The type of tumour 
developed was not different between IRF-I-1- and IRF-l +1+ HCV expressing mice. 
In agreement with previous studies IRF -1-1- mice were not susceptible to 
spontaneous tumour development when compared to their wild type littermates 
within 500 days of observation. Slightly higher levels of spleen, liver and thymic 
hyperplasia was noted in the IRF -1-1- mice suggesting that with time, malignancies 
may develop in these mice (Machida et al. 2009). 
In addition to oncogenes and H CV infection, IRF -1-1- mice are susceptible to 
tumour development when treated with the alkylating agent MNU. Two out of 
twenty five IRF-l +1+ mice developed thymic lymphomas, but 24125 IRF-I-1-
developed thymic lymphomas following MNU treatment. They displayed 
enlarged spleens, lymph nodes and thymus. The splenic T lymphocytes had a 
malignant phenotype with giant multinucleated mitotic figures. MNU treated IRF-
r l - mice showed decreased expression of LTa , L T ~ ~ (Lymphotoxin), IFNy, ILl2-
p35 and IL12-p40, all of which have been shown to be important in immune 
surveillance. In another experiment 80% of IRF -1 +1+ mice survived MNU 
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treatment for 18 weeks, while only 10% of IRF -r l - survived. Treatment of mice 
with IL-12 partially rescued the IRF-l deficiency, as 60% of the IL-12 treated 
IRF-I-I - mice survived. This study shows that IL-12 (an IRF-l target gene), is 
required for the prevention of thymic lymphoma formation, and thus tumour 
immunosurveilance is important for IRF-l tumour suppressor activity (Liu et a1. 
2004). 
From the studies conducted to date it can be concluded that IRF-l does not 
strongly promote tumour initiation, - since loss of both IRF-l allele's does not 
initiate a significant development of tumours. However IRF-l is more likely 
involved in tumour development, as IRF-l loss synergises with either the loss of 
tumour suppressors (pS3) or treatments with tumour inducing agents in promoting 
tumour development. 
1.5.6. IRF -1 and Immunity 
IRF -I is a key player in the immune system and is essential for the proper 
functioning of the innate and acquired immune responses. Evidence for the role of 
IRF -I in immunity includes; 
1. IRF-I is needed for the development of diverse types of immune cell. 
2. IRF -1-1- mice are less able to combat a number of pathological infections. 
3. Co-operation between the pathogen sensing TLR pathway and IRF -1. 
4. IRF-I is required for proper antigen presentation. 
S. IRF-I transcriptionally regulates a large number of cytokines. 
6. IRF-l is important for anti-viral defence. 
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1.5.7. Role of IRF-l in development of immune cells. 
A large body of research suggests that the transcriptional programme initiated by 
IRF-I is required for the proper differentiation of immune cells. IRF-rl- mice 
display a prevalence of immature granulocytes and lack mature functional 
granulocyte cells. Ectopic expression of IRF-I in myeloblast cells promotes 
di fferentiation into the neutrophil lineage, confirming IRF -I plays a role 10 
granulopoesis (Manzella et al. 1999, Coccia et al. 2001 and Testa et al. 2004). 
Dendritic cells are an important group of antigen presenting cells that process and 
expose antigens to immune cells enhancing immunological responses. Several 
subtypes of dendritic cells exist, and IRF-I-I- mice were equipped with an 
abnormal proportion of some subtypes while others are completely absent or 
immature. Dendritic cells from IRF-I-I- mice also have decreased cytolytic activity 
compared to cells from IRF -I +1+ mice (Gabriele et al. 2006, Remoli et al. 
2007 and De Creus et al. 2002). 
IRF-I deficient mice carry normal numbers of natural killer (NK) T cells, but 
functionally, these cells are far less cytotoxic. NK cells from IRF -rl- mice were 
found to be less able to clear tumour cells from mice (Duncan et al. 1996). It has 
been suggested that the lack of IL-15 (an IRF -1 target gene) is responsible for the 
lack of mature functional NK cells in IRF -1-1- mice (Ogasawara et al. 1998). IRF-
1 is also needed for the functioning and development of cytotoxic T cells (White 
et al. 1996 and Penninger et al. 1997). T regulatory cells (Treg) can dampen 
immune responses and are thought to be involved in inflammation. IRF-I-1- mice 
had high levels ofTreg cells. IRF-I can repress the expression of FOXP3, which is 
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needed for Treg development. Consequently IRF-I-1- cells express higher levels of 
FOXP3 which promotes the development of Treg cells (Fragale et al. 2008). 
The ability of IRF -1 to promote differentiation of T helper cells has been intensely 
studied. There are two major subtypes of T helper cells (Type I and II), Type I aid 
immune responses to cellular threats by macrophages, while type II helper cells 
are involved in humoral responses through 8 cells. IRF-I regulates the balance of 
these two subsets, as IRF-I-1- mice express high levels of type II, with very little 
type I cells being present. An explanation for this may involve IRF-I dependent 
regulation of cytokines which regulate T helper differentiation. IRF-l up-regulates 
the expression of IL-12 and the IL-12 receptor. IL-12 excretion promotes 
differentiation of naIve cells into T helper type I cells. IL-4 is repressed by IRF-I; 
IL-4 promotes the differentiation into type II helper cells. Consequently the 
altered balance of cytokines found in IRF-1-1- cells promotes and abnormal 
eschewing of T helper cells (McElligott et al. 1997, Elser et al. 2002 and Kano 
et al. 2008). 
1.5.8 IRF -1 and immune defence against pathogens. 
IRF-I is involved in combating infection from a variety of pathogens. In 
numerous studies IRF-1-1- mice succumb to infection while their wild type 
littermates survive. Some of the pathogens IRF-I-1- mice are less able to combat 
include; Mycobacterium bovis. Brucella abortus. Toxoplasma gondii, and 
Anaplasma phagocytophilum (Ko et al. 2002, Lang et al. 2006 and Thomas et al. 
2005). 
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1.5.9 Co-operation between IRF-1 and the Toll Like Receptor (TLR) 
pathway 
The activities of IRF family members arc closely entwined with the TLR (Toll 
Like Receptor) signalling pathway (Honda and Taniguchi 2006a). IRF-l 
transcriptionally regulates a number of TLR genes including TLR3, TLR4, TLR5 
and TLR9 (Heinz et al. 2003, Nhu et al. 2006 and Guo et al. 2005). IRF-l 
interacts with the TLR adapter protein MyD88 (see table 1.5). This interaction 
increases the shuttling ofIRF-l into the nucleus and causes a shift in the IRF-I pI 
(isoelectric charge), possibly via phosphorylation. The interaction with MyD88 
may be important in the synergy with NFKB, which is an essential requirement 
for the IRF-I dependent immune response (Negishi et al. 2006 and Schmitz et 
al. 2007). The stimulation of TLR9 causes activation and nuclear translocation of 
both IRF-l and NFKB through different pathways involving MyD88. This allows 
both IRF -1 and NFKB to be available in the nucleus at the same time, allowing 
them to co-operate with each other on a number of promoters involved in the 
immune response (Colonna 2007). 
1.5.10. IRF-1 involvement in antigen presentation. 
MHC I and MHC II molecules (major histocompatability class 1/ II) are involved 
in the presentation of cell surface antigens used to define self and non self to the 
immune system. MHC I molecules are involved in the presentation of antigens to 
cytotoxic T cells. MHC II molecules modulate peptide loading on the lysosomal 
membrane. MHC refers to the gene dense region which also contains molecules 
involved in the antigen processing including TAP (Transporter Associated with 
Antigen Processing) and Tapasin while HLA (Human Leukocyte Antigen) refers 
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to the antigen binding molecules. IRF-l is important in the expression of MHC I 
and MHC II in several cell types (Hobart et al. 1997). IRF-l induces MHC I 
expression in synergy with NFKB when induced with Newcastle Disease Virus 
(Ten et al. 1993). 
The IFNy dependent induction of both MHC I and II are reduced in the IRF-I-I-
mice. Lower levels of CTIIA in the IFNy treated IRF-I-I - mice may be involved in 
the lower levels of MHC II (Hobart et at. 1997 and Jarosinski and Massa 2002). 
CTIIA is a master regulator of MHC II transcriptional activation. Promoter 
analysis has shown that the IFN inducible promoter IV is the site in which IRF-l 
binds to help bring about transactivation (Nikcevich et al. 1999, Rahat et al. 
2001 and Morris et al. 2002). 
IRF-I-I- fibroblasts do not express Tapasin following IFNy/TNFa stimulation, 
suggesting a role of IRF-l. Tapasin is involved in peptide loading for MHC I 
(Abarca-Heidemann et al. 2002). The chaperone ~ 2 2 microglobulin, which is 
involved in MHC I antigen presentation, IgG transport and iron metabolism is 
transcriptionally regulated by IRFs (lRF-l, IRF-2, IRF-4 and IRF-8) and the 
NFkB family members pSO and p6S (Gobin et al. 2003). 
The HLA genes are involved in presenting antigens to cytotoxic lymphocytes, and 
are critical for immune response. Many HLA antigens are regulated by IRF-l and 
IRF-2 including HLA-A, HLA-B, HLA-C, HLA-F, HLA-I and HLA-G 
(Girdlestone et al. 1993, Gobin et al. 1999, Lefebvre et al. 2002 and Frontini et 
al.2009). 
80 
Post Translational Regulation of the Tumour Suppressor IRF-l 
Several components of the immunoproteosome complex are regulated by IRF-I 
including LMP-7 (Low Molecular Weight Protein 7), LMP-2 , TAP and MECL-l 
(Multicatalytic endopeptidase complex 1) (Namiki et al. 2005, Foss and Prydz 
1999, Brucet et al. 2004, Chatterjee-Kishore et al. 1998, Chatterjee-Kishore et 
at. 2000, White et at. 1996 and Moschonas et al. 2008). Following 
IFNy treatment, these three components replace constitutive components of the 
proteasome causing a shift to the formation of antigenic peptides. The HIV 
(Human Immunodeficiency Virus) protein Tat is a transcriptional activator which 
is able to cause LMP-7 and MECL-l to be induced, but down regulates the 
expression of LMP-2. This causes the immunoproteosome to form sub-dominant 
and cryptic epitopes. Tat competes for STAT-l binding on the STAT-l /IRF-l 
binding site. It prevents the interaction between IRF -1 and STAT -1 by 
sequestering IRF-l away (Remoli et al. 2006). 
1.5.11 Transcriptional regulation of cytokines. 
IRF-l transcriptionally regulates the expression of numerous cytokines, which are 
essential for the proper functioning of the immune system. IRF-l was originally 
identified for its ability to activate the IFNa and IFNP promoters (Miyamoto et al. 
1988). In addition to IRF-l, IRF-5, IRF-3 and IRF-7 have been shown to be 
involved in induction of type I interferons. Knockouts of IRF-l and IRF 5 have 
normal levels of type I IFN following infection with Newcastle Disease Virus 
suggesting that these factors are redundant in type me signalling. It was found that 
IRF-3 and IRF-7 are required for this signalling (Honda and Taniguchi 2006b). 
IRF-l is also involved in type III IFN signalling, which has similarities to type I 
IFNs (Osterlund et ale 2007). 
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IRF-I regulation of Interleukin 12 (lL-12) has been extensively studied, and is 
believed to be key to the role of IRF-I in regulating T helper cell differentiation 
(Kano et al. 2008). IRF -1 up-regulates the expression of both IL-12 subunits p35 
and p40 (Liu et al. 2004a and Maruyama et al. 2003). IRF-I has also been 
implicated in regulating the expression of the IL-12 receptor sub-units IL-12RP 1 
and IL-12RP (Kano et al. 2008). IRF -I also transcriptionally up-regulates IL-I /3, 
IL-6, IL-8, IL-27, IL-15 and IL-7 (Marecki et al. 2001, Sanceau et a1. 1995, 
Yamaoka et al. 2004, Pirhonen et al. 2007, Liu et al. 2007, Ogasawara et al. 
1998 and Oshima et al. 2004). IRF -1 represses the expression of IL-4 which is 
involved in T helper cell differentiation (Elser et al. 2002). IRF-I increases the 
expression of IL 18BP (Interleukin 18 Binding Protein). This protein interacts with 
and reduces the activity of IL-18 (Hurgin et al. 2002). 
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1.5.12 IRF-l and viral immunity. 
Several viruses have been reported to utilise IRF-l to regulate the expression of 
viral gene products, including Human Papillomavirus 16, Hepatitis B virus and 
HIV-l (Alcantara et al. 2002, Arany et al. 2003a and Sgarbanti et al. 2002). The 
role of IRF-l in HIV infection has been studied further, with IRF-l dependent 
recruitment of CBP/p300 to the HIV LTR promoter and synergy with the NFKB 
family member p65 being proposed as molecular mechanisms by which IRF-l 
acts on the L TR promoter (Marsili et al. 2004 and Sgarbanti et al. 2008). 
Viruses are also able to interfere with IRF-l expression and transcriptional 
activity. Hev infections can be treated with type I IFN, although approximately 
50% of patients are unresponsive to IFN therapy. A large body of evidence 
suggests that IRF-l is a critical mediator of IFN in HCV therapy. The hepatitis C 
protein NS5A reduces IRF-l expression and DNA binding activity (Jung et al. 
2007). Other gene products of the hepatitis C virus also disrupt IRF -1 action, the 
core protein, when over-expressed in HuH7 cells is able to severely reduce IRF-l 
expression, possibly by blocking the activity of the IRF-l promoter (Ptlugheber et 
al. 2002, Kanazawa et al. 2004 and Ciccaglione et al. 2007). Human herpes virus 
8 (HHV -8) is the causative agent of Kaposi sarcoma and encodes a viral relative 
of IRF-l. vIRF is able to block type I and II IFN signalling, and IRF-l mediated 
transcription. This does not occur via competition for DNA binding, or involve 
the DNA binding domain, but may involve another region of IRF -1 important in 
its transcriptional activity (Zimring et al. 1998 and Burysek et al. 1999). 
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1.5.13 Inflammation 
Studies in IRF -1-1- mice suggest that IRF-I is involved in a number of pathologies 
that are associated with inflammation. A summary of the role of IRF-l in these 
pathologies is given in table 1.7. Some of the key genes which are thought to be 
involved in these diseases are IRF-I targets. The inducible form of the enzyme 
cyclooxygenase (COX-2) is involved in the generation of prostanoids from 
arachidonic acid. These signalling compounds are well known to regulate 
inflammation. COX-2 mRNA expression is regulated by IRF-l and IRF-2 (Blanco 
et al. 2000 and Zhang et al. 2002). 
Significant study has been directed towards controlling NO (nitric oxide) 
production via iN OS (Inducible Nitric Oxide Synthase) since the formation of this 
free radical is highly deleterious and is associated with several diseases such as 
enodotoxemia, heart disease and multiple sclerosis (Flodstrom and Eizirik 1997). 
IRF-l 's ability to regulate iNOS expression (and consequently NO release) has 
been thoroughly studied with particular emphasis on identifying agents that 
prevent IRF-l transactivating the iNOS promoter. Some agents which are able to 
do this include anti-oxidants, IL-13 and the DNA binding agent distamycin A 
(Cho et al. 2008 and Baron et al. 2004). Chemokines regulate immune cell 
activity, and play an important role in inflammation. Several chemokines are 
transcriptionally regulated by IRF-l including, RANTES (Regulates on 
!ctivation, !!ormal T cell £xpressed and !ecreted), CXCLIO and CXCL11 (Lee et 
al. 2000, Baker et al. 2003, Liu and Ma 2006, Kanda et al. 2007 and Yang et al. 
2007). The ability of leukocytes to adhere and infiltrate blood vessels is linked to 
inflammation. The VCAM (Vascular Cell Adhesion Molecule) protein is a well 
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studied IRF -1 target gene that is involved in this process (Neish et al. 1995 and 
Lechleitner et al. 1998). IRF-l has also been shown to regulate the expression of 
genes whose products are involved in degradation of cell-cell contacts. Some of 
these genes include; ADAM8 (a disintegrin and metalloprotease 8) and the matrix 
metalloprotease enzymes MMP8 and MMP9 - both of which are linked with 
tumour invasion and are repressed by IRF-l (Schlomann et al. 2000) (Sanceau et 
al. 2002 and Nguyen et al. 2005). MMP-I0 transcripts were found to be 
significantly lower in IRF-I-I - mice infected with Mycobacterium avium. Several 
other genes involved in tissue re-modelling were also identified and may be linked 
to IRF -1 function in developing granulomas during tuberculosis (Aly et al. 2008). 
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Pathology 
Hepatitis 
Psoriasis 
Colitis 
Ischemia 
Diabetes 
lupus 
Graft Rejection 
Endotoxic Shock 
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Role of IRF-l 
IRF-l-'- mice do not develop hepatitis when treated with concavalin 
A. Several gene products known to be involved in leukocyte 
infiltration of the liver are regulated by IRF-l. 
IRF-l levels are low in epidermal cells from patients with psoriasis. 
IRF-l may be involved in the proliferation of T cells 
Dextran sulphate (an inducer of intestinal inflammation) treated 
IRF-I-1- mice display increased disturbance of crypt architecture and 
colonic dysplasia. levels of lethality and severity of colitis are higher 
in IRF-1-l- mice treated with dextran sulphate sodium or 
trinitrobenzene sulfonic acid compared to wild type mice. 
levels of IRF-1 mRNA are increased in neurons from ischemia 
biopsies. IRF-1 immunoreactivity has been found in intravascular 
neutrophils and, later in the clinical course, in neutrophils 
infiltrating ischemic tissues and neurones. IRF-1-1- mice have lower 
infarct volume following induced ischemia then their wild type or -1+ 
littermates, they also show lower neurological defects. IRF-1-1-
hepatocytes are protected from ischemia / reperfusion injury. 
Transduction with Ad-IRF-1 promoted liver damage, as did liver 
transplant from mice with Ad-IRF-1 infected livers 
IRF-1-1- mice crossed with diabetes prone mice do not develop 
diabetes, while their -1+ and +1+ littermates developed spontaneous 
diabetes. Analysis of immune markers involved in the diabetes 
suggest that the T H2 response is protective in the development of 
diabetes, since IRF-1-1- T cell development is eschewed towards T H2 
over T H1, this may explain the lack of diabetes in IRF-1-1· mice 
IRF-1-1- mice crossbred with a strain that develops lupus were found 
to be more resistant to the pathological effects of lupus in the 
kidney. Additionally the IRF-1-1- mice survived longer than the IRF-
1+1+ mice. 
IRF-1 is required for prevention of necrosis in kidney transplant 
mouse models. Wild type mice developed arteritis and tuberitis but 
were otherwise viable twenty one days after transplant, the IRF-1-1-
mice however showed massive necrosis 
IRF-1-1- mice are resistant to lPS poisoning, and express much lower 
levels of TNFa and IFNy following lPS treatment. 
Reference(s) 
(Streetz et 01. 2001), 
(Jaruga et 01. 2004) 
(Jackson et 01. 1999) 
(Mannick et 01.2005)., 
(Siegmund et 01. 2004). 
(Paschen et 01. 1998) 
(Alexander et 01. 2003) 
(Iadecola et 01. 1999) 
(Tsung et 01. 2006) 
(Gysemans et 01. 2009) 
(Nakazawa et 01. 2001) 
(Reilly et 01. 2006) 
(Afrouzian et 01. 2002) 
(Senaldi et 01. 1999) 
Table 1.7 Inflammatory pathologies associated with IRF-l. Summary table to 
some of the inflammatory diseases which are thought to involve IRF -1. 
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phosphorylating ~ ~ -Catenin which in turn allows it to promote transcription of its 
target genes (Yost e/ al. 1996). 
In addition to control of the GSK3 protein, substrates of GSK3 may also require 
prior phosphorylation. This unique mechanism of " priming" greatly enhances the 
interaction between GSK3 and its substrates, thus allowing fUliher fine tuning of 
GSK3 dependent phosphorylation (Frame and Cohen 2001). A third level of 
control of GSK3 is alterations in its subcellular distribution. GSK3 IS 
predominantly located in the cytosol, but can also be found in the nucleus and 
mitochondria (Bijur and Jope 2003). The levels of GSK3 in the nucleus are 
regulated throughout the cell cycle, and are increased during apoptosis (Diehl et 
at. 1998 and Bijur and Jope 200 I). This is impoliant when considering that GSK3 
regulates the activity of a number of transcription factors. 
iv>; 
Pr tein kinore 
e ~ . . PKBlAKT 
-- ... -+ 
Figure 1.12 Schematic of GSIG. A substrate is shown interacting with GSK3 , 
with its + 4 priming residue interacting with the priming site and its target residue 
interacting with the active site. Inactive GSK3 is illustrated with its 
phosphorylated N terminal Ser residue, which is blocking the substrate from being 
phosphorylated. Adapted from Frame & Cohen 2001. 
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1.6.2. GSK-3 substrates 
The GSK3 consensus motif has been identified as T /S-X-X-X-pT/S, where X 
represents any amino acid, and p indicates phosphorylated Thr or Ser re idues 
(see figure 1.13). This priming effect enhances the interaction between GSK3 and 
its substrate significantly. Occasionally the + 4 residue is an acidic aspaliic or 
glutamic acid amino acid. These substrates can be considered to be constitutively 
primed. Some substrates do not require the + 4 priming site, while others posses 
+5 priming sites. Phosphorylation of Ser/Thr residues may promote the formation 
of a new primed site for additional residues in substrate. Consequently GSK3 may 
phosphorylate a series of residues (Doble and Woodgett 2003). Examples of 
GSK3 substrates are given in Figure 1.14. 
Priming site (not GSK3) 
Primed consensus Priming site (GSK3) 
BCl -3 S P S Q S P 
GSK3 site 
• 
SMAD3 T I P R 5 l Acidic Jt!rimed consensus 
HATH1 S l l 0 S T C-MYB T P V S 0 
CDC25A S S E S T S ElFt S P P H A 
GSK-3 L P!llxP overlaJt!s lIb/pical cacseosLls 
NOTCH-1 T P T l S P NACa. T P T V Q E 
C-MYC T P P l S P HIF1a. S P E S A S 
C-JUN T P P l S P P21 T P l E G 0 
lCCHCB T P P l T P CRMP2 T P K T V T 
Figure 1.13 GSKJ B substrates. A selection of GSK3 ~ ~ substrates are ill ustrated 
here, some of these proteins can also be phosphorylated by GSK3 a . The 
substrates are subdivided into groups depending on the amino acids within the 
consensus. Abbreviations SMAD3 (MAD protein 3), HATH! (Human Homolog 
of MATH), ZCCHC8 (Zinc finger CCHC Domain containing 8), NAC (Nacent 
Polypeptide Chain Associated), CRM P2 (Collapsin Response Mediator Protein 2) 
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1.6.3. GSK-3 and transcription 
Proteins involved in transcription constitute the largest functional group of GSK3 
substrates. A number of transcriptional coactivators and co-repressors are 
phosphorylated by GSK3p, including Bcl3 (B Cell Lymphoma 3), SRC-3 (Steroid 
Receptor Coactivator 3), CIITA, PGCla, MAML (Mastermind Like 1), aNAC 
(Viatour et al. 2004, Wu et al. 2007, Olson et al. 2008, Xu et al. 2008 and 
Quelo et al. 2004). For some of these proteins phosphorylation results in 
degradation and reduction in activity (Bcl3 and aNA C), while other coactivators 
require GSK3p dependent phosphorylation for their activity (SRC-3 and CIITA). 
Phosphorylation of CIIT A promotes protein-protein interactions with the 
transcriptional repressor protein Sin3B and HDAC2, and is required to bring 
about repression of type 1 collagen genes (Xu et al. 2008). Phosphorylation of 
MAML by GSK3p alters global histone acetylation, suggesting that GSK3p may 
also playa role in epigenetics. Chemical inhibitors of GSK3 in CLL cells induce 
epigenetic modifications of NFkB target genes, this alterations in tum prevent 
NFkB binding and activity. It is not yet known which agents bring about these 
epigenetic changes (Ougolkov et al. 2007). Phosphorylation also modulates the 
interaction between TFs and coactivators, such as the interaction between CREB 
and CBP (Fiol et al. 1994) and MafA and p300 (Rocques et al. 2007) and 
NFkBp65 and CBP (Martin et al. 2005). The ability of GSK3 p to regulate the 
degradation of a number of TFs has been discussed in section 1.5. 
Phosphorylation of NF ATc by GSK3p promotes nuclear export, preventing 
NF ATc from accessing DNA and promoting transcription (Benedito et al. 2005). 
The TF C/EBPP requires phosphorylation by MAPK and GSK3p to acquire DNA 
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binding activity. Phosphorylation of C / E B P ~ ~ ~ promotes the fonnation of 
disulphide bridges needed for DNA binding (Kim et al. 2007). 
1.6.4. GSK-3 is disease and development. 
GSK3p is important for the development of the nervous system, with a role in 
neurite extension and retraction (Etienne-Manneville and Hall 2003). Proteins that 
regulate the cytoskeleton including kinesin and microtubule associated proteins 
are also regulated by GSK3, suggesting a role for GSK in cell architecture 
(Wakefield et at. 2003). GSK3 proteins are involved in the development of body 
plans in a number of organisms including Drosophila. C. elegans, Xenopus and 
Dictyostelium. GSK3p may not be involved in patterning in mammals, however 
as GSK3p-/- mice do not suffer from development defects (Kim and Kimmel 
2000). Up-regulation of GSK3 expression promotes apoptosis and GSK3 has been 
shown to be an important mediator of apoptosis following DNA damage, hypoxia, 
ER stress and Anoikis (Jope and Johnson 2004). 
GSK3p also regulates cell survival, mice that are devoid of GSK3p die in utero at 
day 14. A contributing factor to GSK3p-l- mice lack of viability is the massive 
TNFu induced hepatic apoptosis. It has been suggested that proper control of 
NFKB family members by GSK3p is needed to restrain this inappropriate 
apoptosis (Hoeflich et al. 2000). GSK3p has been linked to a plethora of human 
diseases, including diabetes, Alzheimers, Bi-polar disorder, cancer and 
Schizophrenia (Jope and Johnson 2004). 
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1.6.5. GSK3 inhibitors 
Unsurprisingly, given the number of human pathologies to which aSK3 has been 
implicated, considerable interest has been directed at the study of aSK inhibitors. 
For over 50 years Lithium salts have been used in the treatment of mania, 
although it has only recently been shown to act through aSK3. Most GSK3 
inhibitors act on the A TP binding pocket, however this region is similar to CDK 
enzymes, producing off target effects. The A TP binding pockets of GSK3a and 
aSK3p are almost identical, making most GSK3 inhibitors non selective for each 
isoform. Alternative approaches to the use of chemical inhibitors, is the use of 
peptides based on proteins that interact with and inhibit GSK3. Most commonly 
these include FRAT and GlD peptides derived from the axin-GSK3 interaction. 
Other sites of GSK3 are also being investigated for their drugability including the 
activator tyrosine phosphorylation site (Meijer et al. 2004). 
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PhD objectives 
Although a small number of IRF-I PTMs have been described, very little is 
known about how these modifications regulate the transcriptional activity of IRF-
1. In addition there is a distinct lack of understanding concerning the mechanisms 
by which IRF-I brings about transcription, as such this project sought to answer 
some of the questions regarding the fundamental control and activity of the IRF-I 
protein. By identifying kinases that modulate IRF -1 activity, it is hoped that novel 
therapeutic agents could later be developed to regulate the IRF-l transcriptional 
programme. 
The specific goals of this project are given below. 
1. Identify novel kinase(s) that phosphorylate IRF-l and locate the residues 
phosphorylated in vivo. 
2. Detennine the role of the kinase and the specific modified residues on the 
transcriptional activity of IRF-I using the TRAIL promoter as a model 
system. 
3. Delineate the mechanism by which the newly identified phosphorylation 
event regulates IRF-I activity, for example through changes in subcellular 
localisation, DNA-protein interactions, protein-protein interactions or 
through PTM crosstalk. 
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Chapter 2. Methods 
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2.1.1 Polymerase Chain Amplification (PCR) 
All PCR reactions were carried out on a Thennal Cycler 2720 (Applied 
Biosystems). The total reaction volume used was 50 ~ L L with the volume being 
bought up with ddH20. All primer sequences are given on table 2.1. A 50 J.l.L 
reaction mix contained 5 ~ l l of reaction buffer (lOX), I ~ L L of 10mM dNTPs, 1.5 
~ L L of 50 mM magnesium chloride, 5 ~ L L of 5 ~ M M primers (Fwd and Rev) 50ng of 
template DNA and 0.25 J.l.L ofTaq Polymerase (1.25U) (Invitrogen). The cycling 
conditions were 30 rounds of; 94°C (180 seconds), 94°C (45 seconds), 55° C (30 
seconds), and 72 ° C (90 seconds) with a final extension of72 0 C for 7 minutes. 
2.1.2 Colony PCR 
Colony PCR was used when a background (ligation controls) level of higher than 
10% occurred (see section 2.1.7), or when a single restriction site was used for 
cloning and the orientation of the insert had to be tested. From the LB-AMP plate, 
single isolated bacteria clones were lifted with a pipette tip and placed in cultures 
containing 50 ~ L L of LB-AMP. These cultures were then incubated for two hours 
at 37°C. The PCR reaction was carried out according to section 2.1.1 with the 
exception that 5 J.l.L of the LB-AMP bacteria was added to the PCR mix. To 
determine if the insert was ligated into the vector, the primers used for the cloning 
were employed. A negative control of ddH20 in place of bacteria, and a positive 
control of expression plasmid (5 ng) were used to check the identity of the PCR 
product. 
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Oligo name 
mlRFl K233R 
mlRFl K276R 
mlRFl K300R 
mlRFl K2SSR 
mlRFl K240R 
mlRFl Tl80D 
mlRFl Sl84E 
mlRFl Tl80A 
mIRFlSl84A 
mlRFl 
Tl80A/Sl84A 
mlRFl YFP 
mlRFl FLAG 
HA-Fbxw7a FL 
HA-Fbxw7J3 FL 
HA-Fbxw7a N 
terminus deletion 
HA-Fbxw7J3 N 
terminus deletion 
HA-Fbxw7 C 
terminus deletion 
T7-Fbxw7a FL 
murine IRF-l 
Hs_GSK3B_8_HP 
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Template 
FLAG-mIRFl WT 
FLAG-mIRFl WT 
FLAG-mIRFl WT 
FLAG-mIRFl WT 
FLAG-mIRFl WT 
pcDNA3.mIRFl WT 
pcDNA3.mIRFl WT 
pcDNA3.mIRFl WT 
pCDNA3.mIRFl WT 
pcDNA3.mIRFl 
S184A 
pcDNA3.mIRFl WT 
pcDNA3.mIRFl WT 
pDEST27 -Fbxw7a 
pDEST27 -Fbxw7J3 
pDEST27 -Fbxw7a 
pDEST27 -Fbxw7J3 
pDEST27 -Fbxw7J3 
pDEST27 -Fbxw7a 
Sequencing 
siRNA 
Sequence (5'--> 3') 
Fwd:GGATGAGGAAGGGAGGATAGCCGAAGACC 
Rev:GGTCTTCGGCTATCCTCCCTTCCTCATCC 
Fwd :GGAGACTTCAGCTGCAGAGAGGAACCAGAGA TTG 
Rev:CAA TCTCTGGTTCCTCTCTGCAGCTGAAGTCTCC 
Fwd:CA TGTCTTCACGGAGATGAGGAA TATGGACTCCATCA TG 
Rev:CATGATGGAGTCCATA TTCCTCATCTCCGTGAAGACATG 
Fwd:GACACACATCGATGGCAGGGGATACTTGCTCAATG 
Rev:CATTGAGCAAGTATCCCCTGCCATCGATGTGTGTC 
Fwd:GATAGCCGAAGACCTTATGAAGGCTCTTTGAACAGTCTGAG 
Rev:CTCAGACTGTTCAAAGAGCCTCATAAGGTCTTCGGCTATC 
Fwd:GGACTTGGATATGGAAAGGGACATAGATCCAGCACTGTCA 
RevTGACAGTGCTGGATCTATGTCCCTTTCCATATCCAAGTCC 
Fwd:AGGGACATAACTCCAGCACTGGAGCCGTGTGTCGTCAGCAGCAGT 
Rev: TCCCTGTATTGAGGTCGTGACCTCGGCACACAGCAGTCGTCGTCA 
Fwd:ATGGAAAGGGACATAGCTCCAGCACTGTCACCG 
Rev:CGGTGACAGTGCTGGAGCTATGTCCCTTTCCAT 
Fwd:CATAACTCCAGCACTGACACCGTGTGTCGTCAG 
Rev:CTGACGACACACGGTGTCAGTGCTGGAGTTATG 
Fwd:GGAAAGGGACATAGCTCCAGCACTGGC 
Rev: GCCAGTGCTGGAGCTATGTCCCTTTCC 
Fwd:ATAATAAGATCTATGCCAATCACTCGAATG 
Rev;ATAATATCTAGACTATGGACAAGGAAT 
Fwd;ATAATAAAGCTTATGCCAATCACTCGAATG 
Rev;ATAATATCTAGACTATGGACAAGGAAT 
Fwd:ATAATAGAATTCATGAATCAGGAACTGCTCTCTGTG 
Rev:TATTATTCTAGATCACTTCATGTCCACATCAAAGTC 
Fwd:ATAATAGAATTCATGTGTGTCCCGAGAAGCGGTTTG 
Rev:TATTATTCTAGATCACTTCATGTCCACATCAAAGTC 
Fwd:ATAATAGAATTCATGAATCAGGAACTGCTCTCTGTG 
Rev:TATTATTCTAGATCAAGATTTGAGTTCTCCTCGCCT 
Fwd:ATAATAGAATTCATGTGTGTCCCGAGAAGCGGTTTG 
Rev:TATTATTCTAGATCAAGATTTGAGTTCTCCTCGCCT 
Fwd:ATAATAGAACCTAAGGTGCTGAAAGGACATGAT 
Rev:TATTATTCTAGATCACTTCATGTCCACATCAAAGTC 
Fwd:TAATACGACTCACTATAGGGAGACCACCATGGATGAATCAGGAACTGCT 
Rev:TATTATTCTAGATCACTTCATGTCCACATCAAAGTC 
Fwd:AGCTGGGCCATTCACACAG 
Rev:GTTCATGGCACAACGGAAGT 
Fwd r(GCA UUU AUC GUU AAC CUA A)dTdT 
Rev: r(UUA GGU UAA CGA UAA AUG C)dAdG 
Table 2.1 Oligonucleotides used in this study. The Oligonucleotides used in this 
study for cloning, mutagenesis, sequencing and siRNA knockdown. All oligos 
were from Sigma Genosys, except the siRNA oligos which were purchased from 
QIAGEN. 
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2.1.3 Site directed mutagenesis 
Primers for site directed mutagenesis were designed using PrimerX software 
(http://www.bioinformatics.org/primerxl). All primers were synthesised by Sigma 
Genosys UK. Site directed mutagenesis was performed using the Stratagene 
Quikchange XL kit (Stratagene). All reactions were carried out according to the 
manufacturer's instructions, using 2S ng of template DNA and 2.S U per reaction 
of Pfu ultra polymerase. The PCR conditions were (denaturing) 9S0C for 110 s, 
(annealing) 62°C for SO s followed by (extension) 68°C for 7 minutes. This was 
repeated 18 times with an additional cycle at 68°C for 7 minutes. Transformations 
were carried out using the supplied Ultra-competent bacteria provided. Following 
transformation of the DpnI digested DNA product, bacteria were plated on AMP-
Agar plates (SO JlglmL) and incubated for 24 hours at 37°C. At least four colonies 
were picked and grown in SmL of LB AMP (50 JlglmL) overnight with mild 
shaking at 37°C. 2mL of the culture was then used for mini-preps. The eluted 
DNA was then subjected to restriction digests with EcoRl, or XbaI / HindIII for 
the pcDNA3.1 or 3X Flag vectors respectively. 
2.1.4 DNA purification 
DNA purifications following gel extraction or PCR I restriction digestion was 
carried out using the YORBIO PCR I gel extraction cleanup kit (YORBIO). When 
purifying DNA from agarose gel, the relevant fragment was excised from the gel 
after visualising on a UV light box. The gel slice was weighed and mixed at a 1: 1 
ratio with binding buffer. The gel slice was incubated at 65°C for 10 minutes, with 
vortexing every two minutes. For purification from PCR or restriction digest, the 
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DNA was mixed 1: 1 with binding buffer, vortexed, and allowed to incubate at 
room temperature for two minutes. The DNA / binding buffer mix was then added 
to a spin column and left to stand at room temperature for a further 5 minutes. The 
spin columns were then centrifuged at 12,000 rpm for 1 minute. The flow through 
was discarded, and the column washed twice with 500 ilL of wash buffer. A final 
spin at 12,000 rpm for 1 minute was used to dry the membrane. The column was 
transferred to a clean collection tube, and 50 ilL of elution buffer was added to the 
membrane. The elution buffer was incubated on the membrane at 37°C for 10 
minutes. The columns were then centrifuged at 12,000 rpm for 1 minute. The 
flow-through was collected in a labelled fresh tube and stored at -20°C. 
2.1.5 Restriction endonuclease di2estion 
Restriction endonuclease digestions were carried out in 30 ilL total volume at 
37°C unless otherwise stated. All restriction enzymes were purchased from 
Roche. Typically 10 units of restriction enzyme were used to cut 1 Ilg of DNA for 
1 hour in a water bath. When two restriction enzymes were used, IOU of each 
enzyme was used and appropriate buffer was selected to enable both enzymes to 
work at 100% efficiency. 
2.1.6 DNA dephosphorylation 
Phosphatase treatment of restriction digested vector was carried out on all vectors 
regardless of use of two different restriction sites. De-phosphorylation was carried 
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out using TSAP (Promega) according to manufacturer's instructions using I U of 
TSAP per reaction. 
2.1.7 Ligation 
Ligations were carried out in a total volume of 10 f..lL. The vector: insert ratios 
used in the ligations varied from 1:2 to 1:4 depending on the size of the insert 
(1=10 ng of DNA). Typically a range of ratios was used to ensure positive 
ligations. Vector and insert DNA were mixed with ddH20 to a total volume of 8 
f..lL in PCR tubes. The DNA was heated at 65°C for 5 minutes followed by rapid 
cooling in ice. One f..lL of lOX ligation buffer and I f..lL (I U) of T4 Ligase 
(Roche) was added to the DNA. Ligations were carried out at 12°C overnight. 
Controls in which no T4 was added, or in which there was no insert were always 
included to check for vector re-ligation. 
2.1.8 Preparation of chemically competent DH5a 
A single colony of freshly grown E.coli DH5a bacteria was picked into 10 mL of 
LB broth and grown overnight at 37°C with shaking at 200-250 rpm. One mL of 
this culture was then added to 100 mL of LB and grown until it reached an OD595 
of 0.3. The contents of the flask were then transferred to two 50 mL tubes and 
centrifuged for 5 minutes at 3500 rpm at 4°C. Supernatant was then discarded and 
the bacteria pellet re-suspended in 20 mL ice cold 100 mM MgCh. The cells were 
then pelleted again as before and re-suspended in 10 mL of 100 mM CaCh, The 
cells were then left on ice for 30 minutes in CaCho The bacteria were then mixed 
with glycerol to produce a 30% glycerol mix, ali quoted and frozen at -80°C. 
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2.1.9. Transformations 
For transformation of plasmid DNA the E.coli DH5a strain was used. For 
transformations from ligation reactions 3 ilL of the ligation mix was added to 50 
ilL of chemically competent DH5a which had been thawed on ice. The DNA was 
incubated with the bacteria for 45 minutes on ice. Bacteria were heat shocked at 
42°C for 2 minutes, and cooled on ice. The transformed bacteria were grown in 
450 ilL of LB-AMP without antibiotics at 37°C with shaking for 1 hour. The 
bacteria were pelleted and re-suspended in 50 ilL of LB-AMP. The pellet was re-
suspended in the LB-AMP and the entire pellet plated on a 10 cm plate containing 
LB-AMP Agar supplemented with 50 IlglmL Ampicilin. For eYFP plasmids; 25 
IlglmL of Kanamycin was used. The plates were incubated overnight at 37°C to 
allow colonies to grow. When known amounts of DNA were being transformed, 
100 ng of DNA was transformed as above; with the exception that 50 ilL of the 
bacterial culture was plated. Transformations from site directed mutagenesis were 
carried out using the Ultra competent bacteria provided with the Quikchange II 
site directed mutagenesis kit (Stratagene). Transformations were carried out 
according to manufacturer's instructions. 
2.1.10. Small scale purification of plasmid DNA 
Small scale purification of plasmid DNA was performed using the YORBIO 
Plasmid purification kit (YORBIO). Three mL of an overnight culture of 
transformed DH5a cells were pelleted in 1.5 mL microfuge tubes. To the pellet, 
150 ilL of solution I was added and vortexed to homogenise the pellet. Cells were 
lysed with 150 ilL of solution II, the microfuge tube was inverted eight times to 
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aid lysis of cells. Lysis was allowed to occur for 5 minutes. 300 ~ L L of solution III 
was then added to stop the lysis and precipitate genomic DNA and protein. The 
contents were gently mixed and allowed to stand at room temperature for two 
minutes. The precipitate was pelleted by centrifugation at 12,000 rpm for 10 
minutes at room temperature. The supernatant was transferred to spin columns, 
centrifuged at 12,000 rpm for 1 minutes followed by two washes with wash buffer 
for 30 seconds. A final spin to remove any remaining wash buffer was performed 
before elution buffer was added to the column (50 ~ L ) ) for 5 minutes at room 
temperature. The column was transferred to a clean collection tube and 
centrifuged at 12,000 rpm for 1 minute. The eluted DNA was transferred to a 
clean capped tube and stored at -20°C until needed. 
2.1.11. Large scale purification of plasmid DNA 
For large scale preparation of plasmid DNA, Nucleobond Maxi (Machery Nagel) 
columns were used. Extraction of DNA was performed according to 
manufacturer's instructions from a culture of200 mL. 
2.1.12. DNA Quantification 
All DNA was quantified using the Nanodrop SpectroanaJyser 2000. 
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2.1.13. Glycerol stocks 
To produce bacterial glycerol stocks, 700 ilL of growing bacterial culture 
transformed with desired plasmid was mixed with 300 III of 50% glycerol (sterile 
filtered). The glycerol stocks were stored at -80°C. To inoculate cultures from 
glycerol stocks, the frozen culture was stabbed with a pipette tip and transferred to 
5 mL of LB containing the relevant antibiotic. This starter culture was then grown 
at 37°C for 5 hours with shaking before being transferred to a 200 mL culture 
which was left to grow overnight at 37°C. 
2.1.14. Agarose gel electrophoresis 
All DNA was run on agarose at a concentration of 0.8-1.0% made up in 1 X TBE 
buffer (40 mM Tris pH 8.3,40 mM Boric acid, 0.037% SDS). DNA was diluted 
to IX in gel loading buffer (0.25% Bromophenol Blue (w/v) 30% glycerol). The 
final concentration of Ethidium Bromide used was 0.05 IlgimL. The gels were 
electrophoresed using the Biorad system (BIORAD). The gels were visualised 
using a Gel Doc 2000 (BIORAD). 
2.1.15. DNA sequencing 
Sequencing of cloned DNA was performed to confirm the identity of cDNA 
donated from external sources, mutagenesis and cloning. DNA was sequenced in 
both the forward and reverse orientation to ensure full coverage of the cDNA 
insert. Longer cDNA inserts (such as for Fbxw7) were sequenced with internal 
primers to ensure full coverage. Sequencing was performed by GATC (Konstanz, 
Germany). 
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2.1.16. 3XFLAG N terminal tagged IRF-l 
N terminal 3x FLAG (Sigma Aldrich) tagged murine IRF-l constructs were made 
by peR amplifying IRF-l from the original pcDNA3.1 expression plasmid using 
primers that add XbaI and HindIII sites. These primers and the PCR conditions 
are detailed in table 2.3. After PCR amplification, DNA was purified, cut with 
XbaI and HindIII, and re-purified according to sections 2.1.4. The 3xFLAG vector 
plasmid was restriction digested with XbaI and HindlII, then purified. Insert and 
vector were ligated together (see 2.1.7). DNA was transformed; positive clones 
were selected and grown in 5 mL of LB-AMP over night. DNA from 5 clones of 
each construct was then purified (2.1.10) and subjected to restriction digest with 
XbaI and HindIII to confirm presence of the IRF-l insert. DNA was sequenced 
(2.1.15) and maxipreped (2.1.11). To confirm the constructs produce viable, in-
frame proteins, transfection of 5 J..lg of DNA was carried out in HEK293 cells, 
followed by immunoblot for both murine IRF-l and FLAG. 
2.1.17. eYFP- IRF-l 
N terminal enhanced YFP (eYFP Cl Clontech) fused murine IRF-l constructs 
were made my PCR amplifying IRF-l from the original pcDNA3.1 expression 
plasmid using primers that add XbaI and BglII sites. These primers and the PCR 
conditions are detailed in table 2.1. After PCR amplification, DNA was purified, 
cut with XbaI and BglII, and re-purified. The eYFP vector was restriction digested 
with XbaI and BglII, then purified. Insert and vector were ligated together (2.1.7). 
DNA was transformed; positive clones were selected and grown in 5 mL of LB-
AMP over night. DNA from five clones of each construct was then purified 
(2.1.4) and subjected to restriction digest with XbaI and BglII to confinn presence 
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of the IRF-I insert. DNA was sequenced (2.1.15) and maxipreped (2.1.11). To 
confirm the constructs produce viable, in-frame proteins, transfection of 5 ~ g g of 
DNA was carried out in HEK293 cells, followed by immunoblot for both murine 
IRF-l and GFP. 
2.1.18. GST - IRF-l 
N terminal GST (glutathione-s-transferase) fused murine IRF-l constructs were 
made by restriction digest of the entire murine IRF-l eDNA from the original 
pcDNA3.1 plasmid with EcoRl. The digested DNA was run on a 0.8% agarose 
gel containing 0.05 ~ g / m L L Ethidium Bromide. The smaller fragment (2.2kb) was 
excised from the gel, purified (2.1.4) and ligated with EcoRl digested pGEX-4Tl 
(GE Healthcare) plasmid. DNA was transformed; positive clones were selected 
and grown in 5 mL of LB-AMP over night. DNA from five clones of each 
construct was then purified and subjected to restriction digest with XhoI to 
determine if the insert was orientated in the correct orientation. To confirm the 
presence of the IRF-l insert. DNA was sequenced and maxipreped. 
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2.1.19. pcDNA4-TO-IRF-l 
The entire murine IRF-l cDNA was transferred into the pcDNA4-Tet Off vector 
(Invitrogen) from the pcDNA3.1 by restriction digest using EcoRl. The cloning 
strategy used was identical to that used for cloning GST-IRF-l with the exception 
that ApaI was used to determine if the IRF -1 insert was in the correct orientation. 
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2.1.20. HA-Fbxw7 
Fbox WD40 repeat containing seven cDNA was transferred from the pDEST27 
GST vector to the CMV -HA vector using primers that introduced restriction 
digest sites specific to the CMV -HA multiple cloning site. Forward primers were 
generated that added an EeaR] site on the 5' end of the Fbxw7a and F b x w 7 ~ ~
cDNA. Reverse primers were designed to add an XbaI restriction digest site. To 
generate truncation mutants in which the entire N terminus (encoding the Fbox) 
was truncated, forward primers were generated that annealed to beginning of the 
WD40 repeats. This primer contained an EcoR 1 restriction site. To generate 
truncation mutants of Fbxw7a1 ~ ~ which do not contain WD40 repeats (only N 
terminus and Fbox) reverse primers were made that annealed before the DNA that 
encodes the WD40 repeats. These reverse primers contained a stop codon and an 
XbaI site. PCR was performed using primer pairs detailed in table 2.1 to generate 
DNA inserts. The PCR amplified inserts was then purified and restriction digested 
with EcoR 1 and XbaI to generate compatible ends. This digested DNA was then 
purified. Two Ilg of the pCMV5 plasmid (containing the HA tag) was restriction 
digested with EcoRI and XbaI, followed by purifications. The DNA inserts were 
then ligated together according to section 2.1.7. Five positive clones were selected 
for each construct and subjected to colony PCR (2.1.2) with pCMV5 being used 
as a negative control and pDEST27-Fbxw7et and p D E S T 2 7 - F b x w 7 ~ ~ being used 
as positive controls. Clones that contained the Fbxw7 inserts were grown in 10 
mL LB AMP overnight. Mini-preps of the cultures were carried out, with the 
DNA being sent for sequencing to check the identity of the clones. 
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Vector 
pcDNA3.1+ 
pcDNA3.1+ Mouse IRF-l WT 
pcDNA3.1+ Mouse IRF-l T180A 
pcDNA3.1+ Mouse IRF-l S184A 
pcDNA3.1+ Mouse IRF-l T180A/S184A 
pcDNA3.1+ Mouse IRF-l T180D 
pcDNA3.1+ Mouse IRF-l S184E 
pCMV-3XFLAG 
pCMV-3XFLAG Mouse IRF-l WT 
pCMV-3XFLAG Mouse IRF-l T180A 
pCMV-3XFLAG Mouse IRF-l S184A 
pCMV-3XFLAG Mouse IRF-l T180A/S184A 
pCMV-3XFLAG Mouse IRF-l T180D 
pCMV-3XFLAG Mouse IRF-l S184E 
pCMV-3XFLAG Mouse IRF-l K233R 
pCMV-3XFLAG Mouse IRF-l K240R 
pCMV-3XFLAG Mouse IRF-l K255R 
pCMV-3XFLAG Mouse IRF-l K276R 
pCMV-3XFLAG Mouse IRF-l K300R 
pCMV-3XFLAG Mouse IRF-l K276R/K300R 
pCMV-3XFLAG Mouse IRF-l K240R/K255R 
pCMV-3XFLAG Mouse IRF-l K255R/K276R/K300R 
pCMV-3XFLAG Mouse IRF-l 
K240R/K255R/K276R/K300R 
pCMV-3XFLAG-HA 
pCMV-3XFLAG-HA Mouse IRF-l WT 
peYFP-Cl 
peYFP-Cl Mouse IRF-l WT 
peYFP-Cl Mouse IRF-l T180A 
peYFP-Cl Mouse IRF-l S184A 
peYFP-Cl Mouse IRF-l T180A/S184A 
peYFP-Cl Mouse IRF-l T180D 
peYFP-Cl Mouse IRF-l S184E 
pcDNA6-TetR 
pcDNA4-TO 
pcDNA4-TO Mouse IRF-l WT 
pcDNA4-TO Mouse IRF-l T180A 
pcDNA4-TO Mouse IRF-l T180A/S184A 
pGEX4T1 
pGEX4T1 Mouse IRF-l WT 
pDEST27 GST 
pDEST27 GST-Fbxw7a 
pDEST27 GST-Fbxw7f3 
pDEST27 GST -Fbxw7y 
pCMV5-HA 
pCMV-HA Fbxw7a 
pCMV-HA Fbxw7J3 
pCMV-HA 6WD40-Fbxw7a 
pCMV-HA 6WD40-Fbxw7J3 
Name 
pcDNA3 
IRF-l WT 
IRF-l T180A 
IRF-l S184A 
IRF-l TS-A 
IRF-l T180D 
IRF-l S184E 
FLAG 
FLAG - IRF-l WT 
FLAG - IRF-l T180A 
FLAG - IRF-l S184A 
FLAG - IRF-l TS-A 
FLAG - IRF-l T180D 
FLAG - IRF-l S184E 
FLAG - IRF-l K233R 
FLAG - IRF-l K240R 
FLAG - IRF-l K255R 
FLAG - IRF-l K276R 
FLAG - IRF-l K300R 
FLAG - IRF-l K276/300R 
FLAG - IRF-l K240/255R 
FLAG - IRF-l 3KR 
FLAG - IRF-14KR 
FHA 
FHA-IRF-l 
eYFP 
eYFP IRF-l WT 
eYFP IRF-l T180A 
eYFP IRF-l S184A 
eYFP IRF-l TS-A 
eYFP IRF-l T180D 
eYFP IRF-l S184E 
TetR 
pcDNA4-TO 
pcDNA4- IRF-l WT 
pcDNA4- IRFl T180A 
pcDNA4- IRFl TS-A 
GST 
GST-IRF-l WT 
GST 
GST-Fbxw7a 
GST-Fbxw7f3 
GST-Fbxw7y 
HA 
HA-Fbxw7a 
HA-Fbxw7J3 
HA-6WD40-Fbxw7a 
HA-6WD40-Fbxw7J3 
Originator 
Invitrogen 
Keiko Ozato, USA 
This study 
This study 
This study 
This study 
This study 
Sigma Aldrich 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
J. Xicluna 
J. Xicluna 
Clontech 
This study 
This study 
This study 
This study 
This study 
This study 
Invitrogen 
Invitrogen 
This study 
This study 
This study 
GE Healthcare 
This study 
Invitrogen 
J Wade Harper, USA 
J Wade Harper, USA 
J Wade Harper, USA 
GS. Winkler 
This study 
This study 
This study 
This study 
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Vector 
pCMV-HA-ubiquitin 
pCMV-FLAG-ubiquitin 
p c D N A - G S K 3 ~ - H A A WT 
p c D N A - G S K 3 ~ - H A A K85A 
p c D N A - G S K 3 ~ - H A A S9A 
p c D N A - G S K 3 ~ - H A A R96A 
p220-TRAll-luc 
p4XIRFl/H4 site II -luc 
pcDNA4-TO-lUC 
pCHllO 
Name 
HA-ubiquitin 
FLAG-ubiquitin 
G S K 3 ~ - H A A WT 
G S K 3 ~ - H A A K85A 
G S K 3 ~ - H A A WT S9A 
G S K 3 ~ - H A A WT R96A 
TRAllluc 
4XISRE-luc 
TET-OFF luc 
CMV- ~ G A l l
Originator 
Carol Prives, USA 
Carol Prives, USA 
Jim Woodgett, Canada 
Jim Woodgett,Canada 
Jim Woodgett,Canada 
Gail Johnson, USA 
Nicole Clarke 
Gary Stein, USA 
Invitrogen 
Pharmacia 
Table 2.2. Plasmid used in this study. Both the full names and abbreviated 
names used in this study are indicated. 
2.2.1. HEK293 cells 
Human Embryonic Kidney 293 (HEK293) cell lines are human embryonic kidney 
cells that were transformed with adenovirus 5 DNA. HEK293 cells were 
maintained in DMEM (Dulbecco's Modified Eagles Media) containing 10% FBS, 
50 U/mL Penicillin-Streptomycin and 2 mM L-Glutamine. HEK293 cells were 
sub-cultured every 4 days to prevent their confluence from exceeding 80%. For 
sub-culture, cells were gently agitated by pipetting to remove from the plate and 
produce a single cell suspension. The cells were re-suspended in new media at a 
1 : 1 0 ratio and maintained at 37°C, 5% C02 with humidity. 
2.2.2. COS-7 cells 
African Green Monkey kidney cells (COS-7) cells are monkey kidney fibroblast 
cells transformed with the SV 40 virus. COS-7 cells were maintained in the same 
conditions as HEK293 cells with the exception that they required trypsinisation. 
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This was carried out by removing the media, followed by 2x washes with pre-
warmed 1 X PBS. For 10 em plates I mL of 0.25% trypsin EDT A (Invitrogen) was 
added to the plate. The plate was then gently rocked to ensure full coverage of 
trypsin before being placed at 37°C for 3 minutes. The trypsinisation was stopped 
by the addition of 9 mL of DMEM media. The media/cell mix was gently pipetted 
to break up any clumps of cells. COS-7 cells were diluted 1: 10. Sub-culture of 
COS-7 was required every 4 days. 
2.2.3. MRC-5 cells 
MRC-5 cells are human foetal lung fibroblast cells. They have not been 
transformed so undergo limited population doublings before succumbing to 
senescence. Typically MRC-5 cells were only used for 15 passages before being 
replaced with new cells. MRC-5 cells were maintained in a-MEM (alpha 
Modified Essential Medium). The media was supplemented with 50 U/mL 
Penicillin-Streptomycin, 2 mM L-glutamine and 10% FBS (specially selected for 
primary fibroblasts -P AA). MRC-5 cells were sub cultured every 3 days using 
trypsinisation as for HEK293 and COS-7 cells. MRC-5 cells were diluted at a 
dilution of 1 :5. 
2.2.4. 83396 cells 
The H3396 cell line is a human breast carcinoma cell line established by Bristol-
Myers Squibb (Seattle USA). The H3396 cell line is not commercially available 
and was used under a Material Transfer Agreement issued to Dr Nicole Clarke. 
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The H3396 cell line expresses endogenous IRF-l which is inducible by a number 
of stimuli, including retinoids and interferons. The H3396 cell line has previously 
been used as a model for IRF-l dependent cell death (Clarke et al. 2004) and 
(Frontini et al. 2009). H3396 cells were maintained in RPMI 1640 (Roswell Park 
Memorial Institute) media supplemented with 10% FBS, 2 mM L-glutamine and 
50 U/mL penicillin-streptomycin. Sub-culture of H3396 cells was carried out as 
for MRC-5 cells. 
2.2.5. Cell counting. 
Counting was carried out on cells diluted 1: 1 in trypan blue stain (Autogen 
Bioclear). 20 ilL of stained cells were counted on a Neubauer improved 
haemocytometer. Cell count in a single central square (0.1 mm2) was multiplied 
by two (to account for 1:1 dilution in trypan blue), then 10,000 to obtain a 
measure of cells per mL3. 
2.2.6. Cryo preservation of cell lines 
Cells are trpsinised as for sub-culture, with the exception, that after 1 minute the 
trypsin was removed and the plate was returned to the incubator. The cells were 
then re-suspended in the appropriate media - 2 mL for a 10 cm dish, counted (see 
section 2.2.5) and diluted to the appropriate concentration. 900 ilL of cell 
suspension was transferred to labelled cryovials containing 100 ilL of DMSO. 
The DMSO cell suspension was then gently pipetted to ensure an even mixing of 
DMSO and media. The vials were then transferred to a -20°C freezer until the 
110 
Post Translational Regulation of the Tumour Suppressor IRF-l 
vials were frozen solid. The cryovials are then placed at -80°C overnight, after 
which the vials are stored in liquid nitrogen. 
2.2.7. Culturing cells from frozen stocks 
Prior to recovery of cryovials from liquid nitrogen, 10 mL of the appropriate 
media was added to a 10 cm cell culture plate (TPP) and returned to the incubator 
to warm the media. Cryovials containing frozen cells were thawed at 37°C for 
approximately 1 minute. The cells were transferred to the pre-warmed media and 
returned to the incubator. Six hours after the cells were plated; the media was 
replaced with fresh media. This is to remove dead and un-attached cells and the 
small volume of DMSO from the frozen cells. The media was then changed again 
24 hours after the cells were plated to remove dead cells. Cells were left for at 
least 7 days prior to be used for any experiments. For Cos7 reporters, cells were 
left for 14 days prior to use. 
2.2.8. Generation of stable cell lines. 
The breast cancer cell line H3396 was chosen as a model system for over-
expression of IRF-l and IRF-I phosphorylation mutants. This H3396 cell line 
offers the benefit that it has been previously described to be sensitive to IRF-l 
dependent apoptosis (Clarke et al. 2004). Transient transfections are problematic 
in this cell line however, as they are prone to undergo cell death after transfection. 
This poses potential problems in studying the ability of IRF-l to promote 
apoptosis. An alternative to transient transfections was pursued in which the 
murine IRF-l gene and its phosphorylation mutants were stably integrated into the 
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H3396 genome. Constitutive over-expression of IRF-I in cell lines is difficult 
given IRF-I's pro-apoptotic activity, as such an inducible system was used, in 
which IRF-I expression could be "switched on" by the addition of doxycline 
(dox). Prior to integration of the IRF-I gene, the gene for the tetracycline 
Repressor (TetR) was integrated. The TetR protein (which is produced from a 
constitutive viral promoter) binds TetR binding sites in DNA and silences 
expression of adjacent genes (Invitrogen). The IRF-I gene inserted into the H3396 
cells is under the control of a promoter containing these binding sites. As such the 
high levels of TetR in the cells are able to repress the expression of IRF-1. 
Addition of dox causes a confonnational change in the TetR protein, which 
prevents it from repressing the target gene (in this case IRF -I) which in tum leads 
to large levels of IRF-I protein expression. The individual steps for generating the 
stable cell lines are explained below. 
2.2.9. Blasticidin response curve 
H3396 cells were plated on six well dishes in RPMI containing blasticidin 
(Mel ford UK) between 3 and 15 IlgimL. Media was changed after 48 hours. 96 
hours post treatment cells were trypsined and counted by trypan blue staining 
(2.2.5). The optimum concentration as which blasticidin prevented any cell 
growth was 8 IlgimL. 
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2.2.10. Transfection of TetR into "3396 cells. 
Low passage H3396 cells were plated at 5% confluency on two 10 cm cell culture 
dishes in RPMI medium. One day later the cells were transfected with 2.5 ).lg of 
pcDNA6-TetR (Invitrogen, Paisley UK). The transfection procedure was the same 
as used in section 2.3.1. Forty eight hours post transfection, the H3396 cells were 
split 1:5 onto new 10 cm plates. The RPMI media was supplemented with 
8).lglmL blasticidin to begin selection of positive clones. Due to the ability of 
H3396 cells to grow in extremely tight islands it was important to keep them at 
low density during the initial stages of transfection. Media was changed every 48 
hours to maintain high levels of blasticidin and remove dead or dying cells. 
Significant cell death occurred approximately 5 days post addition ofblasticidin. 
2.2.11. Selection and testing of TetR expressing cells. 
Two weeks post selection individual colonies of cells were large enough for 
transfer into 96 well plates. Clones were scraped from the original 10 cm plate 
and pipetted vigorously into wells (96 well plate) containing 100 J.lL ofblasticidin 
containing RPMI. The disaggregation of the clones was essential as intact clumps 
of cells do not survive the transfer procedure. In total sixty two clones were 
isolated. Approximately 50% of the clones survived the transfer to the 96 well 
plates. Typically the clones required 5-7 days of growth before they could be 
transferred to twelve well plates. Rather than physically removing the cells, each 
clone was transferred by trypsin disaggregation. A total of twenty four clones 
were transferred onto twelve well plates, with each well containing 1 mL of 8 
).lglmL blasticidin supplemented RPM!. The cells were grown in twelve well 
plates for 1 week. Each clone was then split into two wells of a 6 cm dish. Upon 
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reaching 80% confluence, cells were scraped from one of the two wells and 
protein extracts were made using Whole cell extraction buffer (50 mM Tris-HCI 
(pH 8.0), 420 mM NaCl, I mM EDT A, 0.2% NP40. Supplemented with I mM 
OTT, 10 mM NaF, Ix complete protease inhibitor I mM PMSF, I mM Na3V03 
and 10 mM POP - see section 2.4.1. Immunoblot were carried out on the clone 
lysates against the TetR antibody and p-actin as a loading control. Of the eleven 
clones tested all expressed the TetR protein, although there was wide variation in 
the levels of expression The remaining cells in the six well plate were transferred 
onto 10 cm plates and allowed to grow for an additional 5 days. The clones that 
expressed lower levels of TetR were frozen once they had reached 80% 
confluence on the 10 cm plates (E 11, C08, and G02). The remaining clones were 
further expanded by transferring onto 5x 10cm plates of each. 
To confinn the activity of the TetR, four clones (C06, D04, E04 and E08) were 
each seeded on twelve well plates (six wells per clone). Twenty Four hours post 
seeding cells were transfected with 50 J..lg or 100 J..lg per well ofpcDNA4-TO-Luc 
(Invitrogen, Paisley UK), and lOng/well of a P-OAL expression vector (to serve 
as a transfection control). The transfection was carried out for 24 hours, after 
which media was replaced with either RPMI (+ blasticidin) or RPMI with I 
J..lg/mL dox (+ blasticidin). Luciferase reporter assays were carried out 24 hours 
later (see section 2.3.3.). The pcDNA4-TO-Luc plasmid contains the Luciferase 
gene under transcriptional control of the CMV promoter and TetR binding sites. 
Presence of the TetR protein in the cells causes a repression of Luciferase 
expression, which can then in be relieved by addition of dox. The clone exhibiting 
the highest level of de-repression was chosen as the background for the inducible 
cell lines. Clone E04 was expanded and frozen for future use. 
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2.2.12. Zeocin response Curve. 
As for the blasticidin, a kill curve of zeocin (the selection marker for pcDNA4-
TO-IRF-I expression) was employed to determine the optimum concentration 
required for selection of positive clones. A concentration range between 50 and 
400 )lglmL was used. The cells were counted as in section 2.2.5. Zeocin was 
purchased from Invivogen. 
2.2.13. Transfection of pcDNA4-IRF-l into TetR expressing cells. 
H3396-E08 cells were plated at 5% on 10 cm plates in RPMI media supplemented 
with Tet-free FBS (PAA) and blasticidin for 24 hours. The H3396-E08 cells were 
then transfected with 2.5 )lg of empty vector, pcDNA4-TO wild type, Tl80A or 
TS-A IRF-I for 48 hours. Each plate was then sub-cultured onto 3x 10 cm plates 
in media containing 200 )lg/mL zeocin. Two days later the media was changed to 
remove dead cells. Large levels of cell death occurred within 5 days of zeocin 
treatment. 
2.2.14. Selection and testing of inducible cell lines. 
Seven days after zeocin selection individual clones were large enough for 
selection onto 96 well plates. Scraping cells was carried out exactly as for the 
TetR cell lines. Between 70 and 90 clones of each cell line (vector, wild type, 
T180A, TS-A) were expanded on the 96 well plates. The most vigorous clones 
were then transferred onto twelve well plates as before. Another week of selection 
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was then required prior to clones being divided evenly onto three wells of twelve 
well plates. Upon reaching 75% confluence 1 well from each clone was treated 
with 2 IlglmL of dox for 24 hours, while another well was treated with blank 
media for the same time period. Lysates were then made and immunoblotted with 
IRF-I (M-20) Ab and p-actin as a loading control (see section 2.4.1). For the most 
promising clones, the remaining cells in the twelve well plates were re-seeded on 
6cm dishes for approximately 5 days, and then transferred to 10 cm plates. Once 
the cells reached 80% confluence half of the cells were frozen, while the 
remaining cells were split onto a 10 cm plate and two wells on a twelve well plate. 
To check that the selected clones were re-producible in their expression of IRF-l 
the cells were induced as before and protein lysates made and immunoblotted. 13 
clones were re-tested, the majority of which produced a reproducible induction of 
IRF-l. Each of these clones was then expanded on 15 cm plates, grown for an 
additional week, and frozen to provide a large number of aliquots of cells at the 
same passage. 
2.3.1. Transient transfections 
Transient transfections were carried out using 1 mglmL PEl (Polyethylene Imine). 
4 ilL of PEl was used per Ilg of DNA transfected. Typically for a 10 cm plate no 
more than 10 Ilg of DNA was used for transfection. DNA was diluted in a total of 
500 ilL of media (without FBS) followed by addition of the PEl. The samples 
were then briefly vortexed and allowed to stand at room temperature for 20 
minutes in order for DNA:PEI complexes to fonn. The DNA: PEl mixture was 
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then added directly to the cells. The low toxicity of PEl does not necessitate the 
changing of media after transfection. 
2.3.2. Small interfering RNA transfections 
G S K 3 ~ ~ mRNA was depleted using small interfering RNA duplexes from 
QIAGEN (Hs_GSK3B_8_HP Validates siRNA). A control siRNA which does not 
target any human mRNA was used as a negative control (AllStars Negative 
Control siRNA QIAGEN). Prior to use in reporter assays the knockdown 
efficiency was optimized so at least 60% of GSK313 protein was depleted. A 
titration of siRNA duplexes between 5 and 20 nM was used, in addition to a 
number of concentrations of the INTERferin transfection reagent. Additionally 
length of transfection and cell density required optimization. Knockdown was 
carried out in MRC-5 cells seeded on twelve well plates for 24 hours. siRNA 
duplexes were diluted in re-suspension buffer (QIAGEN) then further diluted in 
FBS free aM EM media with 1.5 J.tL per well INTERferin transfection reagent 
(Polyplus). The solution was then vortexed for 10 seconds, followed by 
incubation for 10 minutes at room temperature. 100 J.tL of media containing 
siRNA's was added per well, with each well containing 900 J.tl of fresh media 
(containing FBS). The final concentration of siRNA in each well was 5 nM. 16 
hours post transfection the media was removed and replaced with fresh media. Six 
hours later the cells were transfected for reporter assays. Each well was 
transfected with 125 ng of TRAIL promoter reporter, 20 ng BGAL internal control 
plasmid and 100 ng of pcDNA3.l IRF-l or pcDNA3.1. Transfections were carried 
out for 24 hours. Cells were lysed and assayed according to (2.3.3). 
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2.3.3. Luciferase reporter assays 
Unless stated otherwise all reporter assays were carried out in COS-7 cells. Cells 
were seeded at 0.03 xl 06 in DMEM media for 24 hours in 24 well plates. 
Transfections were carried out using PEl (see section 2.3.1). Per well, cells were 
transfected with 50 ng of IRF-I expression plasmid, 75 ng of reporter plasmid 
(either TRAIL promoter or 4X ISRE reporter) and 5 ng of ~ G A L L internal control 
plasmid. The total amount of DNA per well was bought up to 250 ng with the 
addition of sheared salmon sperm DNA. DNA was diluted in DMEM media 
without FBS (but containing penicillin-streptomycin and L-glutamine) prior to the 
addition of PEL The samples were briefly vortexed followed by incubation for 20 
minutes prior to being added to well containing cells (in I mL DMEM). Per well 
50 ~ L L of DNA/media was added. Media was changed 16 hours post transfection. 
The cells were lysed 48 hours post transfection. Lysis was carried out essentially 
according to manufacturer's instructions (Applied Biosystems). Media was 
removed from the wells followed by two washes with IX PBS at 0.5 mL per well. 
For twenty four well plates, 50 ~ L L of lysis buffer was added per well, while 100 
~ L L was used for twelve well plates. The plates were placed at -80°C to snap 
freeze the lysates. Plates could be stored at this point until ready for the reporter 
assay. The plates were de-frozen at 4°C, using a pipette tip; the remaining cells 
attached to the plate were scraped into the lysis solution, and transferred to 
microfuge tubes. The tubes were centrifuged at 6,000 rpm for 10 minutes to pellet 
any cell debris. The reporter assays were carried out in white walled 96 well 
plates (Nunc). Per well 10 f..lL of buffer A was added, followed by 5 ~ L L of protein 
lysates. The assay was carried out according to manufacturer's instruction from 
here on. Luminescence was detected on a Berthold Orion micro-plate 
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Luminometer. For analysis, each Luciferase value was corrected to the pGAL 
value. The pGAL dependent luminescence served as both a transfection control 
and a loading control for the assay. These values were expressed as RLU 
(Relative Luciferase Units). IRF-l dependent transactivation of the reporter 
constructs was expressed as a fold change between cells expressing IRF-I and 
those transfected with the appropriate empty vector. This was required as some 
cellular factors were able to produce a basal activity on the Luciferase reporters. 
For GSK3 inhibitor treatments, the inhibitors were added to the wells containing 
fresh media, following the 16 hours media change. Inhibitors which required 
dilution in DMSO were diluted so that the final concentration of DMSO was 
consistent (0.01 %) rather than serial dilution in media. Inhibitors were added to 
wells transfected with either IRF-l or vector, and for each treatment the fold was 
determined between these two. This allowed for compensation for any effects the 
inhibitors may have on background Luciferase expression. For determining the 
knockdown efficiency of GSK3p, 20 Ilgllane of reporter extracts were 
immunoblotted. However, as IRF-l is a highly unstable protein and low 
concentrations were used in the reporter assays, detection by immunoblot was 
problematic and high concentrations of protein extracts were required for 
detection. An alternative method of cell lysis was used in which parallel wells 
were lysed directly with 4 X Lamelli buffer (SOO mM Tris-HCI (pH 6.8), 10% 
SDS, O.S% Bromophenol blue, SO% glycerol and 100 mM DTT) that had been 
pre-heated at 100CC for S minutes. The resulting lysates were scraped from the 
wells and centrifuged at 12,000 rpm for 10 minutes to remove insoluble debris. 
The entire extract for each well was then added per lane for immunoblot. 
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2.4.1. Preparation of whole cell extracts. 
Media was removed from the plate, followed by a single wash in 1 x PBS to 
remove any remaining media. For a 10 cm plate ImL of Ix PBS was used to re-
suspend the cell pellet. HEK293 cells required gentle pi petting to remove them 
from the surface of the plate, while more adherent cells (Cos7, H3396 and MRC-
5) required scraping with cell scrapers. The cell suspension was collected in a 
microfuge tube. The cells were pelleted by centrifugation at 1000 rpm at 4°C for 5 
minutes. The 1 x PBS was removed from the pellet. Typically for a 10 cm plate of 
90% confluent cells 1 mL of WCE buffer was used to make cell extracts between 
2-4 J..lglmL, although when more concentrated extracts were required half this 
volume could be used. The cell pellets were then gently re-suspended in the WCE 
buffer (50 mM Tris-HCI (pH 8.0), 42 OmM NaCI, 1 mM EDTA, 0.2% NP40. 
Supplemented with 1 mM DTT, 10 mM NaF, Ix complete protease inhibitor, 1 
mM PM SF, 1 mM Na3V03 and 10 mM ~ G P ) ) until a homogenous mixture was 
produced. When volumes of 500 J..lL or higher were used the cells were snap 
frozen in liquid nitrogen, then thawed in slushy ice water. This freeze fracturing 
was repeated 3x. Where sample volume was smaller (such as CHX chases or the 
testing of stable cell lines) the samples were placed in a _80°C freezer to snap 
freeze them. Once the extracts were completely thawed (on ice) they were 
centrifuged at 12,000 rpm for 20 minutes at 4°C. The clarified extracts were 
transferred to fresh tubes and frozen at -80°C. 
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2.4.2. Preparation of RIP A extracts. 
Protein extracts that were used for immunoprecipitations were made using RIPA 
(Radioimmunoprecipitation Assay) buffer rather than WCE buffer. Plates were 
prepared in the same manner as for WCE extracts except ImL (for IOcm plates) 
of RIP A buffer (50 mM Tris-HCI (pH 7.5),150 mM NaCI, 1% NP40, 0.1% SDS, 
0.5% sodium deoxycholate and 1 mM EDT A. Supplemented with 1 mM DTT, 10 
mM NaF, Ix complete protease inhibitor, 1 mM PMSF, 100 mM NEM, 1 mM 
Na3 V03 and 10 mM POP) was left on the plate for 5 minutes at 4°C. The resulting 
cell / RIP A mix was then scraped into 1.5 mL centrifuge tubes and left on ice for 
20 minutes. The cell / RIPA mix was then vigorously pipetted 10 times before the 
cells were centrifuged at 12,000 rpm for 20 minutes at 4°C. The extracts were 
then transferred to clean tubes and frozen at -80°C. 
2.4.3. Preparation of NP40 extracts 
For OST-Fbox co-immunoprecipitations extracts were made in NP40 lysis buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 0.5% NP40 and phosphatase/protease 
inhibitors). The extracts were made essentially as for WCE extracts, but with 
NP40 buffer being used instead. 
2.4.4. Preparation of in vivo ubiguitination assay extracts 
HEK293 cells were transfected with expression plasmids for HA-ubiquitin 
(human) at 2.5 J.lg and FLAG IRF-I (mouse) at 2.5 J.lg on a IOcm plate (see 2.3.1). 
Cells were incubated for 40 hours before addition of MG 132 at 10 J.lM for 5 
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hours. Duplicate transfected plates were treated with DMSO as vehicle control. 
The total amount of DMSO in medium was 0.01%. Extracts were made by 
scraping the HEK293 cells in 1 mL of 1 X PBS. Samples were collected in 
microfuge tubes and centrifuged at 1300 rpm for 5 minutes at room temperature. 
The PBS was aspirated from the cell pellets. The cell pellets were snap frozen at -
80°C. Samples were then thawed, for each pellet I mL of ubiquitination assay 
buffer (10 mM Tris-HCI (pH 7.8), 150 mM NaCI, 1% SOS and 1 mM EDT A. 
Supplemented with I mM OTT, 10 mM NaF, Ix complete protease inhibitor I 
mM PMSF, 100 mM NEM, I mM Na3V03 and 10 mM pap) was added, 
followed by quick disaggregation of the cell pellet. Extracts were boiled at 100°C 
for 10 minutes. The denatured extracts were clarified by centrifugation at 13000 
rpm for 30 minutes at 4°C. Extracts were transferred to clean tubes and stored at -
80°C. For determination of protein content, extracts were diluted lOx in lOmM 
Tris pH 8 due to the high levels of SDS interfering with the Bradford assay. 
2.4.5. Protein assay 
Protein assays were carried out according to the manufacturer's instructions using 
the BIORAO Bradford protein assay (BIORAD). A standard curve of BSA 
protein ranging from 2 to 10 J..lglmL was used for calibration. Absorbance was 
detected using an Eppendorf spectrophotometer (Eppendorf). 
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2.4_6 In vitro transcription and translation. 
In vitro transcription and translation was carried out usmg the TnT Rabbit 
Reticulocyte lysates kit (Promega). Fbxw7a was in vitro transcribed and 
translated from a PCR product rather than the plasmid, as pCMV -HA does not 
contain the required T7 promoter. The PCR product contained a T7 binding site 
and a Kozak sequence and was designed using the recommended parameters set 
out by Promega. The primer sequence and PCR conditions can be found in table 
2.1. For a 50 ilL reaction mix, the following was used, 1 Ilg PCR template, 2 ilL 
TnT reaction mix (lOX), 1 ilL amino acid mix (without methionine), 1 ilL RNasin 
ribonuclease inhibitor (Invitrogen), 1 ilL T7 Polymerase, 25 ilL of Rabbit 
reticulocyte lysate and 1 ilL e5S] methionine (1 mM) at 1000 Ci/Ilmol (GE 
Healthcare). The reaction was incubated at 30°C for 90 minutes. A 1 ilL aliquot 
was run on a SDS PAGE gel for quantification. 
2.4.7. Separation of proteins on SDS PAGE gels 
Proteins were separated on SOS-PAGE gels using the Tetra System (Biorad). 
Typically PAGE gels using 8% acrylamide were used as these allow good 
separation ofIRF-l (50 kOa) and J3-actin (37 kDa). 1 mm gels with 15 wells were 
cast according to manufacturer's instructions. Protein extracts were prepared in 
Lamelli buffer supplemented with 100 mM OTT (500 mM Tris-Hel (pH 6.8), 
10% SDS, 0.5% Bromophenol blue, 50% glycerol} to a final concentration of 1 x. 
Typical protein concentrations used were between 10 and 25 Ilg. higher 
concentrations of protein extract result in the ~ - a c t i n n being over-loaded making 
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densitometry problematic. Protein extracts were boiled for 5 minutes, followed by 
centrifugation at 12,000 rpm for 30 seconds. A protein pre-stained 250-10 kDa 
ladder (BIORAO) was used to determine the progress of the electrophoresis as 
well as act as a molecular weight marker and indicator of transfer. For 15 well 
gels 5 ilL was used per lane, while 8 ilL was used for lOwell gels. SDS-P AGE 
gels were subjected to electrophoresis at 100 V in 1 X TGS (25 mM Tris, 200 mM 
Glycine, 3.5 mM SOS) typically for 90 minutes. 
2.4.8. Coomassie brilliant blue staining 
To determine induction ofGST-IRF-1 proteins coomassie staining was employed. 
Gels were stained in coomassie stain (10% acetic acid, 40% methanol and 0.25% 
coomassie blue R250) for 20 minutes with gently rocking followed by de-staining 
overnight with de-stain solution (10% acetic acid and 40% methanoL). 
2.4.9. Transfer to nitrocellulose membrane. 
After electrophoresis gels were removed from the plates by cutting away the 
stacking gel and gently lifting using a piece of blotting paper. Transfer was 
performed using the Tetra system (BIORAO). Protein was transferred onto 0.45 
Ilm nitrocellulose (BIORAD) using Transfer buffer (39 mM glycine, 48 mM Tris 
0.037% SDS 20% methanol (v/v) pH 8.3). Typically the transfer was carried out 
at 300 mAmps for 60 minutes at 4°C. To ascertain if transfer has been successful 
the membrane is stained with Ponceu S stain (Sigma Aldrich) for 2 minutes at 
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room temperature with gentle rocking. Excess stain was then removed using 
ddH 20 until clear pink bands can be visualised. 
2.4.10. Blocking 
After continnation of successful transfer, nitrocellulose membranes were blocked 
with a solution containing 5% milk in 1 X PBS. Blocking was carried out at room 
temperature for 30 minutes with gentle rocking. When the c-Myc phospho 
Thr62/Ser6o antibody was used, blocking was carried out with BlottoB (1 % milk, 
1 % BSA, 0.05% Tween-20, 1 mM NaF, and 1 mM I3GP and 0.1 ~ L l m L L
phosphatase inhibitor cocktail in TBS) rather than 5% milk. This blocking was 
carried out in the same manner as for the 5% milk but was left for 90 minutes. 
2.4.11. Immunoblot 
Immunoblots were carried out in 50 mL tubes containing 5 mL of indicated 
antibody with gentle mixing. The conditions for each antibody are detailed in 
table 2.2. Following incubation with primary antibody, the blots were washed 
with IX TBST (10 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.05% Tween-20) 
for 10 minutes three times. The secondary antibody was then incubated in 50 mL 
tubes as for the primary antibody. Blots were incubated with secondary antibody 
for 1 hour at room temperature. The blots were then washed 3x in IX TBST - the 
final wash being carried out with TBS (no TWEEN-20). The chemilumiscence 
reaction was carried out by preparing ECL reagent (see table) without Hydrogen 
Peroxide. The blots were gentle tapped on paper towel to remove any remaining 
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TBS, then placed flat on saran wrap. Hydrogen Peroxide was then added to the 
ECL reagent, which was then placed on the blot for 2 minutes (ECL reagent 0.2 
mM p-coumaric acid 1.25 mM luminol in 0.1 M Tris pH 8.5, 0.009% hydrogen 
peroxide). For a 6x4 inch blot 5 mL of ECL reagent was used. After 2 minutes of 
incubation at room temperature, the ECL reagent was gentle tapped from the blot, 
which was the wrapped in a single layer of saran wrap. Chemilumiscence was 
detected using a Fujifilm LAS-4000. If further antibodies were to be incubated on 
the blot, washing for 10 minutes with 1 X TBST was carried out prior to the 
addition of new primary antibody. 
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Primary Antibodies 
Antibody Type Species Dilution Incubation Manufacturer 
conditions 
IRF-1 M20 Poly Rabbit 1:1000 (WB) 5% milk Santa Cruz 
IgG 1ug/ml (IP) 
IRF-1 C20 Poly Rabbit 1:1000 (WB) 5% milk Santa Cruz 
IgG 1ug/ml (IP) 
Phospho-c-Myc Poly Rabbit 1:1000 (WB) BlottoB Santa Cruz 
IgG 1ug/ml (IP) 
FLAG M2 Mono Mouse 1:2000 (WB) 5% milk Sigma-Aldrich 
0.2ug/ml (IP) 
HA 12CA5 Mono Mouse 1:1000 (WB) 5% milk In house 
0.5ug/ml (lP) 
~ - a c t i n n Mono Mouse 1:2000 (WB) 5% milk Sigma-Aldrich 
G S K 3 ~ ~ Poly Rabbit 1:2000 (WB) 5% milk CST 
GST Poly Rabbit 1:2000 (WB) 5% milk Sigma-Aldrich 
pT-P Mono Mouse 1:500 (WB) 5%BSA CST 
5ml/ mg extract (lP) 
Secondan: Antibodies 
Antibody Dilution Incubation Manufacturer 
conditions 
Goat anti Mouse IgG - HRP 1:5000 5% milk Santa Cruz 
Goat anti Mouse IgM - HRP 1:5000 5%BSA Santa Cruz 
Goat and Rabbit IgG - HRP 1:5000 5% milk Santa Cruz 
Mouse anti Rabbit Kappa light chain specific - HRP 1:5000 BlottoB Chemicon 
Table 2.2. Antibodies used in this study. Antibody concentration was 200/-lglmL 
for all Santa-Cruz antibodies. 
2.4.12. Stripping blots 
To remove primary antibody (for example when two similar sized proteins which 
the same secondary need to be immunoblotted) blots were stripped with a 
mercaptoethanol based stripping buffer (100 mM ~ - m e r c a p t o e t h a n o l l 2% (w/v) 
SDS 62.5 mM Tris pH 6.7). The blots were placed in a sealable container and 
covered with enough stripping buffer to cover the blot with approximately half a 
mL. The container was then sealed tightly and placed in a rocking incubator at 
65°C. After 30 minutes of incubation the stripping buffer was gently tipped away 
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in a fume hood. The blots were then washed with large amounts of ddH20 to 
remove any remaining stripping buffer. Blots were then re-probed with 5% milk. 
To determine if any secondary antibody remains on the blot, EeL detection was 
carried out on the blot. If any signal remains, the stripping was repeated. 
Otherwise primary antibody was added as per section 2.4.11. 
2.4.13. Densitometry 
Densitometry was performed using the Scion software package. 
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2.5.1. Immunoprecipitations 
The conditions of the various immunoprecipitations carried out are given in the 
table below. 
IP protein IPAb Protein being Beads Washes detected 
eYFP-IRF-l IRF-l M20 p-T/S 3x low salt RIPA ( S O O ~ g ) ) (Rabbit) (Rabbit) Protein A agarose buffer 
Phospho-IRF-l (p-T/S) 
p-T/S IRF-l M20 
2x low salt RIPA, 
( S O O ~ g ) ) Protein A agarose 3x high salt RIPA (Rabbit) (Rabbit) buffer 
FLAG-IRF-l FLAG M2 p-T/S 3x low salt RIPA ( S O O ~ g ) ) (Mouse) (Rabbit) Protein G agarose buffer 
Phospho-IRF-l (p-T/S) p-T/S IRF-l M20 2x low salt RIPA, ( S O O ~ g ) ) Protein G agarose 3x high salt RIPA (Rabbit) (Rabbit) buffer 
Phospho-IRF-l (p-TP) p-TP IRF-l M20 Mouse IgM 3x low salt RIPA (lmg) (Mouse) (Rabbit) agarose buffer 
FLAG-IRF-l 
FLAG M2 HA (GSK313- 3x low salt RIPA (lmg) (Mouse) HA) Protein G agarose buffer 
FLAG-IRF-l FLAG M2 HA (HA-(lmg) (Mouse) Fbxw7) Protein G agarose 3x TNE buffer 
GSK3(3 HA 12CAS FLAG M2 3x low salt RIPA (lmg) (Mouse) (IRF-l) Protein G agarose buffer 
HA-Fbxw7 HA 12CAS FLAG M2 (lmg) (Mouse) (IRF-l) Protein G agarose 3x TNE buffer 
Endogenous human 
Phospho-IRF-l (p-T/S) p-T/S IRF-l C20 Rabbit IgG agarose 3x low salt RIPA ( S O O ~ g ) ) (Rabbit) (Rabbit) buffer 
Endogenous human IRF- IRF-l C20 p-T/S Rabbit IgG agarose 3x low salt RIPA ( S O O ~ ) ) (Rabbit) (Rabbit) buffer 
Table 2.3. IP Conditions. Protein A Agarose was from Santa Cruz, Protein G 
Agarose from Millipore and Rabbit IgG Agarose from eBiosciences. 
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To IP 500 Ilg of protein, lysates were diluted in a total volume of 500 III of low 
salt RIPA buffer supplemented with inhibitors. Or, for co-IP with HA-Fbxw7 
NETN buffer supplemented with inhibitors. lysates were pre-cleared against 
proteins that non specifically interact with the IP beads. Pre-clearing was carried 
out by incubating 5 III packed volume of beads at 4°e with gently rocking for 30 
minutes. After pre-clearing the lysates were centrifuged to pellet the beads and 
removed to a new tube. Overnight at 4°e the lysates were incubated with the 
appropriate antibody, for antibody concentrations see table 2.2. The samples were 
then incubated for 3 hours with the appropriate BSA blocked beads at 4°e with 
gentle rocking. The samples were centrifuged at 3,000 rpm for 30 seconds, the 
protein lysates removed and the beads washed 3x with low salt RIP A buffer. The 
residual volume of buffer was removed using insulin syringes U-I00 (Beckton 
Dickinson) to leave a completely dry pellet, which was re-suspended in 20-30 III 
of 5X lamelli buffer supplemented with 100 nM DTT. The samples were boiled 
for 5 minutes at 1000 e and briefly centrifuged to settle the beads. The eluates 
were removed from the beads using U-I00 insulin syringes and placed in fresh 
tubes. The eluates were centrifuged at high speed for 30 seconds to remove any 
bubbles. The samples were subjected to western blot with the indicated 
antibodies. When phosphorylation was being detected, 81ottoB solution was used 
for blocking an addition of antibodies. Additionally wash steps were perfonned in 
the presence of phosphatase inhibitors. 
130 
Post Translational Regulation of the Tumour Suppressor IRF-l 
2.5.2. Co-immunoprecipitations 
Co-immunoprecipitations were carried out essentially as for section 2.2.1 protein 
extracts for co-immunoprecipitations were made using low salt RIPA. For co-
immunoprecipitation between FLAG-IRF-l and HA-GSK3!3, washes were carried 
out using low salt RIP A buffer, while co-immunoprecipitations between FLAG-
IRF-l and HA-Fbxw7 used TNE buffer (10 mM Tris (pH 7.4), I mM EDTA and 
200 mM NaCl. The buffer was supplemented with 1 mM DTT, 10 IlM NaF, Ix 
complete protease inhibitor (Roche), 1 mM PMSF, 100 mM NEM, 1 mM Na3V03 
and 10 mM !3GP). For all co-immunoprecipitations 1 mg of extract was used. 
2.5.3. In vivo ubiquitination assays 
500 Ilg of protein extract were diluted in 750 III of TNE buffer (10 mM Tris (pH 
7.4), 1 mM EDTA and 200 mM NaCl. Supplemented with 1 mM OTT, 10 IlM 
NaF, Ix complete protease inhibitor, 1 mM PMSF, 100 mM NEM, 1 mM Na3V03 
and 10 mM !3GP) and pre-cleared with 5 III (packed bead volume) of protein G 
agarose beads (Santa Cruz). Pre-clearing was carried out for 30 minutes at 4°C 
with gentle rocking. The protein extracts were centrifuged at 3,000 rpm for 1 
minute to pellet the protein G beads. The extracts were transferred to new 
microfuge tubes with 0.4 Ilg FLAG M2 antibody overnight at 4°C with gentle 
mixing. BSA blocked protein G beads were added to the extracts (5 III packed 
volume) for 3 hrs at 4°C with gentle mixing. Extracts were centrifuged at 3,000, 
4°C for 1 minute to pull down the protein G beads. The beads were washed 3 
times with TNE buffer supplemented with IX protease inhibitor cocktail (Roche). 
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Protein was eluted from the beads using 5x Lamelli buffer supplemented with 100 
mM DTT Beads were boiled with the Lamelli buffer for 6 minutes at lOO°e. 
Lamelli buffer containing eluted protein was drawn off the beads using U-IOO 
0.5mL insulin needles (Becton-Dickinson). Extracts were run on 8% SDS 
polyacrylamide gels, transferred to nitrocellulose, blocked for 30 minutes in 5% 
milk and blotted with anti HA antibody. Following immunoblot with HA 
antibody, FLAG antibody was used to determine immunoprecipitation of FLAG-
IRF-I. 
2.5.4. In vivo GST pull-downs 
500 J,tg of extracts containing transfected GST-Fbxw7 and FLAG-IRF-l were 
incubated with gentle rocking at 4°C in a total reaction mix of 500 J,tL with 1 0 ~ L L
(packed bead volume) of glutathione - sepharose beads (GSH beads) (GE 
Healthcare). The protein extracts were diluted in low salt NP40 buffer (50 mM 
Tris pH 7.5, 150 mM NaCI, 0.5% NP40 and phosphatase/protease inhibitors). The 
beads were incubated with the protein extract for 3 hours, after which the samples 
were centrifuged at 3,000 rpm for 30 seconds and washed with 500 ~ l l of low salt 
NP-40 buffer, followed by two washes with medium salt NP40 buffer and a 
further wash with low salt NP40 buffer. The samples were centrifuged and NP40 
buffer removed using a V-I00 insulin needle (8D) The beads were incubated at 
100°C for 6 minutes with 20 J,tL of 5x Lamelli buffer supplemented with 100 nM 
DTT. The protein eluates were then removed from the beads using a V-I00 and 
transferred to fresh tubes. The samples were centrifuged briefly and subjected to 
PAGE and western blot against FLAG and GST antibodies. 
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2.5.5. In vitro GST pUlldown assays. 
For in vitro GST pulldown assays between GST-IRF-l and e5S] Met labelled 
GSK3p or Fbxw7a approximately 1 f.lg of each protein was used. The GST-IRF-l 
conjugated GSH beads were diluted in 1 mL NETN buffer (20 mM Tris pH 8, 100 
mM NaCl, 1 mM EDT A, 0.5% NP40 and I x complete protease inhibitor 
cocktail). The IVT product was mixed with the beads overnight at 4°C on a 
rotating wheel. The beads were washed 3 times with NETN buffer before being 
dried in a speed-vac vacuum. The dried beads were re-suspended in 2x Lamelli 
buffer supplemented with 100 mM OTT. The eluates were then separated by 
SOS-PAGE for 45 minutes at 200 V. The gel was fixed in fixing solution (10% 
acetic acid 10% methanol) for 30 minutes before being treated with amplifier 
solution (Amersham) for 30 minutes with gentle rocking. The gels were then dried 
and exposed to film at -80°C. 
2.5.6. Cycloheximide time courses 
HEK293 cells were seeded on six well plates at O.3x I 06 in OM EM media and 
allowed to attach for 24 hours. The cells were then transfected with 2.5 f.lglwell of 
IRF-I plasmid. For transfections with more than one plasmid, GSK3p-HA was 
also transfected at 2.5 f.lglwell or empty plasmid. Transfections were carried out as 
in section 2.3.1. Twenty four hours post transfection cells were treated with 
Cycloheximide at 25 f.lglmL for the indicated time period. MRC-5 cells were 
seeded on 6cm dishes for the same period of time as for HEK293 cells. 4 Jlg of 
IRF -I plasmid was transfected in MRC-5 cells according to section 2.3.1. Cells 
were lysed according to section 2.4.1. Extracts were separated on 8% SOS 
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polyacrylamide gels at 15 f.!g!lane, transferred to nitrocellulose, blocked with 5% 
milk for 30 minutes and immunoblotted with the indicated antibodies. 
2.6.1. Small scale preparation of GST proteins 
To identify a bacterial clone that expressed high levels of the GST fused IRF-I 
protein, mini inductions were carried out as a screen. The GST constructs (1 f.!g) 
were transformed in chemically competent BL21 cells using the same protocol as 
for DH5a cells (see section). Five colonies of each construct were picked and 
grown in 2.5 mL of LB AMP for 2 hours with shaking. The cultures were then 
split into two 1 mL aliquots in microfuge tubes, with the remaining 500 f.!l being 
kept back to inoculate further cultures. To one of each clone, 25 f.!l of 20mM 
IPTG was added, while the same volume of water was added to the other half of 
the culture as a control. The BL21 cells were then grown for a further 2 hours at 
37°C with shaking. Bacteria were then centrifuged at 12,000 rpm for 60 seconds 
to form a pellet. The LB-AMP was aspirated, and the pellets were re-suspended in 
50 f.!l of 4X Lamelli loading dye. The pellets were then boiled for 5 minutes to 
denature the protein. 20 f.!l of the sample was loaded onto SDS polyacrylamide 
gels (8%) and separated by electrophoresis. The gels were then stained with 
Coomassie Brilliant Blue to determine GST protein induction. Clones that 
produced a high amount of GST fused IRF-l were then grown overnight in 5 mL 
ofLB AMP. 
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2.6.2. Medium scale preparation of GST proteins 
The 5 mL overnight culture was first inoculated into a 50 mL volume of LB AMP 
and grown for I hour at 37°C. IPTG was then added to the culture at a final 
concentration of 0.5 mM. The cultures were incubated for an additiona I 3 hours at 
37°C. The bacteria were then pelleted by centrifugation at 4,000 rpm for 5 
minutes, media was aspirated and the pellet was re-suspended in 5mL of NETN 
buffer (20 mM Tris pH 8, 100 mM NaCl, 1 mM EDT A, 0.5% NP40 and 1 x Roche 
complete protease inhibitor cocktail). The lysates was sonicated for 30 seconds 
and 20 seconds off three times at medium power with a Diagenode Bioruptor. The 
debris was centrifuged at 4,000 rpm at 4°C for 10 minutes. Glutathione sepharose 
beads (Amersham) were mixed at a 1: 1 ratio with NETN buffer and 0.5% milk. 
The slurry was centrifuged at 2,000 rpm for 2 minutes; supernatant was removed 
leaving a small volume on top of the packed beads. An equal amount of the 
NETN/milk solution was then added to the beads, and the washing was repeated 
twice more. On the last step the supernatant was not removed, but was used to 
make a 1: 1 slurry mixture which was added to the cleared bacteriallysates. In a 15 
ml tube 150 j..I.l of glutathione sepharose beads was mixed with the lysates and 
incubated on a rotating wheel at 4°C for 1 hour. Beads were span down at 2,000 
rpm, 4°C for 2 minutes, supernatant was removed and replaced with 5 mL of 
NETN buffer without milk. This wash step was repeated three times. GST fusion 
proteins were eluted from the beads using a glutathione elution buffer (20 mM 
Glutathione, 100 mM Tris-HCI pH 8 and 120 mM NaCl) which was added to the 
bead pellet (l mL of elution buffer per 0.25 mL of beads). The samples were then 
rotated at 4°C for 1 hour. Beads were then centrifuged at 13,000 rpm for 5 
minutes, the supernatant was transferred to a fresh tube and stored ready for 
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protein detennination usmg the Nanodrop according to manufacturer's 
instructions. Protein was then ali quoted into small volumes and stored at -80°C 
until ready to use. 
2.6.3. In vitro kinase assays 
Recombinant GSK3p (New England Biolabs) was diluted to 20 ng/J.-lL in the 
supplied kinase buffer and incubated with 4 J.-lg of GST-IRF-l. The final 
concentration of A TP was 250 J.-lM, which was supplemented with 0.16 J.-lCi of 
[yp32]_ATP (Becton Coulter) per reaction. The final reaction volume was 25 J.-lL in 
1 x kinase buffer. The reaction was carried out at 37°C for 30 minutes, and was 
terminated by the addition of 6 J.-lL of 5X Lamelli buffer (with 100 mM DTT). 
Samples were subjected to gel electrophoresis on a 8% acrylamide gel. The 
acrylamide gel contained a 14% skirt at the bottom of the gel to help contain free 
[yp32]_A TP. This skirt was removed, and the gel dried before being subjected to 
autoradiography. For cold kinase assays, conditions were identical, but with non 
radioactive A TP and 60 minute incubation. 
2.6.4. Direct immunofluorescence microscopy 
HEK293 and COS-7 cells were seeded on six well dishes at 2x 105 cells per well 
on sterile lOxlO mm coverslips. The cells were transfected with eYFP-IRF-I 
constructs according to section 2.3.1. Twenty four hours post transfection media 
was removed from the wells, followed by 4x washes with IX PBS. Cells were 
fixed for 10 minutes with fixative solution (4% Paraformaldehyde in Ix PBS 5 
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mM NaOH). Fixative solution was then removed and the wells washed 5x with 
1 X PBS. The cells were then incubated with 0.5 ~ g / m L L Hoechst 33258 for 5 
minutes in PBS. The hoechst 33258 was then removed and the cells were washed 
a further 5x with 1 X PBS. The coverslips were removed from the wells, inverted 
and placed on microscope slides with 10 ~ L L of mounting media (49% PBS 49% 
Glycerol 2% (w/v) n-propyl gallate), dried and sealed using nail polish. A Zeiss 
LSM 510 META Confocal microscope was used to image the eYFP-IRF-l 
transfected cells. Fluorescence from the eYFP was detected using 488 nm laser 
excitation at 2% power and the Long Pass 505 filter for emission. The hoechst 
counter stain for DNA was measured using a mercury bulb. The lens used was a 
63x/l.4 oil lens (Zeiss). 
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Chapter 3. 
IRF -1 is phosphorIlated 
at Thr180 bI G S K 3 ~ ~
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3.1. Introduction 
IRF-l was described as a phospho-protein over two decades ago, to date; 
only two IRF -1 kinases have been identified. There is no evidence that either 
of these kinases phosphorylate IRF -1 in vivo, and almost nothing is known 
about the molecular outcomes of IRF-l phosphorylation. In this chapter, I set 
out to identify potential IRF-l kinases by in silico prediction. A conserved 
ThrlSer pair situated just outside the mapped TAD of IRF-l was chosen for 
this study. GSKJP was predicted to phosphorylate Thrlso, with SerlS4 being 
phosphorylated first and acting as "priming" site for GSKJJ3. Direct 
phosphorylation of IRF-l by GSKJJ3 was demonstrated by an in vitro kinase 
assay, this was followed by in vivo experiments in which over-expressed 
GSKJJ3 was shown to phosphorylate IRF-l in HEK293 cells at threonine 180. 
Phosphorylation of IRF-l in the human breast cancer cell line H3396 and the 
primary fibroblast cell line MRC-5 was also demonstrated suggesting that 
this phosphorylation occurs with endogenous GSKJJ3. Direct interaction 
between IRF-l and GSKJJ3 was demonstrated by GST pulldown assays, 
while co-immunoprecipitations in HEK293 cells demonstrated an in vivo 
interaction. This interaction was independent of phosphorylation, as kinase 
inactive GSKJP interacts with IRF-l, while wild type GSKJJ3 was also 
capable of interacting with mutants of IRF-l. Collectively I have identified a 
novel interacting partner of IRF-l in GSKJJ3, while also pin-pointing a 
specific target residue in Thrlso. 
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3.2. Prediction of potential phosphorvlation sites on mouse IRF-1. 
To predict potenti all y phosphorylated residues, and the kinases which 
phosphorylate them, the amino acid sequences of human and mouse IR F-I were 
submitted to ten online prediction programmes (figure 3. 1 A) . Human lRF-l 
contains thirty four serine residues, eighteen threonine residues and seven tyrosine 
residues, most of these residues are conserved between human and mouse (figure 
3.18) . 
A. 
B. 
>giI49456387IembICAG46514.11 IRFl [Homo sapiens] 
MPITRMRMRPWLEMQINSNQIPGLIWINKEEMIFQIPWKHAAKHGWDINKDAC 
LFRSWAIHTGRYKAGEKEPDPKTWKANFRCAMNSLPDIEEVKDQSRNKGSSAVRV 
YRM LPP LT KNQRK E R KSKSSR DAKS KAKRKSCG DSS PDTFSDG LSSS TL PDDHSSYT 
VPGYMQDLEVEQALTPALSPCAVSSTLPDWHIPVEVVPDSTSDLYNFQVSPMPSTS 
EATTDEDEEGKLPEDIMKLLEQSEWQPTNVDGKGYLLNEPGVQPTSVYGDFSCKEE 
PEIDSPGGDIGLSLQRVFTDLKNMDATWLDSLLTPVRLPSIQAIPCAP 
>gi\710597971 emb I CAJ18442.11 Irfl [Mus musculus] 
MPITRMRMRPWLEMQINSNQIPGLlWINKEEMIFQIPWKHAAKHGWDINKDAC 
LFRSWAI HTG RYKAG EK EPDP KTWKANFRCAMNS LPDI EEVKDQSRN KGSSAVRV 
YRMLPPLTRNQRKERKSKSSRDTKSKTKRKLCGDVSPDTFSDGLSSSTLPDDHSSYTT 
QGYLGQDLDMERDITPALSPCVVSSSLSEWH MQMDIIPDSTTD LYNLQVSPMPST 
SEAAKDED EEGKI AEDLM KLFEQS EWQPTHIDGKGYLLN EPGTQLSSVYGDFSCKEE 
PEIDSPRGDIGIGIQHVFTEMKNMDSIMWMDSLLGNSVRLPPSIQAIPCAP 
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Figure 3.1. Human and Mouse IRF-l amino acid sequences. A) The human 
and mouse lRF-\ amino acid sequences used throughout this study. B) The 
number of serine, threonine and tyrosine residues in human IRF-l (red) and the 
number of residues conserved with mouse (blue). 
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Of the 59 potentially phosphorylated Ser / Thr / Tyr residues, 49 amino acids were 
predicted as potential phosphorylation sites by at least one of the programmes. To 
filter out the predictions, several steps were employed (figure 3.2). First, all of the 
non conserved residues were removed, as mouse IRF -1 was to be used in this 
study, and residues that were not conserved at least between human and mouse 
IRF-l were not of interest. Next, tyrosine residues were removed. Studies by 
Kautz et aI, have established that IRF-l is phosphorylated at TyrI09, but this is the 
sole Tyr phosphorylated (Kautz et al. 2001 and la Sala et al. 2009). The 
kinase(s) responsible remains to be identified. Four of the seven Tyr were 
predicted to be phosphorylated by multiple prediction programmes; however no 
single kinase was consistently selected for any of these Tyr residues making 
identification problematic (there are over one hundred Tyr kinases in the human 
genome). Consequently Tyr phosphorylation of IRF-l was not pursued. Next, 
eihgt residues which have previously been mutated in the study of CK2 
phosphorylation were eliminated. Four of these residues were found not to be 
phosphorylated by CK2, and their mutation had no effect on IRF-l activity, as 
such they were of no interest. The remaining residues were found to be 
phosphorylated by CK2 in vitro .. so did not constitute novel discoveries (Lin and 
Hiscott 1999). Further to these eight residues, additional predictions were 
discarded in which only CK2 was predicted as the responsible kinase, as CK2 
phosphorylation has already been mapped in IRF-l. Finally all amino acids in 
which there was little agreement between the prediction programmes were 
discarded. This resulted in a short list of seven amino acids (figure 3.3) 
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59 amino acids 
In slllCO predicted residues 
49 aluino acids 
Remove non conserved 
residues _----..... -----... 
Remove all Tyr residues 
34 amino acids 
Remove studied CK2 residues and 
any residue only predicted to be a _----..... ------... 
target of CK2 
Remove residues that are not 
consistently predicted 
26 amino acids 
7 amino acids 
Figure 3.2 Work flow of phosphorylation prediction. Flowchart of rationale 
used to produce a shortlist of potentially phosphorylated residues in IRF-l. 
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Figure 3.3 Shortlist of predicted phosphorylation events in IRF-l. Table of the 
seven sholilisted amino acids, and the potential kinases. ](jnases highlighted in 
red were predicted four or more times, Abbreviations CKI (Casein Kinase I) , 
CK2 (Casein Kinase II), PKA (Protein Kinase A), PKC (Protein Kjnase C), 
DAPK3 (Death Associated Protein Kina e 3), PAKA (P21 Activated Kina e I), 
PKGl (Protein Kinase G), RSK (Ribosomal Protein S6 Kinase), CAMK 
(Calmodulin Dependent Kinase) Akt (Protein Kinase B), PDK (Pyruvate 
Dehydrogenase Kinase), GPRKI (G Protein Receptor Kinase I), Chkl 
(Checkpoint Kinase I) ROCKl (Rho- Associated coiled coil containing Protein 
Kina e), CDK ( yclin Dependent Kina e), GSK-3 (Glycogen Synthase Kina e-
3), ERK (Extra-cellular Regulated Kinase), FRAP (Mammalian Target of 
Rapamycin) 
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Three residues, Ser125, Ser127 and Ser l28 are all in close proximity. All three were 
matched to multiple kinases, including CK I, PKA and Chk I. Additionally; all 
were predicted to be substrates of PKC. Previous studies have shown that IRF-I 
interacts with and is phosphorylated by PKCa (Giroux et al. 2003), although the 
residues targeted were not identified. PKC has been suggested to regulate IRF-I 
localisation, so it was interesting to note that the three predicted residues were all 
located close to the IRF-I NLS. As this study was an attempt to identify entirely 
novel phosphorylation events in IRF -1, it was decided not to investigate PKC 
phosphorylation of IRF-I. Ser l62 was only predicted to be phosphorylated by CKI 
(not including CK2 which had been previously discounted). It was preferable to 
study amino acids that could be targeted by more than one kinase, in order to 
increase the probability that a kinase would be identified. For this reason Ser l62 
was not studied further. The three remaining amino acids were each predicted by 
numerous kinases. All three were predicted to be phosphorylated by GSK3 
(Glycogen Synthase Kinase 3). An unusually feature of GSK-3 phosphorylation is 
its preference for "priming" of a +4 Ser / Thr residue by phosphorylation, often by 
another kinase. As such when studying GSK-3 substrates the +4 residue is of 
equal interest. For Thr l80 the +4 residue would be Ser184, which was itself 
predicted to be phosphorylated by numerous kinases, including many proline 
directed kinases. The +4 priming site for Se.-2 15 would be Se.-2 19• This amino acid 
was discarded, because only a single prediction was made for its phosphorylation. 
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Looking further at the ami no acid sequence of IRF- I an adjacent potential GSK-3 
site was also identifi ed (see figure 3.5). The spacing of the residues is not optima l 
for a fo ur amino acid phosphorylation cascade (such as those noted fo r other 
GSK-3 substrates such as ~ ~ C C t e n i n n and MafA (Yost el al. 1996 and Rocques et 
al. 2007). The amino acids sun-ounding thi s region were then aligned against IRF-
1 fro m seven di ffe rent species. Conservation was high among amino acids 213-
229 among mammals, but less conserved with chicken IRF-I (see fi gure 3.4). The 
amino acids sun-ounding Thr l 80 and Ser l 84 were then aligned in the same fashion 
(see figure 3.5). Again these residues were well conserved throughout evolution, 
but unlike Ser2 15 and Ser2 19, potenti al phosphorylati on by GSK-3 was maintained 
in chicken IRF-1. 
A. 
B. 
QVSPM P S T ~ E A T T D E D D
Q V S P M P S T ~ E A A K D E E E
Human 
Mou e 
Dog 
Elephant 
Hedgehog 
Cow 
Chicken 
G S ~ ~ ( 11 CI 2 cu 
(PI! GH 3 SI 3 
COl 
lU lU 1n za 1 17 lI i : ., H O U I lU HI U4 I n I II ll 7 U ¥ln 
QVSPMPSTSEATTDED 
QVSPMPSTSEAAKDEE 
QVSPMPSTSEATTDED 
QVSPMPSTS-------
QVSPMPSTSEAATDED 
QVSPMPSTSEAATDE 0 
QVSP LGSS SEGDYKT 
;K3 consensus x x IS X X X f l ~ ~ X t l ~ ~ X X X" X X X 
HUMAN IRF-l 
MOUSE IRF-l 
Figure 3.4 Conservation of Ser21S• A) The top curved arrows represent the 
" priming" events (see text) . Bottom arrows indicate kinases that are predicted to 
phosphorylate the surrounding residues' ) B) Top number indicate amino acid 
number relative to human IRF-I. Bottom is the GSK3 consensus, where x is any 
amino acid and TIS is threonine I serine, 
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1 7 178 1 79 180 lSI 18218 3 18J ISS 18 6 18 7 189 1'30 1 9 1 
Human Q A L T PALSPCA V S S 
Mouse R DI T PALSPCV V S S 
Dog R D L T PALSPCA V T S 
Elephant R A L T PALSPCA V S S 
Hedgehog R S L T PALSPRV S S T 
Cow R T L T PALSPCG V S S 
Chicken T S V S G 
GSK3 consensus x x x Tis x x x T/S X x x x x x 
Figure 3.5 Conservation Thrlso and Ser lS4 among seven different species of 
IRF-l. Top numbers indicate the amino acid number relative to human IRF-I . 
Bottom is the GSK3 consensus, where x is any amino acid and TIS is threonine I 
senne. 
Thrl 80/Serl 84 also offered a benefit to the study in that Thrl80 is the only Thr 
residue followed by a proline in mouse IRF-I (but not human lRF-I) . Antibodies 
that recognise p-T-P motifs have been extensively used in the study of threonine 
phosphorylation, and as such would offer an economical alternative to generating 
phospho specific lRF-1 antibodies. Although phospo-Ser-Pro antibodies have also 
been developed that could be u ed in the tudy of IRF-I , there are four er-Pro 
pair in mouse IRF-1. Con equentl y use of thi antibody may have required 
ubstitution of multiple Ser re idue to detelmine antibody specificity. A more 
specific phospho antibody could also be used in the study of Thr1 80/Ser1 84. 
Phosphorylation of c-Myc at Thr58/Ser62 by G S K 3 ~ ~ has been extensively studied, 
and an antibody that detects dual phosphorylation is available. Crucially, this 
antibody has been shown to be non pecific towards other protein that carry 
similar phosphorylation motifs, and has been used to identify novel GSK-3 
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substrates (Gustafson et al. 2005). Finally, in addition to the high potential for 
GSK-3 phosphorylation of Thr180, both Thr l80 and Ser l84 are nested within a 
protein-protein interaction motif named the PxLxP motif. These short amino acid 
sequences serve as ligands for the zinc finger MYND (MTG8-Nervy-DEAFl) 
domain (Ansieau and Leutz 2002). Although the PxLxP - MYND domain 
interactions are poorly characterised, the potential that phosphorylation of 
Thrl80/Serl84 modulates protein-protein interactions warranted further study. 
Figure 3.6 shows the IRF-l PxLxP aligned against other known PxLxP motifs. 
IRF-l T P A L 5 P Unknown 
skNAC L P P L I P 5MYD21 
ElA M P N L V P B5692 
EBNA2 M P E L 5 P B5692 
MGA M P K L T P B5692 
EM5Y M P R L V P B5693 
ZHXl P P V L I P B5694 
PRKDC M P K L K P SMYD25 
AHll S P P L S P SMYD25 
CLASP2 V P R L S P SMYD25 
NCoR P P P L P P ETO' 
NCoR P P P L P ETO' 
PxLxP protein MYND domain protein 
Figure 3.6. The IRF-l PxLxP motif. Alignment of known PxLxP motifs, and the 
MYND domain proteins in which they interact. References I :(Sims et al. 2002) 2: 
(Ansieau and Leutz 2002) 3: (Hughes-Davies et al. 2003) 4: (Ogata-Kawata et al. 
2007) 5:(Abu-Farha et al. 2008) 6: (Liu et al. 2007). Abbreviations ElA 
(Adenoviral EIA protein), EBNA2 (Epstein Barr Nuclear Antigen), MGA (Myc 
related cellular factor), ZHXl (Zinc finger and Homeobox I), PRKDC (Protein 
Kinase DNA activated), BS69 (Adenovirus 5 EIA binding), AHIl (Abelson 
Helper Integration Sitel), CLASP2 (CLIP Associated Protein 2), NCoR (Nuclear 
Receptor Co-Repressor), SMYD2 (SET and MYND domain Protein 2), ETO 
(Eight-Twenty-One) and skNAC (Skeletal Nascent Polypeptide Associated 
Complex). 
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3.3. IRF-l is phosphorylated il1 vitro by GSK3P 
To detennine if IRF-l is phosphorylated directly by GSK3p, an in vitro kinase 
assay was perfonned using recombinant GSK3p (Cell Signalling Technology) 
which was incubated with GST-IRF-l wild type and T180A. The reaction was 
carried out in the presence of [yp32]_ATP which enabled detection of phosphate 
transfer by GSK3p to IRF-I. GST-IRF-l incubated with GSK3 but in the absence 
of "hot" A TP did not result in detection of IRF -1. No phosphorylated IRF -1 was 
detected without the addition of GSK3p, but [yp32]_ATP labelled TRF-l was 
detected when incubated with GSK3p . Both wild type and T180A IRF-l were 
phosphorylated by GSK3p. 
ATP + + + + + + 
yP32ATP + + + + 
GST-IRF-1 wr + + + 
GST-IRF-1 T180A + + + 
GSK313 + + + + 
Figure 3.7 GST-IRF-l is phosphorylated vitro by GSK3B. 4 flg of GST-IRF-l 
was incubated with 250 flM ATP, 0.8 flCi [yp32]-ATP and GSK3p for 30 minutes 
at 37°C. Phosphorylation was detected by autoradiography. 
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Although IRF-l was detennined to be a substrate of GSK3p ill vitro, the Tl80A 
mutant was found to be equally phosphorylated in comparison to the wild type 
IRF-I. This suggested that other residues are potentially phosphorylated by 
GSK3p in vitro. An antibody that detects phosphorylated threonine-proline was 
used to detennine if Thr l80 was phosphorylated by GSK3p. Thr l 80 is the only Thr 
residue followed by a proline in mouse IRF-I (although human IRF-l contains 
two) . An in vilro phosphorylation was carried out without [yp32]_ATP. The 
products of the reaction were subjected to SDS-P AGE and immunoblotted with 
the pT-P Ab (Antibody). In the absence of GSK3p , GST-IRF-I was not 
phosphorylated at Thr I80 ; however addition of GSK3p resulted in a detectable 
shift in IRF-l migration. The slower migrating fonn ofIRF- l was detected by the 
pT-P Ab suggesting that Thr l 80 is one of the phosphorylated residues. 
75kOa 
75kOa 
75kOa 
WT GST-IRF-l 
Ci phospho-
Threonine-Proline 
Ci IRF·1 
~ ; ; . ; ~ ; ; ; J J Coomassie Blue 
+ + 
GSK3(3 + 
Figure 3.8 Thrlso is phosphorylated by GSK3B in vitro. 1 J..lg of wild type 
GST-IRF- l was incubated with and without GSK3p in the presence of 250 J..lM 
ATP. The samples were separated by SDS-PAGE. The gel was stained with 
Coomassie Blue to highlight the decreased migration following phosphorylation. 
Immunoblot was carried out to detect p-T-P and total JRF-l. 
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3.4. IRF-l is phosphorylated at Thrlso ill vivo 
To detemline if IRF-\ is phosphorylated in response to G S K 3 3 , , HEK293 cells 
were co-transfected with FLAG-HA-IRF-\ and G S K 3 ~ ~ HA. The phospho-Till·-
Pro Ab was used to determine if IRF-l was phosphorylated at Thr l8o . Protein 
extracts were immunoprecipitated using the p-T -P Ab and immunoblotted with 
IRF-l Ab (figure 3.9). FHA-IRF-l (3x-FLAG-HA) was immunoprecipitated by 
the p-T-P Ab in the absence of G S K 3 3 , , suggesting that when expressed in 
HEK293 cells FHA-IRF-l is phosphorylated at Thr l8o . Increasing the expression 
of G S K 3 ~ ~ by transfection increased the proportion of IRF-l that was 
phosphorylated at Thr I80 , without increasing the amount of FHA-IRF-l in the 
protein Iysates. The blots were re-probed with the p-T-P Ab to determine the 
amount of total protein immunoprecipitated by the p-T-P Ab. The amounts of 
phosphorylated proteins were similar between different extracts. 
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.I:: '51><0. 
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9; 
1IkOo 
50'0. 
VI 
. ' ' ~ ~I-::> D-
~ ~ 37kc. 
FLAGWT IRF1 
WT GSK38-HA 
• 
+ + 
+ + 
ex phospho-
Threonine-Proline 
Figure 3.9 Thrl80 is phosphorylated by GSK3B in vitro. HEK293 cells were 
transfected with 5 )lg of FHA-IRF-l and G S K 3 ~ - H A A for 48 hours. 6 hours prior 
to lysis cells were treated with MG 132. Protein lysates were immunoprecipitated 
(I mg) with pTP Ab and imrnunoblotted with IRF-l Ab. Blots were re-probed 
with p-TP Ab to determine the level of imrnunoprecipitation. Lysates (\ 0 )lgllane) 
demonstrate expression oftransfected proteins. FHA-IRF-I , G S K 3 ~ - H A A and actin 
were probed on a single blot. 
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3.5. Dual phosphorylation of Thrlso /Ser1S4 in HEK293 cells 
Many substrates of GSK3p require priming on a + 4 residue to stabilise the 
interaction between substrate and GSK3p. Serl84 was predicted to be a priming 
residue towards Thrl8o. Although antibodies that detect p-Ser-Pro are available, 
there are four S-P pairs in mouse IRF-I, any of which may be phosphorylated. 
This complicated the study of Serl84 phosphorylation. The Thrl8o/Serl84 pair 
exhibit strong similarity to the Thr58/Ser62 pair in c-Myc (see figure 1.14). This 
pair of residues is known to be phosphorylated by MAPK (Mitogen Activated 
Protein Kinase) and GSK3p and antibodies are available that detect dual 
phosphorylated c-Myc. This antibody has recently been shown to recognise a 
degenerate motif and detects numerous other phosphorylated proteins. The p-T/S 
antibody also immunoprecipitates numerous other proteins which also contain 
similar phosphorylation pairs, for example, Zcchc8 and EB 1 A were discovered as 
GSK3p substrates due to their recognition and immunoprecipitation with this 
antibody (Gustafson et al. 2005). When protein extracts of HEK293, MRC-5 and 
H3396 cells were probed with the p-T/S Ab, numerous bands were detected 
following stringent blocking and washing steps (data not shown). The ability of 
the p-TIS Abs to detect IRF -1 was then tested in HEK293 extracts expressing wild 
type eYFP-IRF-I with and without GSK3p-HA expression (figure 3.10). IRF-I 
was immunoprecipitated from cell extracts and immunoblotted with the p-T/S 
antibody. 
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A strong increase in IRF-I phosphorylation was detected when GSK3p-HA was 
expressed, while the amount of phosphorylation without GSK3p was weak, but 
detectable. The amount of G S K 3 ~ ~ detected in the protein extracts uggests that 
endogenous GSK3p may be able to phosphorylate IRF-l at ThrI 80/SerI 84. To 
detennine the specificity of the p-T/S antibody, alanine mutants of each residue 
singly, and in combination (TA T180A, SA S184A and TS-A T180A / S184A) 
were co-expressed with G S K 3 ~ ~ (3.10). The p-T/S antibody did not react with any 
of the alanine substitute of TRF-l, proving that this antibody is recognising the 
Thr1 80/Ser1 84 pair on eYFP-IRF1. 
.-4 
I 
u.. 
0:: 
Q.. 
75kDa -
75kOa -I 
:.==========::::::: 
750a -{ 
500a - l j ~ = = = = = = = = = = ' '
eYFP + + 
eYFP WT IRF 1 + + 
eYFP SA IRF 1 - + + 
eYFP TS-A IRF 1 + + 
eYFP T-A IRF1 
WT GSK-3j3- HA + + + + 
a-IRF 1 
+ + 
+ 
Figure 3.10 eYFP-IRF-1 phosphorylation at Thrl8o/Serl84 is increased by 
GSK3B. HEK293 cells were transfected with 5 Ilg of eYFP-IRF-l and empty 
vector or G S K 3 ~ - H A A wild type for 48 hours. Protein extracts (500 Ilg) were 
immunoprecipitated with IRF-l M20 Ab and immunoblotted with the p-T/S Ab. 
The blot was re-probed with M20 to determine the IP efficiency. 10% protein 
lysates are shown to indicate expression level of h'ansfected proteins. (WT 
wildtype, TA T180A, SA S 184A and TS-A T180AlS 184A). 
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Reciprocal IP ' s were carried out in which eYFP-IRF-l was immunoprecipitated 
with the p-TIS antibody (see figure 3.11). In agreement with figure 3.10, eYFP-
IRF-J was phosphorylated when G S K 3 ~ ~ was over-expressed, while lower levels 
of phosphorylation could be detected without G S K 3 ~ - H A A being expressed. The 
pT/S Ab was much less able to IP the alanine mutants of IRF-I. 
VI 75kD. -1 la-IRF 1 
"-~ ~ .... Q. 
75kDa 
VI 50kDa (l-IRF 1 
w 
.... 
37kDa c:( 
VI ( ( - ~ ~ Actin >-
-' 
50kDa 
( l - G G K 3 ~ ~
eYFP + + 
eYFP WT IRF1 - + + 
eYFP TA IRF1 - + + 
eYFP SA IRF1 - + + 
eYFP TS·A IRF1 - + + 
G S K 3 ~ · H A A WT - + + + + + 
Figure 3.11 eYFP-IRF-l can be immunoprecipitated by the p-T/S Ab 
HEK293 cells were transfected with 5 flg each of eYFP-IRF-l and empty vector 
or G S K 3 ~ - H A A WT for 48 hours. Protein extracts (500 flg) were 
immunoprecipitated with p-T/S Ab and immunoblotted with the IRF-l M20. 
High salt washes were used to remove any non specific interactions of the p-TIS 
Ab. 10% protein lysates are shown to indicate expression levels of transfected 
proteins. (WT wildtype, TA T180A, SA S 184A and TS-A T180AlS 184A). 
154 
Post Translational Regulation of the Tumour Suppressor IRF-l 
Figure 3.10 was then repeated, but with the FLAG-IRF-l in place of eYFP-IRF-l 
(see figure 3.(1). This was to discount any effect the large YFP protein tag may 
have had on phosphorylation of IRF-l. The results in figure 3.12 are broadly 
similar to those in figure 3.10. Increased phosphorylation of FLAG- wild type 
IRF-l was detected when GSK3p-HA was expressed, although phosphorylation 
of wild type FLAG IRF-I could be more easily detected without increased 
expression of GSK3P-HA. Additionally, the p-T/S antibody was not able to detect 
the Alanine substitution of IRF-l confirming the specificity ofthis antibody. 
~ ~ 50kDa-1 .... a p-T/S 
<t 
..... 
LL. 
Q.. 50koal a FLAG 
50koal a- FLAG 
VI 5Okoal UJ a - G S K 3 ~ ~~ ~
<t 
VI 
>-
..... 50koal ( l - ~ A c t i n n
FLAG WT IRF-1 + + 
FLAG TA IRF-1 + + 
FLAG SA IRF-1 + + 
FLAG TS-A IRF-1 + + 
G S K 3 ~ - H A A + + + + + 
Figure 3.12 FLAG-IRF-l phosphorylation at Thr180/Ser184 is increased by 
GSK3B. HEK293 cells were transfected with 5 Ilg of FLAG-IRF-I and empty 
vector or GSK3p-HA wild type for 48 hours. Protein extracts (500 ~ l g ) ) were 
irnmunoprecipitated with FLAG M2 Ab and immunoblotted with the p-T/S Ab. 
The blot was re-probed with FLAG to determine the IP efficiency. 10% protein 
lysates are shown to indicate expression levels of transfected proteins. (WT 
wildtype, TA T180A, SA S 184A and TS-A T180NS 184A). 
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Next, mutants of GSK3(3-HA were tested for their ability to promote 
phosphorylation of IRF-l. A kinase inactive mutant of GSK3J3-HA was tested 
(K85A). This mutation causes the collapse of the A TP binding pocket, preventing 
GSK3J3 from phosphorylating any substrate (Cole et al. 2004). A second mutant 
was employed (R96A) this mutant cannot interact with substrates which contain a 
negative charge (phosphate ion) on the +4 residue. The R96A mutant has been 
used by several groups to test substrates for the presence of phosphorylation on a 
priming residue, and can be used to discriminate between primed and non primed 
substrates (Cho and Johnson 2003). These mutants, and wild type GSK3J3-HA 
were co-expressed with eYFP and FLAG tagged wild type IRF-I (figure 3.13). 
Phosphorylation was detected by immunoblot of IRF -I immunoprecipitates. In 
agreement with figures 3.10, 3.11 and 3.12 increased expression of GSK3J3-HA 
promotes phosphorylation of IRF-l. In both experiments, neither GSK3J3-HA 
mutant was able to promote as high an increase in phosphorylation of IRF-I 
(compared to wild type GSK3J3). Differences in the amount oflRF-1 co-expressed 
with GSK3J3 may partially explain the reduced phosphorylation detected with the 
K85A and R96A mutants of GSK3J3, however. It is likely that the kinase activity 
of GSK3 J3 is required to promote phosphorylation of IRF -1, and therefore IRF-l 
is being directly phosphorylated by GSK3J3 and that Thrlso may be a primed 
substrate of GSK3J3. 
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Figure 3.13 Kinase inactive (K85A) and priming ~ 9 6 A ) ) mutants of GSK3B 
do not increase IRF-l phosphorylation at Thr sO/Ser1S4• HEK293 cells 
expressing 5 Ilg of IRF-l and G S K 3 ~ - H A A were lysed 48 hours post transfection. 
Lysates were irnrnunoprecipitated with IRF-l M20 (A) or FLAG (B) and 
irnmunoblotted with p-T/S Ab. IP efficiency wa te ted by blotting with the IP 
Ab. 10% lysates are shown to illu trate expre sion of tran fected protein . 
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3.6 IRF-l is phosphorylated at ThrJ8°/SerJ84 in MRC-5 and 83396 cells. 
The phosphorylation of IRF-l was then studied in H3396 and MRC-5 cells 
without transfecting GSK3p. Both cell lines express IRF-I at low levels, with 
IRF-l migrating at -50 kDa. To help confirm the identity of immunoprecipitated 
IRF-l, both cell lines were treated with IFNy (lOOOU/mL) for 3 hours to induce 
high levels of IRF-I expression (figure 3.13). H3396 cell extracts were 
immunoprecipitated with the p-T/S Ab, and the eluates probed with IRF-l C20 
Ab. IRF-l was efficiently immunoprecipitated by the p-T/S Ab, suggesting that in 
H3396 cells, dual phosphorylation of Thrl8o/Serl84 occurs without the need to 
increase expression of GSK3p. Similar experiments were carried out in MRC-5 
cells, but the IRF-l C20 Ab (a rabbit polyc1onal raised against human IRF-I C 
tenninus) was used to immunoprecipitate IRF-I after which phosphorylation was 
detected using the p-T/S Ab. The levels of IRF-I are lower in MRC-5 cells; as 
such almost no IRF-I could be detected in the lysates, or the IP without treatment 
with IFNy. In both cell lines IFNy causes a large increase in IRF-l protein levels, 
with a concomitant increase in IRF-l phosphorylation. The increase in IRF-l 
phosphorylation is approximately relative to the increase in total IRF-l, 
suggesting that IFNy does not increase the proportion of phosphorylated IRF -I. 
Therefore the increase in phosphorylation seen in the IFNy treated lanes in figure 
3.14 is caused by an increase in the total amount of IRF -1 rather than an increase 
in the proportion of phosphorylated IRF-l. Phosphorylation of IRF-l does 
however occur on newly synthesised IRF-l protein. 
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Figure 3.14. IRF-l is phosphorylated at Thrl8o/Serl84 in human cell lines. 
H3396 and MRC-5 cells were treated with IFNy (1000 U/mL) for 3 hours prior to 
lysis. Extracts (500 ~ g ) ) of H3396 cells were immunoprecipitated using the p-TIS 
Ab and immunoblotted with human IRF-J Ab (C20). MRC-5 extracts (500 ~ l g ) )
were immunoprecipitated with IRF-l C20 Ab and blotted against p-T/S Ab and 
IRF-l C20 Ab (to determine IP efficiency). \ 0% lysates are shown below IP 
panels to indicate expression of IRF-J following IFNy treatment. 
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3.7. Proteasome inhibition increases the proportion of phosphorylated IRF-l 
IRF-l is a highly unstable protein with a t l/2 (half life) of approximately 30 
minutes (Pion et al. 2009). Many proteins have been shown to be degraded by the 
proteasome following phosphorylation by GSK3p, with the phosphorylation 
serving as a mark for destruction (Xu et al. 2009a). Detection of phosphorylated 
IRF-l was often found to be problematic, even when protein levels were relatively 
high. It was postulated that IRF-l exists in a Thr180/Ser184 phosphorylated state for 
a brief period of time prior to its destruction. It was also noted that 
phosphorylation of c-Myc at Thr58/Ser62 is difficult to detect without the cells 
being treated with proteasome inhibitors. Experiments in which HEK293 cells 
were transfected with empty vector or GSK3p-HA with or without MG 132 were 
carried out to determine if IRF-l phosphorylation was more detectable following 
proteasome inhibition (3.15). As expected MG132 treatment resulted in an 
increase in IRF-l protein levels. The phosphorylation of IRF-l was barely 
detectable in DMSO treated cells that expressed empty vector and FLAG-IRF-l, 
while MG 132 increased the detection of phosphorylated IRF-l, although the total 
level of IRF-l was also increased. When cells were co-transfected with FLAG-
IRF -1 and GSK3 p-HA the phosphorylation of IRF -1 at Thr180/Ser184 was detected 
in DMSO treated cells, in agreement with previous figures which showed that 
increased GSK3(3 expression enhances the proportion of phosphorylated IRF-l. 
MG 132 treatment more than tripled the proportion of phosphorylated IRF-l, 
while importantly the increase in total IRF-l was less than two fold. This 
suggested that MG132 increased the fraction of phospho_Thr180/Ser184 IRF-l 
rather than increasing the total IRF-l levels, in the way that IFNy increased IRF-l 
protein. 
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Collectively, this suggests that Thrl 8o/Serl 84 phosphorylated IRF-I is labile, 
possibly due to its ability to target IRF-l for destruction. The levels of GSK3p 
protein were not increased by proteasome inhibition. 
II) 5 0 k D a ~ ~ liP pTS ......... Q.I- WBFLAG - c. 
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Figure 3.15. Proteasome inhibition increases detection of IRF-1 
phosphorylation at Thr180/Ser184. HEK293 cells were transfected with FLAG-
lRF-J and GSK3p-HA (5 ~ g g each,) for 48 hours. 6 hours prior to lysis, cells were 
treated with J 0 11M MG 132. Protein lysates (500 ~ g ) ) were immunoprecipitated 
with p-TIS Ab and immunoblotted with IRF-l Ab. 10% lysates are indicated 
below the IP to demonstrate the expre sion of relevant proteins. 
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3.8 IRF-l and GSK3l3-HA interact ill vitro. 
GSK3p has been shown to f0I111 relatively stable contacts with a number of its 
substrates, including NFKB-p65, p53 and E2F I (Garcia-Alvarez et al. 2007; Gong 
ef at. 2008; Eom and Jape 2009), during the process of phosphorylation. To 
confin11 that IRF-l and G S K 3 ~ ~ interact with one another an in vitro GST 
pulldown assay (figure 3.16) was perfonned using wild type GST -IRF -1 and 
G S K 3 ~ ~ that had been in vitro transcribed and translated in the presence of esS] 
Met (IVT G S K 3 ~ ) . . As a control, esS] GSK3p was incubated with GST. No esS] 
GSK3p was pulled down by the GST conjugated beads, showing the interaction 
does not occur through the GST tag on IRF- l. When IVT GSK3p and GST-IRF-l 
were incubated together, the esS] labelled IVT product was pulled down, 
suggesting that these two proteins interact in vitro. 
L--______ -I  G S K ' ~ - H A A
GST + + 
GST-IRF-1 + 
SH-G SK3f\ 10% + + 
Figure 3.16. GST-IRF-l and GSK3B-HA interact in vitro. In vitro GST 
pulldown assay using approximately 1 Jlg of GST or GST-LRF-l conjugated to 
GSH-sepharose beads. 10% input (0.2 JlL) of IVT product is used as a control. 
Experiment performed by J.xicluna. 
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3.9. FLAG-IRF-t and GSK3l3-HA interact in vivo. 
The in Filro conditions used in figure 3.16 poorly reproduce the physiological 
conditions that occur in a cell. To confirm that IRF-l and GSK3p interact with 
one another in cells, co-immunoprecipitations were performed on proteins 
expressed in HEK293 cells. FLAG-IRF-1 and GSK3p-HA were transfected in 
HEK293 cells singly and in combination, followed by immunoprecipitation with 
HA antibody and immunoblot detection using FLAG Ab (figure 3.17). To 
detennine the efficiency of the immunoprecipitation, blots was also probed with 
HA antibody. As expected, the HA Ab immunoprecipitated a band at - 45 kDa 
only in lanes that expressed GSK3p-HA. A protein at - 50 kDa was detected when 
both G S K 3 ~ - H A A and FLAG-IRF-l were co-expressed, but not when either 
protein were expressed alone. The identity of this protein was confirmed using the 
M20 IRF-l Ab (data not shown). 
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Figure 3.17. FLAG IRF-l interacts with GSK3l3-HA. HEK293 cells transfected 
with 5 j..Lg of GSK3p-HA and FLAG-IRF-l (or relevant empty vector) for 48 
hours. 1 rng of protein extract was immunoprecipitated with HA Ab, Eluates were 
subjected to immunoblot against FLAG and HA Ab. Lysates (50 j..Lg) demon trate 
expression of transfected proteins. 
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Next, the interaction between FLAG-IRF-J and G S K 3 ~ - H A A was tested further by 
carrying out a reciprocal co immunoprecipitation using the FLAG Ab to 
immunoprecipitate proteins that were associated with FLAG-IRF-l (figure 3. 18). 
In addition to the wild type FLAG-lRF-I, phosphorylation mutants ofFLAG-IRF-
1 were also tested to detennine if the interaction between FLAG-IRF-l and 
G S K 3 ~ - H A A was solely due to phosphorylation at the mutated residues. All of the 
IRF-I constructs were capable of co-immunoprecipitating with G S K 3 ~ - H A . . The 
interaction between G S K 3 ~ ~ and IRF-I SA, TS-A and SE (SI84E) was greater 
than the wild type or T180A mutant. The interactions generally varied between 
experiments, although the interaction was always detectable. As expected no 
G S K 3 ~ ~ was immunoprecipitated when no G S K 3 ~ - H A A was co-transfected. 
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Figure 3.18. GSK36-HA interacts with FLAG-IRF-1. HEK293 cells 
transfected with 5 f..I.g o f G S K 3 ~ - H A A and FLAG-IRF-l plasmid (or relevant empty 
vector) for 48 hours. 1 mg of protein extract was immunoprecipitated with FLAG 
Ab, Eluates were subjected to immunoblot against FLAG and HA Ab. Lysates (50 
f..I.g) demonstrate expression of transfected proteins. (WT wildtype, T A T180A, 
SA S 184A, TS-A T180NS 184A and SE S 184E). 
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Interactions between the K85A and R96A mutants of G S K 3 ~ ~ with TRF-l were 
next tested. This was to confirm that the inability of the K85A and R96A mutants 
to phosphorylate IRF-I was not due to their inability to form protein-protein 
interactions. Transfections were carried out as for figure 3. J 8, but using wild type 
FLAG-IRF-l and GSK3p-HA wild type, K85A and R96A. When the FLAG Ab 
was used to IP IRF-l from HEK293 cell extracts, all three GSK3p-HA proteins 
were found to Co-IP with IRF-l. This confinns that GSK3p interacts with IRF-\ 
independently of phosphorylation. 
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Figure 3.19. GSK3 13- HA inter acts with FLAG-IRF-1. HEK293 cell s 
transfected with 5 /-lg of GSK3p-HA and FLAG-IRF-l (or relevant empty vector) 
for 48 hours. J mg of protein extract was immulloprecipitated with FLAG Ab, 
Eluates were subjected to immunoblot against FLAG and HA Ab. Lysates (50 /-lg) 
demonstrate expression of transfected proteins. 
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3.10. Discussion 
IRF -1 has a predicted molecular weight of 37 kDa, but migrates closer to 50 kDa 
in a variety of different cell types. This 13kDa discrepancy has been attributed to 
phosphorylation (and possible other PTMs). This study aimed to identify a 
phosphorylated residue and the kinase responsible for the modification. 
In vitro phosphorylation was the first assay used to demonstrate that IRF -I is a 
substrate o f G S K 3 ~ . . Both the wild type and TI80A IRF-I were studied, and both 
were found to be phosphorylated by G S K 3 ~ , , suggesting that although IRF-I is a 
substrate it probably has more than one residue phosphorylated by G S K 3 ~ . . This 
suggests that IRF-I is a direct target for G S K 3 ~ ~ phosphorylation, and that no 
additional proteins are required for phosphorylation. Additionally it proves that 
PTMs on IRF-I are not essential for prior phosphorylation by GSK3(3. This seems 
to be in conflict with the requirement for Ser l84 phosphorylation to prime ThrI80 ; 
however the priming increases the interaction but is not always essential. In vitro 
phosphorylation of Bax by GSK3(3 does not require priming, however in vivo it 
does (Linseman et al. 2004). It is most likely that in an in vivo setting in which 
much lower concentrations of GSK3(3 are encountered by IRF-I, priming 
compensates, and while in vitro the higher concentration of G S K 3 ~ ~ and lack of 
other competing proteins enables phosphorylation. Given that figure 3.4 shows 
phosphorylation ofthe Tl80A mutant, and the GST -S 184A mutant was not tested, 
it is also possible that GSK3(3 phosphorylated both residues. GST protein alone 
was not subjected to in vitro phosphorylation, although it has been shown 
previously not to be a GSK3(3 substrate. Additionally, later in figure 3.16 it was 
shown not to interact with GSK3(3 in vitro. To detennine if Thrl80 is a target of 
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GSK313, cold in vitro kinase assays were used (un labelled A TP followed by 
immunoblot with phospho antibodies). Phosphorylation of IRF-I was detected 
only when GSK313 was incubated with IRF-I, in addition, only the more slowly 
migrating band was detected as being phosphorylated. The phosphorylation 
reaction did not result in a complete shift in migration of IRF-I, suggesting the 
reaction may not have gone to completion. This could be due to the lack of 
priming on Ser184 making the reaction less efficient. It would be interesting to test 
the SE mutant in these experiments to determine if this increases the proportion of 
phosphorylated IRF-l. The inability of the p-TP Ab to detect the lower migrating 
(un-modified) band of IRF-I confirms that GST-IRF-l is not phosphorylated in 
the E.coli BL21 cells. GST-IRF-I also migrated at -70 kDa which is exactly the 
expected mass of this protein. It is also matches the data of Upreti & Rath who 
utilised mouse GST-IRF-l. There is no difference in the migration of the GST-
IRF-I TS-A mutant when expressed in BL21 cells also, while when expressed in 
mammalian cells the TS-A mutant of IRF -1 migrates as a faster doublet compared 
to wild type IRF-l (data not shown). It remains to be determined whether the 
change in migration of the double mutant TS-A is a result of loss of 
phosphorylation on Thr180/Ser184, or is caused by other PTMs that are added to 
IRF-I as a result of Thr180/Ser184 phosphorylation. The differences in apparent 
molecular weight between IRF-l expressed in bacteria and mammalian cells is 
therefore likely to be caused by PTMs. Subsequently it was concluded that, in 
vitro IRF-l may be phosphorylated on multiple residues, but Thr180 was among 
the modified residues. 
To determine if Thrl80 could be phosphorylated in vivo, co-transfections were 
carried out in HEK293 cells. An increase in phosphorylation was detected when 
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GSK3f3 was over-expressed with IRF-l (figures 3.9-3.13). Phosphorylation on 
Thr180 was also detected in the absence ofGSK3f3 over expression, suggesting that 
either endogenous GSK3 or another kinase is able to phosphorylate ThrlSO. It 
should be noted that MG 132 had to be used in order to detect phosphorylation of 
Thr1SO; this will be discussed later, but suggested that the Thr180 phosphorylated 
fraction of IRF-I is sensitive to proteasomal degradation. 
Next, dual ThrlSo/SerlS4 was assessed to determine if both residues are 
phosphorylated, to support the theory that phosphorylated Ser1S4 acts as priming 
site for Thr1SO. The c-Myc phospho Thr5s/Ser62 rabbit polyclonal antibody was 
used for these studies (figures 3.10-3.13). Epitope tagged IRF-l (eYFP or FLAG 
constructs) were used rather than untagged IRF -1 for technical reasons. 
Phosphorylation was detected only on the wild type IRF-l, with an increase being 
detected when co transfected with GSK3f3. The antibody did not cross react with 
any of the alanine mutants, suggesting that it only detects the phospho-ThrlSer 
motif of IRF-l. Additionally the p-T/S Ab was able to immunoprecipitate IRF-l, 
with more IRF-l being immunoprecipitated following over-expression of GSK3f3, 
suggesting that increasing cellular GSK3f3 concentration enhances the amount of 
phospho-Thrl SO/Ser1 84 IRF-l (figure 3.11). Since the Ab only detects dual 
phosphorylated substrates it is not possible from these studies to determine if the 
modifications can occur independently of one another, although the previous 
figures confirmed that Thr lsO is phosphorylated. The status of SerlS4 
phosphorylation has not been fully studied. It has been reported that similar 
phosphorylated pairs can be uncoupled from one another. It has been shown that 
Ser62 phosphorylation of c-Myc promotes functions that are completely 
independent of its ability to promote phosphorylation of Thr58 (Benassi et a/. 
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2006; Seo et al. 2008). It should be considered, that G S K 3 ~ ~ is a tightly regulated 
protein, and is not always available to phosphorylate its nuclear substrates. 
Consequently phosphorylation of priming residues can have completely 
independent roles from G S K 3 ~ ~ priming. 
The dual phosphorylation motif which is recognised by the p-T/S Ab may be 
quite prevalent in cells, a database search identified over 200 human proteins 
which also possessed the T/S-P-X-L-S/T-P motif; this could explain the large 
number of bands detected when the p-T/S Ab is used in immunoblot. 
Occasionally, when over-expressed alongside G S K 3 ~ , , a band corresponding to 
IRF-I could be detected by the p-TIS Ab in direct immunoblot, however, the large 
number of other bands made difficult to use directly for these purposes. 
Consequently IRF-I always had to be immunoprecipitated in order to isolate it for 
immunoblot with the p-T/S Ab. The ability of both the p-T-P and p-T/S Abs to 
immunoprecipitate IRF-I suggests that the phosphorylated residues were surface 
exposed. Although small amounts of detergent in the buffers used may have 
altered surface exposure on the IRF -1 protein. It would be of interest to use 
buffers without detergents to determine if the phospho Abs are able to IP IRF-I. 
A kinase inactive mutant of G S K 3 ~ ~ was next used to confirm that the antibodies 
detected an increase in phosphorylation of IRF-l. When both YFP and FLAG 
tagged IRF-I were used, no increase in phosphorylation could be detected. It is 
notable that there was no decrease in phosphorylation. It is possible that K85A 
G S K 3 ~ ~ does not prevent endogenous G S K 3 ~ ~ from phosphorylating IRF-l. 
Alternatively other kinases (that are not affected by K85A G S K 3 ~ ) ) may be able to 
phosphorylate ThrI80• The dual detection of the p-T IS Ab may also explain the 
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residual phosphorylation detected, as this may be due to the phosphorylation of 
Ser184. A priming mutant of G S K 3 ~ ~ was next used (R96A). This mutation does 
not prevent G S K 3 ~ ~ from phosphorylating its substrates as the kinase domain is 
unaffected, however, it does not phosphorylate substrates that carry a negative 
charge on the + 4 residue. This negative charge is usually provided by 
phosphorylation. In confirmation of the studies with the dual p-T/S Ab, no 
increase in phosphorylation could be detected when this mutant was expressed 
with IRF-I. Most likely this is because the Ser l84 is phosphorylated. 
An important consideration for this study was to show that IRF-I was 
phosphorylated at Thr180 in cells without the need to over-express G S K 3 ~ . . All of 
the data previous to figure 3.10 employed mouse IRF -I, and figure 3.10 is the first 
evidence that human IRF-I is also phosphorylated at these residues. Figure 3.10 
highlights that G S K 3 ~ ~ does not need to be over expressed to promote 
phosphorylation of IRF -I, and most likely a small fraction of IRF -I will contain 
the phospho Thr180/Ser184 mark. To determine if IRF-I phosphorylation levels are 
altered by IFNy, cells were treated to induce de novo IRF-I protein synthesis. This 
also served as a control to be sure the immunoprecipitated protein was IRF-l. 
Other studies (Hu et al. 2006 and Tsai et al. 2009) have suggested that G S K 3 ~ ~
activity is linked to IFNy, although not yet well understood, it has been shown that 
IFNy reduces the inhibitory phosphorylation of G S K 3 ~ ~ at Ser9, thereby making 
more G S K 3 ~ ~ available towards its substrates. It has been suggested that IFNy 
transcriptionally regulates one of the phosphatases that removed the inhibitor Ser9 
mark. Additionally G S K 3 ~ ~ regulates the activity of STAT transcription factors 
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which regulate IRF-l expression In response to IFNy treatment. The relative 
amount of IRF-l phosphorylation was not enhanced by IFNy treatment, rather the 
proportion stayed static, with an increase in phospho-IRF-l being detected 
following treatment matching an overall increase in IRF -1 total protein 
expression. Figure 3.14 did show however, that during the 3 hour treatment in 
which new IRF-l protein was made, phosphorylation was occurring, suggesting a 
dynamic process. It would be of interest to determine if the phosphorylation levels 
of IRF-l are different in cell lines that are known to be poorly responsive to IRF-
1. 
. Th 180/S 184 b d These above data shows that IRF -1 IS phosphorylated at r er, ut oes 
not conclusively show that G S K 3 ~ ~ is responsible for the phosphorylation, 
although it has been shown that when it is over-expressed in HEK293 cells there 
is an increase in phosphorylation. Both cell lines express G S K 3 ~ ~ protein, although 
the levels of inhibitory 1 activation phosphorylation were not accessed. Most 
likely G S K 3 ~ ~ is active and able to phosphorylate IRF-l. Use of siRNA against 
G S K 3 ~ ~ to determine if the level of basal phosphorylation is decreased would have 
been helpful in confirming that G S K 3 ~ ~ is important for this modification. It 
should be noted that several other kinases were predicted to phosphorylate both 
residues, and as such knockdown of G S K 3 ~ ~ may lead to other kinases 
compensating. Numerous proteins are subjected to proteasomal degradation 
following phosphorylation by G S K 3 ~ ; ; it was therefore not surprising that MG 132 
treatment lead to an increase in the phosphorylation state of IRF -1. This is the first 
evidence that the Thrl80/Serl84 phosphorylation is a short lived event, most likely 
because it promotes degradation of IRF-l; therefore Thr180/Ser184 phosphorylated 
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IRF -1 IS marked for destruction. Reverse IPs in which IRF -1 was 
immunoprecipitated and immunoblotted with the p-T/S Ab were also performed 
and produced similar results to figure 3 .11 (data not shown). Previous 
experiments had confirmed that the relative amount of phosphorylation on these 
residues was small, when the amount oftotal IRF-l was considered. This could be 
due to the reversibility of the phosphorylation, or the rareness of the modification. 
To support the findings that GSK3(3 phosphorylated IRF-l, the interaction 
between the two proteins was studied. In vitro GST pull down assays demonstrated 
that GSK3(3 interacts with IRF-l directly. The in vitro conditions in which this 
assay was carried out mostly preclude other proteins serving as adapters or 
scaffolds in this interaction. One caveat however, is that the rabbit reticulocyte 
(from which the IVT GSK3p is produced) may contain other proteins that 
modulate the interaction between IRF-l and GSK3p. However as phosphorylation 
occurs between these two purified protein in vitro it is more likely the interaction 
is direct. Figure 3.4 also shows that IRF-l does not require PTMs to allow the 
interaction with GSK3(3. It is highly unlikely that PTMs will occur on IRF-l, as it 
was expressed in bacteria, which have a far more restricted repertoire of PTM 
machinery. These findings also suggest that IRF-l does not need to be in a DNA 
bound state to become an interacting partner of GSK3(3, although DNA binding 
may enhance phosphorylation by stabilising the interaction. Use of GST - GSK3(3 
and e5S] Met labelled IRF-l would have been useful to validate this interaction. 
To verify the interactions occur in cells, Co-IPs were carried out HEK293 cells. 
This was because HEK293 cells were used for the phosphorylation studies, and so 
it was expected that an interaction would occur in these cells. The 12CA5 HA Ab 
was used for detecting and immunoprecipitating GSK3j3-HA to prevent 
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background GSK3(3 from interfering with the results. Use of G S K 3 ~ ~ Ab may, 
however have been useful for demonstrating an interaction between endogenous 
(untagged) G S K 3 ~ ~ and IRF-l. When CoIP's were carried out with FLAG or HA 
Ab, the results showed an interaction between the two proteins which was specific 
for their co-expression. The interaction also occurred when lower levels of 
G S K 3 ~ ~ was transfected (data not shown) suggesting that the interaction does not 
come about due excessive amounts of G S K 3 ~ ~ being expressed in cells. As 
expected; all of the IRF-J mutants were capable of interacting with G S K 3 ~ . . This 
confirms that the absence of phosphorylation of the alanine mutants was not 
caused by a loss of interaction with G S K 3 ~ . . This also suggests that the interaction 
between IRF-J and G S K 3 ~ ~ occurs in another region of IRF-J and is not 
dependent on the interaction with the GSK3 consensus site. Most kinases possess 
docking sites that are separate from the target consensus site. These docking sites 
serve to greatly increase the specificity of the kinases, especially when 
considering their degenerate consensus motifs (Ubersax and Ferrell 2007). It 
would be of interest to map the docking site between G S K 3 ~ ~ and IRF-l. It could 
be assumed that mutation of the G S K 3 ~ ~ docking site would prevent IRF-J from 
being phosphorylated. This could be relevant when considering splice mutants of 
IRF-J that are found in certain cancers. Relatively few substrates have had their 
interaction with G S K 3 ~ ~ mapped, although Axin, GBP (GSK3 Binding Protein), 
LANA (Latency Associated Nuclear Antigen) and NFkB-p65 all interact with via 
amino acids 262-299 of G S K 3 ~ ~ (Farr et al. 2000, Ferkey and Kimelman 2002, 
Fujimuro et al. 2005 and Gong et al. 2008). Alternatively p53 interacts with 
amino acids 78-92 of G S K 3 ~ ~ (Eom and Jope 2009). Both the G S K 3 ~ ~ mutants 
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used in this study were equally able to interact with IRF-l, confinning that a loss 
of their catalytic activity is the reason for the reduced phosphorylation, rather than 
a reduced interaction. It would also be of interest to study if binding of G S K 3 ~ ~
also plays a role in IRF -I activity that is independent of phosphorylation. For 
example, p53 is phosphorylated by G S K 3 ~ , , but the interaction also increases 
acetylation of p53 and as such alters its activity (Eom and Jope 2009). The 
interaction between G S K 3 ~ ~ and E2F I regulates the activity of the latter to a more 
significant degree then phosphorylation (Garcia-Alvarez et af. 2007). 
In conclusion G S K 3 ~ ~ phosphorylates IRF-I at Thr l80 (and possibly other 
residues), while the Ser l84 kinase remains to be identified. The modification 
occurs in nonnal and breast cancer cells, but is unstable, potentially because it 
acts as ubiquitination signal. 
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Chapter 4. 
Phosphorylation of Thr180/Ser184 regulates 
IRF -1 transcriptional activity 
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4.1. Introduction. 
A key aim of this study is to determine the effects of phosphorylation on IRF-
1 activity. In this section reporter assays were employed to determine the 
effects of substitution of the mapped phosphorylation sites on IRF-l 
transactivation activity against the TRAIL promoter. To confirm the 
importance of GSK3(3 in IRF-l transcriptional activity, small chemical 
inhibitors, siRNA and a dominant negative allele (K85A) of GSK3P were 
used. Collectively these assays show that both Ser1S4 and ThrlSO are important 
for IRF -1 activity against the TRAIL promoter and a synthetic multimerised 
reporter (4X ISRE). Chemical inhibition, siRNA transfection or over-
expression of K85A all caused a decrease in IRF-l transcriptional activity. 
Interestingly phospho mimetic mutations of IRF-I (T180n and S184E) did 
not increase the activity of IRF-I; neither did over-expression of wild type 
GSK3(3 or treatment with the PI3K inhibitor wortmann in. Potential 
mechanisms for this discrepancy are discussed. To confirm the importance of 
Thr1SO/SerlS4 for IRF-I's transcriptional activity, stable cells lines were 
employed which express wild type or alanine mutant IRF-I under the control 
of the Tet repressor. While clones that expressed wild type IRF-I were able 
to produce a robust increase in TRAIL mRNA, both Tl80A and TS-A IRF-I 
expressing cells were significantly less capable of producing TRAIL mRNA. 
In conclusion, the GSK3p_ThrISO/SerlS4 axis is important for IRF-t 
dependent transcription of TRAIL. 
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4.2. Thrlso and SerlS4 are important for IRF-l transcriptional activity. 
IRF-l brings about most of its functions in the cell through its ability to regulate 
gene expression at the transcriptional level. Early studies suggested that IRF-l's 
OBO is essential for IRF-I anticancer activity (Kirchhoff et al. 1993) as such the 
activity of IRF-l as a transcription factor were the focus for this work. IRF-l acts 
as a positive transcriptional regulator of the TRAIL (TNFa Related Apoptosis 
Inducing Factor) gene in a number of cell lines in response to I F N a / ~ / ' Y , , retinoids 
and HIV infection (Clarke et al. 2004, Park et al. 2004, Papageorgiou et al. 
2007, Huang et at. 2009). In addition other members of the IRF family are able to 
regulate TRAIL including IRF-3, IRF-4, IRF-5 and IRF-7 (Kirshner et al. 2005, 
Yoshida et al. 2005, Romieu-Mourez et al. 2006 and Hu and Barnes 2009). IRF-
2 was found to be localised on the TRAIL promoter, but its function is not yet 
known (Clarke et al. 2004) the sites on which IRF family members interact with 
the TRAIL promoter have also been mapped, allowing a fragment of the promoter 
to be used in reporter assays (Clarke et al. 2004). Significantly, the IRF-I-TRAIL 
axis has been shown to be important in apoptosis, with TRAIL induction being 
one of the major mechanisms by which IFN and retinoids (via IRF-I) bring about 
apoptosis in cancer cells. Consequently the TRAIL promoter was used as the 
model system in these studies, particularly the minimal region required for IRF-I 
dependent transactivation. To study IRF-I transcriptional activity, reporter assays 
were employed in Cos7 cells. A region of the TRAIL promoter was fused up-
stream of a Luciferase reporter gene. Cos-7 cells were employed due to their ease 
of transfection and their lack of any endogenous IRF-I expression. 
Transactivation of the TRAIL promoter was assayed by an enzyme activity assay 
for Luciferase protein, which is a product of IRF-I transactivation of the TRAIL 
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promoter fragment which controls the expression of the Luciferase gene. 
Luciferase protein is only produced when IRF-I binds the reporter plasmid and 
recruits the relevant coactivators and RNA Pol II. 
The contribution of Thr l80 and Ser l84 to IRF-l transcriptional activity was 
measured using amino acid substitutions (hereafter referred to as mutants) of each 
residue to alanine singly and in combination. alanine cannot be phosphorylated, 
but is structurally similar to Thr and Ser and so minimises any structural effects of 
the substitution. Schematics of the mutants used are given in figure 4.9. Transient 
transfections were carried out for reporter assays for 24 and 48 hours, with either 
100 or 50 ng ofpcDNA3.1 IRF-l wild type, T180A, Sl84A and TS-A (data not 
shown). Results were consistent among the two time points and concentrations, 
but the lower concentration and longer time-point were selected to reduce the 
toxicity of IRF-l over-expression and to allow greater time for the Luciferase 
protein to accumulate. 
Consistently the alanine mutants of IRF-l exhibited lower reporter activity than 
wild type IRF-l, despite the expression of the mutants and wild type being 
comparable (figure 4.1). Intriguingly the S 184A mutant exhibited the same 
activity as the Tl80A mutant. The double TS-A mutant produced the same level 
of transactivation at either single mutant, suggesting that loss of both residues has 
the same effect as loss of either single residue. The consequence of phosphate 
group attachment to SerfThr residues is the gain of a negative charge (SerfThr 
residues are uncharged). This gain of negative charge can be mimicked by the 
substitution of potentially phosphorylated residues with the acidic amino acids 
aspartic acid (D or Asp) or glutamic acid (E or GIu). These phospho-mimetic 
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mutants can be regarded as constitutively phosphorylated forms of protein. IRF-1 
T180D and S 184E were constructed to determine if a negative charge on these 
residues is important for transcriptional activity (see figure 4.1). Surprisingly both 
of these mutants demonstrated significantly reduced activity compared to wild 
type IRF-1, again both mutants were expressed at similar levels to wild type, with 
no apparent change in molecular weight. To determine if the Thr l80 and Ser l84 
residues are important for IRF-1 activity on other promoters, a synthetic 
multimerised ISRE reporter was used. This reporter construct is derived from the 
histone 4 promoter and contains four tandem copies of an ISRE sequence which is 
recognised by a number of IRF family members (Xie et al. 2001). The higher 
numbers of binding sites leads to the potential for multiple IRF proteins to act 
together in synergy, as it has been reported that IRF-1 can homodimerise 
(Kirchhoff et al. 1998) and a number of genes contain multiple IRF binding sites 
in tandem (see table 1.4). The stochiometry of IRF-1 transactivation on this 
promoter is potentially quite different to the TRAIL promoter, which contains 
only two IRF binding sites (an IRF-E and an ISRE). 
The reporter activity of wild type and all of the IRF-1 mutants was broadly 
comparable between the TRAIL and 4X ISRE reporters. As such it is possible that 
the effects on IRF activity are not confined to the TRAIL promoter and could 
potentially globally impact the IRF-l transcriptional programme (figure 4.1). 
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Figure 4.1 Substitution of phosphorylated residues for either alanine or 
acidic residues severelv reduces IRF-l transcriptional activity. A) Cos7 cells 
transfected with 50 nglwell IRF-l expression plasmid, 75 nglwell TRAIL 
promoter reporter and 5 nglwell ~ G A L L for 48 hours. B). Immunoblot of lRF-1 
expression in Cos7 reporter extracts. C). Rep0l1er assay as for A. but using a 4X 
multimerised ISRE reporter. Schematics for each repot1 are shown in the top right 
of each figure. Values are expressed as a fold difference between empty vector 
and IRF-I expressing cells . Error bars denote standard deviation and * represents 
significant difference «0.05) as determined by Students t-test. Values are from 
three independent experiments carried out in triplicate. 
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4.3. Inhibition of GSK3 reduces IRF-l activity on the TRAIL promoter 
[n addition to inhibiting the ability of IRF- [ to be phosphorylated at Thr ' 8o and 
Ser 184 , the activity of G S K 3 ~ ~ was inhibited by use of small molecule inhibitors. 
GSK3 inhibitors have equal selectivity for both of the GSK3 isofonns, and can 
potentially inhibit other enzymes. To account for any effect specific to a certain 
inhibitor, two different classes of inhibitor were selected. Lithium ions have been 
extensively studied for their ability to inhibit GSK3 (Martinez et al. 2002). When 
reporter assays on the TRAIL promoter were carried out in the presence of Liel , a 
dose dependent reduction in activity was observed (figure 4.2) Sodium Chloride 
was used as a control to compensate for any effect on osmolarity of the chloride 
ions. 10mM LiCI did not produce a statistically significant reduction, while 20 
mM LiCI reduced IRF-I transactivation of the TRAIL reporter. 
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0 
• NaCI 
~ ~
::l 
"0 
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n "'6 LL 
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Figure 4.2. GSK3 inhibitor Lithium reduces IRF-l transcriptional activity on 
the TRAIL promoter. Cos7 cells transfected with 50 ng/well IRF-l expression 
plasmid, 75 ng/well TRAIL promoter reporter and 5 ng/well ~ G A L L for 48 hours. 
Inhibitor treatments were can-ied out for 15 hours. All Luciferase values are 
relative to ~ G A L L expression. Values are expressed as a fold difference between 
empty vector and IRF-l expressing cells treated with the same concentration of 
inhibitor. Error bar denote standard deviation and * represents significant 
difference «0.05) as detennined by Students t-test. Values are from three 
independent experiments carried out in triplicate. 
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The second class of inhibitor used was those based on indirubin (Meijer et at. 
2003). These compounds are thought to act through the A TP pocket of G S K 3 ~ , , a 
region which is not targeted by lithium ions. Two structurally similar inhibitors 
were used, inhibitor IX (not shown) and inhibitor X (see figure 4.3). Both of these 
inhibitors promoted a dose responsive reduction of IRF -1 reporter activity on the 
TRAIL promoter. Inhibitor X exhibited a more potent reproducible inhibition of 
IRF -1 reporter activity then inhibitor IX. A third compound - Inhibitor VII 
(Methyl-BIO) was used as a control. Addition of a methyl group greatly reduces 
the activity of this compound. As expected inhibitor VII had no effect on IRF-1 
reporter activity when compared to DMSO control. 
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Figure 4.3 GSK3 inhibitor X reduces IRF-l transcriptional activity on the 
TRAIL promoter. Cos7 cells transfected with 50 ng/well IRF-J expression 
plasmid, 75 ng/well TRAIL promoter reporter and 5 ng/wen pGAL for 48 hours. 
A) Treatment with aSK3 inhibitor X, B) treatment with GSK3 inhibitor XIV. 
Inhibitor treatments were carried out for 15 hours. All Luciferase values are 
relative to pGAL expression. Values are expressed as a fold difference between 
empty vector and IRF-1 expressing cells treated with the same concentration of 
inhibitor. The final DMSO concentration was 0.01 %. Error bars denote standard 
deviation and * represents significant difference «0.05) as detennined by 
Students t-test. Values are from three independent experiments canied out in 
triplicate. C) Structures of inhibitors used. 
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4.4. Depletion of GSK3B reduces IRF-l transcriptional activity. 
A significant disadvantage of using chemical inhibitors to probe the activity of 
GSK3(3 is that they lack specificity, due the structural similarities between CDK 
and GSK kinases and a certain degree of cross inhibition is unavoidable (Meijer et 
al. 2003). Inhibitors also prevent kinases from phosphorylating their substrates, 
but do not necessarily prevent physical association with substrates. Chapter 3 
established an interaction between GSK3(3 and IRF-l, to determine if depleting 
GSK3p protein from cells has a similar effect to inhibiting its catalytic activity, 
siRNA knockdown was employed. Duplex siRNA oligos that were validated to 
only target GSK3p were purchased from QIAGEN and used to knockdown 
GSK3p in MRC-5 cells (see figure 4.4). 
MRC-5 cells were selected for these assays because it had already been shown 
that the mutants of IRF-l behave identically in MRC-5 as in Cos7 cells in reporter 
assays (data not shown). Knockdown efficiency was determined in protein 
extracts used in the reporter assays to check that efficient depletion of GSK3(3 was 
occurring (figure 4.48). Transfected IRF-l in cells expressing less GSK3(3 were 
approximately half as effective at transactivating the TRAIL promoter (figure 
4.4A). Activity was expressed as a fold change between cells transfected with 
empty vector and IRF-I to cancel out any effects GSK3p siRNA had on basal 
activity of the TRAIL promoter. However the basal activity was not significantly 
altered (data now shown). 
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Figure 4.4. siRNA mediated depletion of GSK3B reduces IRF-l 
transactivation of the TRAIL promoter. A) MRC-5 cells transfected with 5 nM 
of either control non targeting siRNA, or GSK3p siRNA for 15 hours followed by 
transfection with 125 ng of TRAIL reporter, 100 ng ofIRF-I and 20 ng of pGAL 
expression plasmid for 24 hours. Data is from three experiments carried out in 
triplicate. Data is shown as fold induction using empty vector. Error bars indicate 
standard deviation. * Denotes statistical difference (non targeting siRNA v. 
GSK3p siRNA) a determined by Students t-test (p less than 0.05). B) 
Representative western blot of GSK3p expression in extracts used for reporter 
assay (20 1J.g/lane). 
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4.5 Over-expression of DN (Dominant negative) GSK3B reduces IRF-l 
transcriptional activity. 
The K85A kinase inactive mutant of GSK3p used in chapter three has also been 
reported to have dominant negative activity, due to its ability to bind, but not 
phosphorylate substrates. Potentially, this prevents endogenous GSK3p from 
phosphorylating substrates. To determine if over-expressed K85A GSK3p was 
able to reduce IRF-l activity, it was transfected in reporter assays containing IRF-
1. Increasing expression of K85A GSK3p caused a significant reduction in IRF-ls 
ability to activate the TRAIL reporter. Additionally there was a slight decrease in 
the basal (vector transfected) levels, suggesting that GSK3p may playa role in the 
basal activity of the TRAIL promoter (see figure 4.5). 
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Figure 4.5. Dominant negative (K8SA) GSK38 reduces IRF-l transcriptional 
activity on the TRAIL promoter. Cos7 cells transfected with 50 ng/well IRF-l 
expression plasmid, 75 ng/well TRAIL promoter reporter and 5 ng/well POAL for 
48 hours. A titration of HA-OSK3P K85A between 50 and 200 ng was co-
transfected either with empty vector or IRF-l.Values are expressed as a fold 
difference between empty vector and IRF-l expressing cells. Error bars denote 
standard deviation and * represents significant difference «0.05) between empty 
vector and GSK3p-HA K85A. Values are from three independent experiments 
carried out in triplicate. 
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4.6 Increasing GSK36 activity and protein does not increase IRF-t activity. 
Increased expression of the K85A mutant of GSK3(3 causes a dose dependent 
reduction in IRF-l activity, to determine if wild type GSK3(3 was able to increase 
the activity of IRF-l, GSK3(3 was co-expressed with IRF-l (figure 4.6). 
Surprisingly, increased expression of GSK3(3 did not promote a statistically 
significant increase in IRF -1 activity. To a small (not significant) degree GSK3(3 
was able to reduce the activity of IRF-l. Titrating GSK3(3 with IRF-l at a set 
concentration also did not enhance the activity of IRF-l to an appreciable degree. 
Both IRF -1 and GSK3 (3 proteins were expressed in the cell extracts (data not 
shown). An alternative strategy was then employed in which rather than 
increasing the amount of GSK3(3 protein, the activity of endogenous GSK3(3 
protein was enhanced with wortmannin treatment. Wortmannin is a PI3K 
(Phosphoinositide 3 Kinase) inhibitor. This leads to reduced activation of 
PKBI Akt, which in turn leads to a reduction in the phosphorylation of Ser9 on 
GSK3(3. This has been shown to enhance the activity of GSK3(3, by relieving the 
auto-inhibition of the kinase domain. Titration of wortmannin did not lead to any 
significant increase in IRF -1 activity (figure 4.7), suggesting that wortmannin 
does not regulate IRF-l activity towards the TRAIL promoter. Additionally a 
mutant of GSK3(3 which does not possess the auto-inhibitory Ser9 residue 
(GSK3(3-HA S9A) was also titrated and found to have no significant effect on 
IRF-l activity (data not shown). 
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Figure 4.6. GSK3B over-expression does not enhance IRF-l reporter 
activity. Cos7 cells transfected with 75, 150 and 250 ng of IRF-l expression 
vector, and 150 ng of TRAIL promoter reporter. lOng per well of ~ G A L L
expression plasmid was used as a transfection control. 75 ng of GSK3f3-HA wild 
type or empty vector were co-transfected with the above plasmids. Transfection 
was for 48 hours. Values are from three independent experiments carried out in 
triplicate. Data is expressed as fold increase compared to empty vectors or 
GSK3f3-HA wild type alone (X axis). Error bars denote standard deviation; no 
statistical significance was detected between vector and GSK3f3 transfected cells 
at any concentration. 
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Figure 4.7. Wortmann in does not increase IRF-l transcriptional activity on 
the TRAIL promoter. Cos7 cells were transfected with 50 ng IRF-l , 100 ng 
TRAIL reporter and 5 ng CMV ~ G A L L for 48 hours. 24 hours prior to lysis for the 
reporter assays, cells were treated with DMSO (0.01 %) or the indicated 
concentration of wortmannin. lnduction was determined as a fold increase in Luc 
expression over empty vector expressing cells treated with the appropriate 
concentration of inhibitor. Experiments were carried out in triplicate in three 
independent experiments. Data is expressed as % of vehicle control (0.01% 
DMSO). Error bars denote standard deviation. 
189 
Post Translational Regulation of the Tumour Suppressor IRF-l 
4.7 Thr180/Ser184 are required for IRF-l dependent gene expression in Breast 
cancer cells 
Previously, the activity of the TRAIL promoter reporter has been shown to closely 
match the activity of IRF-l on TRAIL mRNA and protein (Clarke et al. 2004). To 
detennine if phosphorylation is important for the production of TRAIL mRNA, 
stable cell lines were generated (see 2.2.8). Stable H3396 Tet-Off cells were 
employed due to the difficulty in transiently transfecting H3396 cells. It also 
allows for a relevant cell system to be used in which the IRF-I-TRAIL pathway 
has been shown to induce apoptosis. Stable clone that express empty vector (V A4, 
VA7), wild type IRF-l (WXI4, WX3), TI80A-IRF-I (TC5, TOl) or TS-A 
(TSX2, TSX 15) were treated with doxycline for the indicated time period to 
induce the expression of IRF-l. The cells were then lysed and mRNA extracted. 
Neither vector clones were able to significantly increase expression of TRAIL 
mRNA, showing that dox does not induce the cells to produce TRAIL mRNA. As 
expected the wild type clones were able to produce a robust level of TRAIL 
mRNA within a short period of time. All of the mutant clones (TC5, TO 1, TSX2, 
and TSX 15) were significantly less able to induce the expression of TRAIL 
mRNA at each time point tested. Without dox treatment none of the clones 
significantly induced TRAIL mRNA above the levels seen in the empty vector 
clones. This shows that IRF-l is responsible for the induction of TRAIL mRNA. 
The mRNA (not shown) and protein levels of murine IRF-l were tested to 
detennine if the expression of IRF-l was comparable. With the exception of 
TSX 15 all of the clones produced near identical levels of IRF -1 protein. The 
lower level of TSX 15 IRF -1 protein is likely attributed to the lower levels of 
protein blotted (see the actin levels below). 
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Figure 4.8 TRAIL mRNA expression of 83396 IRF-l Tet-Off cell lines. Each clone 
was seeded at 1 x 1 06 and treated with 2 ).tg/mL dox for the indicated time periods. 
Experiments were can;ed out in triplicate, with an additiona l plate being used to check 
protein . A). TRAIL mRNA expression at 0, 24 and 36 hour of dox treatment. TRAIL 
mRNA levels are expressed as ratio to ~ - a c t i n n mRNA B) As for A, but with different 
stable cell lines. C) I 0 ~ ~ g g of protein extract from parallel experiment was 
immunoblotted again t lRF-l M20 and [3-actin to demonstrate expression of induced IRF-
I protein . Data is representative of tlu"ee experiments can"ied out in trip licate. Error bars 
denote standard deviation . * indicate tati tically different from the wild type clone. 
cDNA preparation and QPCR performed by A Rettino . 
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4.7. Discussion 
Alanine substitution ofThr l80 and / or Ser l84 promotes a reduction in the ability of 
IRF-I to bring about transactivation ofa TRAIL promoter fragment (figure 4.IA). 
Alanine does not posses the function hydroxyl group required for 
phosphorylation; consequently the alanine mutants used here have lost their 
ability to be phosphorylated. It should also be noted that other PTMs such as 0-
glycosylation cannot be conjugated to alanine, possibly causing multiple effects 
that are independent of GSK3p signalling. Mutation of Thr and Ser to Ala was 
used because of structural similarities between the amino acids, although it cannot 
be ruled out that these substitutions lead to structural changes. No crystal structure 
is available for IRF-l outside of the DBD, although secondary structure 
predictions can provide some insight into the potential changes in IRF-l structure. 
The PSIPRED programme was used to predict the secondary structure of IRF-l 
(see figure 4.9). No changes were induced by alanine or acidic substitutions, in 
adjacent amino acids of murine IRF-l. Although only a prediction, this suggests 
that major structural changes in IRF-l are unlikely to account for the reduced 
transcriptional activity of IRF-l mutants. 
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Figure 4.9 Predicted secondary structure of IRF-l Phosphorylation 
mutants. Top, diagrams of the amino acids Thr, Ser and the three 
amino acids used to make phosphorylation mutants. Amino acid 
sequences of mouse IRF-J WT, TJ 80A, S1 84A, TS-A, T l 80D and 
S 184E were submitted to the PSIPRED (psipred@cs.ucl. ac. uk) 
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Both the alanine mutants, T180A and S 184A behaved almost identically in both 
reporter systems, as did the double TS-A mutant (see figure 4.1). This suggests 
that the Serl84 does not have a major effect on IRF -1 activity, but acts as a priming 
site for Thr180. The use of two different reporter constructs proves that this 
phenomenon is not restricted to the TRAIL promoter. There are two potential IRF 
binding sites on the TRAIL promoter reporter that are separated by several base 
pairs, while the ISRE reporter contains four concatermized ISRE sequences. It is 
possible that the ability of IRF-I to form conjugates with each other is reduced in 
the alanine mutants. All of the alanine mutants retain some activity suggesting 
that Thrl80 and Serl84 are not completely essential for IRF -1 activity. 
Substitution of either Thrl80 or Serl84 for acidic residues was not able to rescue 
their activity (see figure 4.1). Although in other reports acidic residues have been 
shown to act as phospho-mimics, in some cases they do not behave as expected. It 
should be noted that although the acidic amino acids carry a negative charge, they 
cannot be phosphorylated. Phosphorylation is also a dynamic process, and it is 
possible that the phosphate on Thr180 and Ser184 is added and removed several 
times during the lifespan of IRF-l. Phosphorylation can be added to a protein 
during translation or following translation. Addition of phosphate after the IRF-I 
protein is fully folded could have quite different consequences to the presence of 
acidic residues during translation. Constitutive presence of acidic residues may 
also promote protein-protein interactions that would not normally occur without 
phosphorylation. 
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Lithium modulates a number of TFs activity in reporter assays including, 
E2F 1, ~ ~ catenin, NFKB, AR, ERa and Rev-erba (Espada et al. 2007, Nowicki et 
al. 2008 Nemeth et al. 2002, Wang et al. 2004, Mendez and Garcia-Segura 
2006 and Yin et al. 2006). In reporter assays using the TRAIL promoter, lithium 
chloride was able to cause a dose dependent reduction in activity. The activity of 
IRF -1 in vehicle control treated cells was slightly lower in these assays, possible 
due to the use of NaCI as a control. Osmotic stress may have reduced the activity 
of IRF -1, use of water (the lithium chloride solvent) allowed for a much greater 
induction of IRF-I, and a more significant change in reporter activity at lower 
concentrations oflithium (data not shown). Lithium is a poor inhibitor of G S K 3 ~ , ,
with concentrations of 1 mM in the blood of patients being needed for any 
therapeutic benefit. Lithium is a direct reversible inhibitor of GSK3 with an 1Cso 
of 2 mM in vitro. Numerous potential mechanisms by which lithium inhibits 
GSK3 activity have been proposed, although no consensus has yet been reached. 
Lithium may compete with the Mg2+ ion associated with A TP, or it could inhibit 
the phosphatase responsible for the removal of the inhibitory Ser9 modification. 
Lithium also inhibits a number of other enzymes, including inositol 
monophosphatase (O'Brien and Klein 2009). Lithium chloride treatment did not 
alter the abundance of IRF-I protein in Cos7 or HEK293 cells; it also did not 
promote a change in IRF-l localisation in the latter cell type (data not shown). 
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Modified indirubins that have substantially higher selectivity were used in 
reporter assays to detennine the effect of GSK3 on IRF-I reporter activity. GSK3 
inhibitor IX (6 Bromoindirubin 3'oxime) has an in vitro ICso of 5 nM and inhibits 
CDK enzymes at between 83 and IO,OOOnM). Compared to DMSO control 
inhibitor IX caused a decrease in IRF-I reporter activity (data not shown). A 
similar GSK3 inhibitor (inhibitor X - 6 bromoindirubin 3'acetoxime) produced a 
more significant and consistent decrease in IRF -I reporter activity. It is not known 
why Inhibitor X effected a greater reduction in IRF-l activity then Inhibitor IX. 
The ICso of Inhibitor X is slightly higher than Inhibitor IX (10 nM compared to 5 
nM). Inhibitor X exhibits much greater selectivity towards GSK3 over CDKs 
(ICSO ranging from 2.4-63 J.lM). It is possible that the difference in selectivity is 
responsible for the difference in activity. A control inhibitor was also used; 
methyl-BIO is a methylated derivative with an ICso towards GSK3J3 of more than 
100 J.lM. No significant change in IRF-I activity, compared to DMSO was 
observed when methyl-BIO was added to cells, suggesting that it is the GSK3 
inhibitory activity that is altering IRF-l function. Dose ranges were used to 
detennine any cytotoxic effects of these inhibitors. It was found that 
concentrations greater than 5 J.lM produced a marked decrease in cell growth, 
while concentrations above 10 J.lM initiated cell death (data not shown). 
Collectively, this data suggest that endogenous GSK3 regulates the 
activity of IRF-I while transactivating the TRAIL promoter fragment. The 
maximal reduction in activity was approximately 50% which is close the 
reduction in IRF-l activity following substitution of Thr l80 for alanine. Should the 
GSK3 inhibitors have produced a greater reduction in IRF-I activity then the 
alanine mutants, it might suggest that other aSK3 phosphorylated sites were 
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involved in IRF-I activity. Since this is not the case it could be argued that Thr180 
is the most important GSK3p acceptor residue in IRF-l. 
Knockdown of GSK3p was employed to determine if it was specifically 
this enzyme that was involved in IRF-I transactivation of TRAIL. Knockdown of 
GSK3p promoted a significant reduction in IRF-I reporter activity compared to 
the non targeting siRNA. By reducing the GSK3p protein, both the ability to 
phosphorylate and interact with IRF -I is reduced. The reduction in IRF -1 activity 
is similar to the inhibitors, as such it could be postulated that the major effect of 
GSK3 is brought about by phosphorylation rather than interaction. Knockdown of 
GSK3p also shows that GSK3a is not able to completely compensate for the loss 
of GSK3p. The ability of GSK3a to interact with and phosphorylate IRF-I has 
not been studied here, but a number of substrates have been shown to be 
preferentially phosphorylated by only one isoform (Force & Woodgett 2009). A 
complete knockdown of GSK3J3 was not achievable, most likely due to the high 
stability of GSK3J3 protein. It is possible that the remaining activity in IRF-l is 
due to the remaining GSK3J3 protein. It should also be considered that not all 
GSK3J3 protein is available to phosphorylate IRF-I and so an incomplete loss of 
GSK3p protein may still have significant effects on IRF-I activity. Use of 
exogenously expressed IRF-I rather than using endogenous IRF-l (following de 
novo induction with IFNy) also allowed any effects on IRF-l induction to be 
discounted from the action of GSK3. For example, the IFNy signalling pathway 
relies on a number of phosphorylation events and transcription factors, many of 
which could be regulated by GSK3J3. A recent report suggest that STATs are 
regulated by GSK3J3, suggesting that GSK3J3 may alter the ability of IFNy to 
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induce functional IRF-l protein (Tsai et al. 2009). Knockdown of GSK3p had no 
significant effect on basal (empty vector transfected) activation of the TRAIL 
promoter compared to non targeting siRNA transfection, confirming that GSK3 is 
not regulating basal transcription factors that promote a small induction of 
reporter activity in the absence of IRF -1. In addition to use of inhibitors and 
siRNA a dominant negative mutant of GSK3p was used (K85A). The K85A 
GSK3p was able to promote a dose dependent reduction in IRF-l activity. 
Consequently, GSK3p K85A would appear to act as a dominant negative towards 
IRF -1 activity. 
Figure 4.1 did not show that phosphorylation (or gam of negative charge) 
increases IRF -1 activity on the TRAIL promoter. As figures 3.9-3.12 
demonstrated that increasing GSK3p in cells enhances IRF-l phosphorylation, 
and figure 4.1 shows that the phosphorylated residues are needed for activity, the 
effect of increased wild type GSK3 p was assayed. Increasing the concentration of 
IRF-l and GSK3p on a 1: 1 ratio had no effect of IRF-l reporter activity, as there 
was no significant difference between IRF-l and vector and IRF-l and 
GSK3p (figure 4.6). Increasing the concentration of GSK3p, while keeping the 
IRF -1 concentration static also had no significant effect on IRF -1 activity (data 
not shown). Numerous combinations of IRF-l and GSK3p were used in reporter 
assays, and consistently, no significant increase in activity for IRF-l was detected. 
It is possible that increasing the phosphorylation of IRF -1 does not promote 
increased activity. Potentially proteins that interact with phosphorylated IRF-l are 
limiting in these assays, so no increase in activity is detected. It is also possible 
that increased GSK3p concentration leads to an inappropriate phosphorylation of 
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IRF-l, either in the wrong cell compartment, at the wrong point in the 
transcription cycles, or possibly during the cell cycle. Other PTMs throughout the 
IRF-\ protein may also be needed for full transcriptional activity, the enzymes 
that supply these additional modifications may be rate limiting. GSK3p may also 
phosphorylate other proteins that are involved in the IRF-I dependent 
transcription activity; as such an indirect mechanism may mask the actual increase 
in activity. In all experiments the amount of reporter was increased to allow for an 
increased reporter activity, and titrations of IRF-I had shown that the reporter 
activity was in the linear range during these assays (data not shown). 
Rather than Overexpression of GSK3p protein, an alternative approach was used 
to modify the activity of endogenous GSK3p. Figures (4.1-4.4) suggest that the 
endogenous GSK3 likely plays a role in IRF-I transcriptional activity, so 
increasing the activity of GSK3p was performed with the PI3K inhibitor 
wortmannin. A range of doses were added to reporter assays for 24 hours, but no 
concentration had an effect on IRF-I reporter activity. The level of Ser9 
phosphorylation has not been assayed in the Cos? cells used in this assay, so it 
possible that the wortmannin treatment did not bring about the decrease in 
phosphorylation. It is also possible that very little GSK3p is Ser9 phosphorylated 
in Cos7 cells. Multiple kinases are known to regulate GSK3p via the Ser9 
modification, so it is possible that other kinases could compensate. The activity of 
GSK3p is also controlled by localisation, and sequestration into large protein 
complexes, subsequently treatment by wortmannin may have had little effect on 
the activity of GSK3p. The data from figure 4.6 also suggest that even if the 
activity of GSK3p was increased by wortmannin and enhanced phosphorylation 
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of IRF -1 occurred, this may not increase its reporter activity. These results 
contrast those of Wang et al. 2002, in which wortmannin was shown to enhance 
TRAIL mRNA expression in colon cancer cells. This group then went on to show 
that GSK3p regulates TRAIL mRNA expression, as inhibitors of GSK3p prevent 
TRAIL induction by wortmannin. This study predated the discovery of IRF -I as a 
major regulator of TRAIL expression (Wang et al. 2002). Collectively these 
figures suggest that although Thr180/Ser184 and phosphorylation are important for 
IRF -I activity, these modifications are tightly regulated, as constitutive 
phosphorylation (acidic mutants) or enhanced phosphorylation (GSK3p over 
expression) do not promote IRF-I transcriptional activity. Finally to determine if 
the reporter assays correlate with mRNA induction, H3396 cells which express 
IRF -I following treatment with dox were assayed for their TRAIL mRNA. In a 
very similar fashion to figure 4.1, neither Tl80A nor TS-A IRF-I expressing cells 
were able to induce as much TRAIL mRNA as wild type clones despite 
expressing comparable levels of IRF-l protein. Two clones of each were tested 
and found to produce similar amounts of TRAIL mRNA. Consequently, the 
reporter assays predict the outcome of IRF-I on the full TRAIL promoter. 
Although not tested here, it is likely that GSK3p inhibitors and siRNA would 
have similar effect on TRAIL mRNA as TRAIL reporter activity. High sustained 
induction of IRF-l is required to efficiently induce TRAIL dependent apoptosis, 
possible due to the large amounts of TRAIL mRNA (and therefore protein) 
needed to trigger apoptosis (Clarke et al. 2004). As such from this data it is 
unlikely that the TI80A or TS-A mutant would be able to promote apoptosis to a 
similar degree as wild type IRF -I. 
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CHAPTER 5 
IRF-l TURNOVERIS 
REGULATED BY 
PHOSPHORYLATION 
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5.1. Introduction 
In this chapter, potential mechanisms by which phosphorylation effects IRF-
1 function were investigated. The subcellular localisation of IRF-l was not 
affected by alanine substitution, GSK3B expression or GSK3B inhibitors 
(Supplementary figure S3 and data not shown). However, replacement of 
Thr180 and/or Ser184 to alanine reduced in vivo ubiquitination and promoted 
an increase in IRF-l t1l2. Conversely phosphomimetic mutants of IRF-l were 
more ubiquitinated and less stable. Increasing GSK3B expression destabilised 
IRF-l, while dominant negative GSK3B stabilised IRF-l. To determine if 
stability of IRF-l is responsible for the variation in transactivation, reporter 
assays using the TRAIL promoter were carried out in the presence of the 
proteasome inhibitor MG132. While inhibition of the proteasome (and IRF-l 
turnover) had no effect on the phosphorylation mutants of IRF-l, wild type 
IRF-l activity was greatly reduced. To confirm that IRF-l 
ubiquitination/degradation was essential for its transcriptional activity, lysine 
mutants of IRF-l that were less ubiquitinated were designed. Lys240 and 
Lys2SS were identified as potential ubiquitin acceptor residues. K240R and 
K255R mutants of IRF -1 were less able to transactivate the TRAIL 
promoter, suggesting that ubiquitination and proteasomal degradation of 
IRF -1 is regulated by phosphorylation, and are needed for full 
transcriptional activity. 
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5.2. Mouse IRF-l is ubiguitinated 
Previous reports have identified human IRF -1 as a ubiquitinated protein 
(Nakagawa and Yokosawa 2000). To confirm that mouse IRF-l was also 
ubiquitinated in vivo ubiquitination assays were performed in which murine IRF-l 
was co-expressed with FLAG-Ubq (figure 5.1). Transfected cells were either 
treated with vehicle (DMSO) or the proteasome inhibitor MG 132. In concurrence 
with figure 3.7 the levels of IRF-l protein are increased following MG132 
treatment, suggesting that mouse IRF -1 is degraded through the proteasome. The 
levels of FLAG-Ubq conjugates are also increased following MG 132 treatment 
showing that ubiquitinated proteins are not stable - due to its ability to act as a tag 
for protein destruction. FLAG-Ubq migrated as mUlti-ubiquitin conjugated protein 
polymers rather than a single band at the predicted 10 kDa. This is due to the 
integration of FLAG-Ubq onto cellular proteins. When co-immunoprecipitation 
was carried out using the FLAG Ab to IP FLAG-Ubq, IRF-l was brought down 
(figure S.IA). This confirms that mouse IRF-I interacts with FLAG-Ubq. The 
amount of IRF-l co-immunoprecipitated by FLAG-Ubq was greater following 
MG132 treatment possibly because of the higher levels ofIRF-l and FLAG-Ubq 
in the MG 132 lysates. Next, an alternative strategy was employed in which 
FLAG-IRF-I was co-transfected with HA-Ubq (figure 5.1 8). This was due to the 
inability of the IRF -1 M20 Ab toimmunoprecipitate the poly-ubiquitinated IRF-I 
(data not shown). Protein extracts expressing IRF-I alone, HA-Ubq alone and 
both in combination with and without MG 132 were immunoprecipitated with 
FLAG Ab, and immunoblotted with HA Ab to detect the poly-ubiquitinated IRF-
I. The HA Ab did not detect any immunoprecipitated Ubq conjugated proteins in 
control extracts containing FLAG-IRF-l or HA-Ubq alone. Ubq conjugated 
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proteins could also not be immunoprecipitated by FLAG Ab in DMSO trcated 
cells. A poly-Ubq IRF-I smear cou ld on ly be detected in the extracts in which 
both IRF-I and Ubq were co-expressed in MG 123 treated cel ls. The protein smear 
began at approximately 75 kDa and extended to just under 250 kDa. Given the 
approximate 10 kDa mass of HA-Ubq, this suggests the lowest detected bands are 
di-ubiquitinated IRF-I and the highest band contain approximately twenty 
ubiquitin conjugates. 
A. 
5Ot<De1 __ I ex IRF-1 
5OI<Dal ____ I ex ~ A c t i n n
FLAG-UBQ + + + 
WTIRF-1 
MG132 
- + + 
+ 
B. 
~ ~ ~ ~ = = = = = = = = ; : : : ~ I · · ~ ~SOkD. ~ ~ II i a FLAG 
~ ~ ~ ~ ~ I · ~ ~
S O k D D - 1 ~ = = = = · = _ = = . = s = = : 1 1 a FLAG 
MG132 - + + + 
HA-Ubq + + + + 
FLAG-WT IRF-1 + + + + 
Figure 5.1. Murine IRF-l ubiguitination is detectable in MG132 treated 
protein extracts. A) HEK293 cells transfected with 5 flg of mou e IRF- I and 
FLAG-ubiquitin or FLAG empty vector for 48 hours. 6 hours plior to lysis cells 
were treated with DMSO or MG 132. Protein lysates (0.5 mg) were 
immunoprecipitated with FLAG Ab and immunoblotted with IRF-l M20 Ab. 
Lysates (10%) are shown to indicate the levels oftransfected proteins. B) As for 
A, but using HA-Ubq and FLAG-IRF- I (mouse), IP was perfonned using FLAG 
Ab and WB with HA 12CA5 Ab. 10% lysates indicate the expression of 
transfected proteins. 
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5.3. IRF-l phosphorylation mutants show differential ubiguitin conjugation. 
To detennine if the phosphorylation status of IRF-I modulates the incorporation 
of HA-Ubq, the alanine and phospho mimic mutants were expressed in HEK293 
cells as for figure 5.1. All protein lysates were from cells treated with MG 132, as 
without MG132 no poly-Ubq IRF-l could be detected (see figure 5.1). 
Consistently all of the alanine substitution mutants showed reduced incorporation 
of HA-Ubq, with the Ubq smears pulled down by the FLAG Ab being fainter or 
absent (figure 5.2). The total amount of IRF-I immunoprecipitated was detected 
by immunoblot with FLAG Ab. The amount of un-modified IRF-I was similar 
between each mutant, showing the total IRF-l was unchanged between IRF-l 
mutants. The phosphomimetic mutants demonstrated similar or higher levels of 
HA-Ubq conjugation to wild type IRF-l. No HA-Ubq conjugation was detected in 
extracts expressing empty vector, showing that ubiquitinated IRF-I was being 
detected rather than a non specific protein immunoprecipitated by FLAG Ab. 
Curiously, MG132 treatment reveals a second IRF-I band with a faster migration. 
This species was found in all of the mutants and could only be detected in extracts 
from MGl32 treated cells. This lower band was detected using FLAG and IRF-I 
M20 Ab, confirming its identity as IRF-l. The band migrated slightly above 40 
kDa. 
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37kDa 
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fLAGWT IRF-1 + 
FLAGT180A IRF-1 + 
FLAG S184A IRF-1 + 
FLAGTS-A IRF-1 + 
FLAG T1.80 D IRF-1 - + 
FLAGS184E IRF-1 + 
MG132 + + + + + + + 
Figure 5.2 Differential ubiguitination of IRF-l phosphorylation mutants. HEK293 cells 
were transfected with 2.5 )lg of HA-UBQ and 2.5 )lg FLAG-IRF-l for 48 hours. 6 hours 
prior to lysis cells were treated with 10 )lM MG 132. Protein 1ysates (0.5 mg) were 
immunoprecipitated with FLAG and immunoblotted with HA Ab. Blots were re-probed with 
FLAG Ab to confinn FLAG-rRF-l immunoprecipitation. Lower panel (lysates) 10% inputs 
to demonstrate expression of transfected proteins. (WT wildtype, TA T180A, SA S 184A, 
TS-A TI80A/S 184A TO T 1800 and SE S I 84E). 
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5.4 GSK3B modulates incorporation of Ubg onto IRF-l 
To confirm the importance of phosphorylation on IRF-l ubiquitination, wild type 
FLAG-IRF-l was co-expressed with HA-Ubq and G S K 3 ~ - H A A (figure 5.3). 
Controls of G S K 3 ~ - H A A transfected with HA-Ubq confirmed that FLAG Ab does 
not IP ubiquitinated G S K 3 ~ - H A A (data not shown). All protein lysates were from 
MG 132 treated cells as ubiquitin conjugation could not be detected in cells with 
active proteasome. Lysates illustrating the levels of transfected proteins show that 
G S K 3 ~ - H A A expression does not alter the expression of HA-Ubq or FLAG-IRF-l. 
HA-ubiquitination of IRF-l in cells not expressing G S K 3 ~ - H A A were similar to 
previous figure showing that increased DNA transfection did not alter HA-Ubq 
incorporation. The relative amount of HA-Ubq conjugated IRF-l was greater in 
cell extracts expressing wild type G S K 3 ~ - H A A then vector, while the K85A mutant 
of G S K 3 ~ - H A A did not promote increased ubiquitination of IRF-l. Additionally 
G S K 3 ~ - H A A was consistently co-immunoprecipitated with FLAG-IRF-l in these 
assays confirming the experiment presented in figure 3.9 that FLAG-IRF-l and 
G S K 3 ~ - H A A interact with one another. 
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MG132 + + + GSK3pHA WT + 
GSK3 P HA K8SA + 
MG132 + + + 
Figure 5.3 GSK36 regulates IRF-l Ubiguitination. Assays were performed as 
described in figure 5.2, but with the additional transfection of 2.5 ~ g g of HA empty 
vector, G S K 3 ~ - H A A WT or G S K 3 ~ - H A A K85A. Left panel demonstrates expression 
of lysates. The band in the HA panel above 37 kDa is G S K 3 ~ - H A . . Right panel in 
vivo ubiquitination assay with additional co-immunoprecipitation of G S K 3 ~ - H A . .
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5.5. Thrl80/Serl84 are important for IRF-l stability 
Most fonns of poly ubiquitination result in degradation of its substrates. 
Ubiquitinated IRF-l could not be detected without the addition of the proteasome 
inhibitor MG132; as such it is likely that the ubiquitination of IRF-l is related to 
its degradation. Cycloheximide (CHX) chases were carried out in MRC-5 cells 
expressing IRF -I and its phosphorylation mutants. Addition of CHX to cells 
results in a block in translation. This prevents any new IRF-I from being 
produced in the cells, leaving the remaining IRF -I to be degraded. Time courses 
of CHX addition were then carried out to determine the rate of loss of IRF-I 
protein. Various concentrations of CHX were tested, but all were found to have 
the same effect on IRF -I, as such the middle concentration (25 f-Lg/mL) was used. 
Time points ranging from 15 minutes to 4 hours were tested. In all experiments 
the amount of wild type IRF-I decreased 90% by 2 hours and did not decrease 
any further, to prevent any unwanted side effects of CHX treatment, time points 
longer than 2 hours were not used. Short time points such as 15 minutes were not 
used because of the difficulty in preparing protein samples accurately for this time 
point. 
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mlRF l J) Actin 
IRF-l WT 
IRF -l T180A 
IRF- lS184A 
IRF- l TS-A . - . ~ ~
Time post CH X ~ ~ 45 50 
addition / minutes 
l l 45 
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.. 
~ ~ 12 
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~ T 1 8 0 A A
~ S 1 8 4 A A
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Figure 5.4 lRF-l Alanine mutants exhibit increased stability. CHX assays were 
perfonned on MRC-5 cells transfected with 4 )lg of IRF-1. 2.5 )lglmL CHX for the 
indicated time points. Protein lysates (15 )lg) were immunoblotted with IRF-l M20 and ~ ~
actin . lRF-J protein was divided by ~ - a c t i n n protein to COITect for protein loading. Data is 
expressed as a precentage of the 0 minute time point. CHX time point versus time in 
minutes. Data is from three independent experiments with each set of extracts being 
immunoblotted in duplicate. En'or bar denote standard deviation. The upper panel IS a 
representative immunoblot of lRF-1 and ~ - a c t i n . . (TS-A T 180AfS 184A) 
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wild type IRF-l was found to have a half life of approximately 35-37 minutes, 
(figure 5.4) this is close to the other halflives reported in the literature (Pion et al. 
2009). Wild type IRF-I stability in HEK293 cells is almost identical (not shown). 
All three alanine substitution mutants exhibited slower turnover, with half lives in 
the range of 50-60 minutes. The half life of the double TS-A mutant was greater 
than the half life of the individual T180A and S 184A. This data is consistent in 
the HEK293 cell line and the H3396 -IRF-l Tet Off cell lines (data not shown). 
Conversely, the two phosphomimetic mutants of IRF-l (T180D and S184E) were 
less stable then wild type IRF-I, with a reduced half life of 20-25 minutes (figure 
5.5). Both phosphomimetic mutants were also less stable in HEK293 cells (data 
not shown). 
211 
Post Translational Regulation of the Tumour Suppressor IRF-l 
IRF-l P Actin 
IRF -I WT 
IRF-I TI800 .. 
IRF-I SI84E 
Time post CHX 0 30 45 60 120 0 30 45 60 120 addition / minutes 
Figure 5.5 IRF-l phospho-mimic mutants exhibit decreased stability. CHX assays 
were performed on MRC-5 cells transfected with 4 jlg of lRF-l. Cells were treated 
with 2.5 jlglmL CHX for the indicated time points. Protein lysates (15 jlg) were 
immunoblotted with IRF-l M20 and p-Actin. IRF-l protein was divided by p-Actin 
protein to COITect for protein loading. Data is expressed as a precentage of the 0 minute 
timepoint. Data is from three independent experiments with each set of extracts being 
immunoblotted in duplicate. Error bars denote standard deviation. The upper panel 
shows representative immunoblots of IRF-l and p-Actin. 
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5.6. GSK3B regulates IRF-l stability 
As increasing phosphorylation of IRF-l by transfecting G S K 3 ~ - H A A promotes 
increased ubiquitination (figure 5.2), the effects of G S K 3 ~ ~ expression on IRF-l 
turnover was assed using CHX chase assays in MRC-5 cells (figure 5.6). Wild 
type G S K 3 ~ ~ promoted a drastic reduction in IRF-l half life, reducing from 30 
minutes to 25 minutes. The K85A mutant which interacts with IRF-l (figure 
3.18), but does not phosphorylate IRF-l (figure 3.13) did not increase IRF-l 
ubiquitination. To determine if this was translated to a change in IRF -1 stability, 
K85A was also used in these assays. The K85A mutant of G S K 3 ~ - H A A promoted 
an increase in IRF-l half life, from 30 minutes to 60 minutes. The lower panels 
showing expression of transfected proteins shows that GSK3 ~ ~ protein is not 
reduced by CHX treatment during these assays. To study the effects of G S K 3 ~ ~ on 
endogenous IRF-l in MRC-5 cells, G S K 3 ~ - H A A wild type and K85A were 
transfected for 24 hours (figure 5.7). Prior the CHX chase, a three hours IFNy 
treatment was used to induce human IRF-l protein. The levels oflRF-l in MRC-5 
are too low for accurate measurement in CHX chase assays. IFNy induced IRF-l 
has a half life that is almost identical to the half life of mouse IRF-l when 
expressed in MRC-5 cells. Wild type G S K 3 ~ ~ promoted a very small decrease in 
IRF-l stability, with a decrease of 5 minutes in half life. The K85A mutant of 
G S K 3 ~ ~ increased IRF-l half life by over 10 minutes. Neither the endogenous 
(lower) or exogenous (upper) G S K 3 ~ ~ protein expression were altered by CHX 
addition. 
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Figure 5.6 GSK3B decreases IRF-l stabilitv. CHX assay were performed on 
HEK293 cell s transfected with 2.5 ~ g g G S K 3 ~ ~ and 2.5 ~ g g IRF-I . Cells were 
treated with 2.5 ~ g l m L L CHX for the indicated time points. Protein lysates (IS J.1g) 
were immunoblotted with lR F- 1 M20, HA and ~ - a c t i n . . IRF-I protein was divided 
by ~ - a c t i n n protein to correct for protein loading. Data is expressed a a precentage 
of the 0 minute time point. Data i from three independent experiment with each 
set of extracts being immunoblotted in duplicate. Error bars denote standard 
deviation . The lower panel how representative immunoblot of IRF-l , HA and 
~ - a c t i n . .
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Figure 5.7 GSK3B decreases human IRF-l stability. MRC-5 cells were 
tran fected with 2.5 Ilg G S K 3 ~ - - A A or empty vector. Cell s were induced for 3 
hour with 1000 ImL IF y, wa hed and treated with CHX for th indi cated time 
point (2.5 IlglmL). IS ).lg of protein lysate were blotted aga inst human IRF- I 
(C20), G S K K ~ ~ and ~ ~ a c c i n . . Data wa calcul ated a for figure 5.4 onwards. Lower 
panel , representati ve immunoblot of IRF-l , G K K ~ ~ and ~ ~ a c c i i . . The 45 minute 
time point is not plotted on the graph . Error bars denote standard deviation. 
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5.7 MG132 inhibits IRF-l transcriptional activity on the TRAIL promoter 
Variation in IRF-l stability may explain the differences in transcriptional activity 
between wild type and the phosphorylation mutants of IRF-l. To determine if 
increasing the stability of the phosphomimic mutants enhanced their 
transcriptional activity, reporter assays were carried out on TRAIL reporter with 
each mutant of IRF-l either treated with DMSO or MG132 (figure 5.8). 
Proteasomal inhibition had no effect on the activity of any of the alanine 
substitutes. The activity of the phosphomimics was not increased by MG 132 
treatment; despite the vast increase in IRF -1 protein levels for these mutants 
(figure 5.8 bottom panels). Significantly, the activity of wild type IRF-l was 
reduced following MG 132. The increase in protein expression following MG 132 
treatment is demonstrated in the western blot below, showing that following 
MG 132 all mutants are expressed at equal levels. 
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Figu re 5,8 MGJ32 in hi bits I RF-I transcriptional activity, Cos7 cells were 
transfected with 5 ng pGAL control plasmid, 50 ng IRF- I and ISO ng TRAIL 
promoter reporter for 48 hours. 16 hours plior to repOlter assay cells were treated 
with 10 )lM MG 132 or DMSO (0.0 I %). Results are expressed as fold induction 
compared to empty vector tran fection for each treatment. Data is from three 
independent experiments carried out in triplicate. ElTor bars denote standard elTor. 
* signifies significant difference as detennine by Students t-test (p<0.05). Lower 
panel immunoblot of IRF- l (M20) and ~ - a c t i n n from para ll el transfected wells . 
Each lane contains total protein lysates from a single well. (TS-A Tl80A/S l84A). 
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5.8 Prediction of potential ubiguitin acceptor lysine 
To detennine if the stability of IRF -I was important for its transcriptional activity 
a ditferent approach to the use of proteasome inhibitors was pursued. It has been 
established that ubiquitination of IRF -1 predominantly leads to degradation (Pion 
et al. 2009). Lysine residues are the major amino acid that can be conjugated to 
ubiquitin, so the potential acceptor Lys residues were mapped on IRF-l. Previous 
reports have suggested that IRF -I degradation occurs through residues in the far C 
tenninus of human IRF-l. The first report by Nakagawa suggested the last 39 
amino acids of IRF-l are required for degradation (Nakagawa and Yokosawa 
2000). Later Kim and co-workers suggested that Lys275 and Lys299 were major 
ubiquitin acceptor residues. SUMO-I ylation also occurs on these residues and it 
was noted that SUMO-I ylation of IRF-I increases the protein half life (Park et al. 
2007). Work on a series of splicing mutants of human IRF -I also suggested that 
the stability of IRF-I is controlled via the C tenninus (Lee et al. 2006). To help 
predict which lysine may be ubiquitinated, two prediction programmes were used, 
with the amino acid sequences of human and mouse IRF -I being submitted to the 
UniPred and UbPred programmes (figure 5.9) only the Lys that are conserved 
between human and mouse IRF-I are shown. 
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Figure 5.9 Prediction of potential ubiguitin acceptor Ivsines in IRF-l. A. 
Schematic diagram of human IRF-l and it major domain . Location of individual 
ly ine re idue i indicated. 8) Two ubiquitination prediction programme 
(UniPred and UbPred) were us d to predict potential Ubq acceptor residues. Only 
ly inc residues which are con erved between human and mou e IRF-I are 
illu trated. Indicated Lys re idue are highlight in pink. Surface expo ure data wa 
from experiment with mouse IRF-l carried out in Schaper el al. 2000. Amino 
acids in bracket repre ent the position in murine lRF-l. 
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The predicted residues were different between the two programmes, with the 
UniPred programme predicting several residues within the DBD of IRF-I. Data 
from epitope mapping (Schapcr e/ al. 1998) shows that thi s region is not solvent 
exposed, and as ubiquitin acceptor Lys need to be available to E2 enzymes, these 
residues were discounted . Additionally crystal structure data for the IRF-\ DBD 
also suggested that these residues are all buried in DNA bound mouse IRF-I 
(Escalante el al. \998). Neither programmes detected Lys within the NLS of IRF-
I, although several Lys residues in this region are known to be solvent exposed . 
Several predictions were madc in the C tel111inus, which has already been shown 
to be important for IRF-I ubiquitination ( akagawa and Yokosawa 2000). The 
five C terminal Lys were studies fUl1her, with each re idue being substituted for 
arginine, which is structurally and chemically similar to lysine, but cannot 
undergo ubiquitination (figure 5.10). 
'),.:.? ~ r : , , '),4' <0-'" ~ ~ ~
WT IRF-1 .Ii(I.A5DLMKLFEQSEWQPTHIDGK GYLLNEPGTQLSSVYGDFSCKEEPEIDSPRGDIGIGIQHVFTEMK 
K233R IRF-1 RIAEDLMKLFEQSEWQPTHIDGKGY LLNEPGTQLSSVYGDFSCKEEPEIDSPRGDIGIGIQHV FTEMK 
K240R IRF-1 K IAEDLMRLFEQSEWQPTHIDGKGY LLNEPGTQLSSVYGDFSCKEEPEIDSPRGDIGIGIQHVFTEMK 
K255R IRF-1 KIAEDLMKLFEQSEWQPTHIDGRGYLLNEPGTQLSSVYGDFSCKEEPEIDSPRGDIGIGIQHV FTEMK 
K276R IRF-1 KIAEDLMKLFEQSEWQPTHIDGK GY LLNEPGTQLSSVYGDFSCREEPEIDSPRGDIGIGIQHV FTEMK 
K300R IRF-1 KIAEDLMKLFEQSEWQPTHIDGK GY LLNEPGTQLSSVYGDFSCKEEPEIDSPRGDIGIGIQHV FTEMR 
K2761300R IRF-1 K IAEDLMKLFEQSEWQPTHIDGK GYLLNEPGTQLSSVYGDFSCREEPEIDSPRGDIGIGIQHV FTEMR 
3KR IRF-1 KIAEDLMKLFEQSEWQPTHIDGRGYLLNEPGTQLSSVYGDFSCREEPEIDSPRGDIGIGIQHVFTEMR 
4KR IRF-1 KIAEDLMRLFEQSEWQPTHIDGRGYLLNEPGTQLSSVYGDFSCRE EPEIDSPRGDIGIGIQHV FTEMR 
K240J255R IRF-1 K IAEDLMRLFEQSEWQPTHIDGRGYLLNEPGTQLSSVYGDFSCKEEPEIDSPRGDIGIGIQHVFTEMK 
S.lO. lysine-arginine mutants used in this study. Amino acid sequence of 
murine lRF-\ , with lysine residues indicated in bold. Where lysine residues are 
substituted for Arg the residue is indicated as a red R. 
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5.9 Mapping of potential Lys Ubg acceptor residues 
Each FLAG-IRF-I K -7 R mutant was expressed in HEK293 cells (figure 5.11 A). 
All of the K -7 R mutants of IRF -I migrated at 50 kDa. No K -7 R mutant was 
found to express at higher levels than wild type IRF -I. When treated with MG 132 
all of the mutants increased at the protein level. This indicated that all of the 
K -7 R mutants were undergoing proteasomal degradation. In addition high 
molecular weight conjugates of IRF-I could be detected in MG 132 treated cell 
extracts, these bands could potentially be poly-ubiquitinated IRF-I (figure 5.11 B). 
The two double mutants (K240/255R and K276/300R) were also not expressed at 
higher levels than wild type IRF-I, and like the single mutants were sensitive to 
MG 132 and exhibited poly-ubiquitination. To confirm the addition of ubiquitin to 
each of these K -7 R mutants, in vivo ubiquitination assays were performed (figure 
5.12). With the exception of K240R and K255R, all of the K-7R mutants 
exhibited similar levels of ubiquitin incorporation to wild type IRF -I. 
Ubiquitination appeared to be slightly lower in the K276R mutant; however inputs 
show that the HA-Ubq was not as highly expressed in those extracts. Next CHX 
chases in HEK293 cells were performed to determine if the half life of each 
mutant was affected (figure 5.13). Neither the K300R nor K276R exhibited any 
change in half life. A small increase in half life was observed in the K233R 
mutant, while a doubling of half life was observed in the K240R and K255R. This 
data agrees with figure 5.12 and suggest that while they are not the sole acceptor 
residues, K240 and K255 are important residues for IRF-I ubiquitination and 
degradation. Many substrates are ubiquitinated on multiple residues rather than 
relying on a single Lys acceptor. To determine if this was the case; the double 
mutants were subjected the CHX chase (figure 5.14). An increase in half life was 
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ob erved in the K276/K300R mutant, although n t a very large increa e. Joint 
substitution of K240 and K255 to Arg did not produce any further increase in half 
life compared to the K240R and K255R single mutants. A triple (K300/276/255R) 
and quadruple (K300/276/255/240) mutant of IRF-I wa produced . Surpri ingly 
these mutant had a significantly decrea ed half life compared to wild type IRF-l . 
It is poss ible that these substitutions promote mi sfolding of IRF-I and cause 
destruction of the protein. The 3KR and 4KR mutants were also sensitive to 
MG 132 and underwent in vivo ubiquitination (data not shown). 
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Figure 5.11. lRF-1 K-R substitution mutants expression in HEK293 cells. 
A) Each mutant was expres ed in HEK293 cell (2.5 Ilg/plate) for 48 hours. 
Prior to I y is cells were treated with DMSO or 10 )..I M MG 13 2 for 6 hours. 10 
)..Ig of protein extract wa ubjected to immunoblot with FLAG Ab. B) Longer 
exposure of MG 132 treated extract reveals the presence of poly-Ubq IRF-1 
conjugate . 
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Figure 5.12. In vivo ubiguitination of K ~ R R substitution mutants of IRF-
!.:...HEK293 cells expressing FLAG-IRF-l K ~ R R mutants and HA-Ubq (2.5 Ilg 
of each) were treated for 6 hours with 10 IlM MG 132 prior to lysis. 0.5 mg of 
protein extracts were immunoprecipitated with FLAG Ab, Eluates were 
subjected to immunoblot with HA Ab. Blots were re-probed with FLAG Ab to 
dete1111ine efficiency of IRF-l IP by FLAG. Lower panels (10% Lysate) 
demonstrate expression of transfected proteins. 
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Figure 5.13 K240 and K255 are important for IR F-J stability. HEK293 celIs 
transfected with 2,5 ~ g g of FLAG-IRF-I wi ld type and K ~ ~R mutants were chased 
with CHX (2.5 ~ g - m L ) ) for the indicated times . Protein Iysates were 
immunoblotted for FLAG and ~ - a c t i n n (10 J..lgllane) in duplicate. A) Data is from 
three individual experiments. Data is expressed as % IRF-I expression compared 
to the 0 minute time point. B) Repre entative immunoblots of K ~ R R substitution 
mutants. The half lives of each mutant are indicated in C). Error bars denote 
standard deviation and * significant difference as determined by Students-t test p 
<0.05 . 
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Figure 5.14 Multiple K ~ R R substitutions do not increase IRF-l stability. HEK293 
cells transfected with 2.5 )..lg of FLAG-IRF-J WT and KR mutants were chased with 
CHX (2, 5 ~ l g - m L ) ) for the indicated times. Protein Iysates were immunoblotted for FLAG 
and ~ - A c t i n n (10 )..lg/lane) in duplicate. Data i from three individual expeliments. Data is 
expressed as % IRF-l expression compared to the 0 minute time point. B) Representative 
immunoblots of K ~ ~R substitution mutants. 
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5.10. Full ubiguitination of IRF-l is needed for transcriptional activity. 
Although an ubiquitin insensitive mutant of IRF-I could not be produced in this 
work, the small changes in stability and ubiquitination were similar to the levels 
achieved with the alanine mutants of IRF-I. These mutants were tested to 
determine if they had decreased transcriptional activity in reporter assays using 
the TRAIL promoter reporter. The K233R, K240R and K255R mutants exhibited 
a significant reduction in activity compared to wild type IRF-I, while the K276R 
mutant possessed activity close to that of wild type IRF-I (figure 5.15). To be sure 
that the decrease in reporter activity was not due to loss of phosphorylation at 
ThrI8°/SerI84, each mutant was co-expressed with empty vector or G S K 3 ~ - H A A in 
HEK293 cells (figure 5.16). Phosphorylation on ThrI8°/SerI84 could be detected on 
all of the K -7 R substitutions. The levels of phosphorylation varied greatly 
between experiments, however consistently all of the K-7R mutants were 
phosphorylated at ThrI8o/SerI84. This suggests that phosphorylation occurs 
upstream prior to ubiquitination, and that ubiquitination is not dependent on 
phosphorylation at ThrI8°/SerI84. However the status of the lysine residues in the 
far C terminus may have an impact on the phosphorylation of IRF-I at 
ThrI8°/SerI84. 
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Figure 5.15 Reduced ubiguitination of IRF-l decreases transcriptional 
activity. TRAI L reporter assays were carried out in Cos-7 cells transfected with 
50 ng FLAG-IRF-I , 75 ng TRAIL reporter promoter and 5 ng ~ G A L L control 
pia mid. Transfections were calTied out for 48 hours. Data is shown as a fold 
increa e in reporter activity compared to empty vector transfected cells. Data i 
from three independent experiments canied out in triplicate. Error bars denote 
tandard deviation and * denotes statistical significance determined by Student t-
te t p>0.05 . 
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Figure 5.16 K-7R mutants of IRF-l are phosphorylated at Thr'8o/SerI84 in 
response to GSK36 expression. HEK293 cells were transfected with 5 ~ g g of 
FLAG-IRF-I and G S K 3 ~ - H A A or empty vector for 48 hours. Protein Iysates (1 
mg) were immunoprecipitated with FLAG Ab and immunoblotted with p-T/S Ab. 
Blots were stripped and re-probed with FLAG Ab to confirm the presence of IRF-
1. Lower panels (5% lysates) demonstrate expression of transfected proteins. 
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5.11 Discussion 
A positive interaction between mouse IRF-l and human ubiquitin was shown by 
co-immunoprecipitation (figure 5.1). The interaction only occurred in the 
presence of MG 132 suggesting that this modification quickly promotes 
degradation. No mono or multi-mono ubiquitination could be detected; rather the 
poly-ubiquitination was uniform. As such it can be assumed, that like human IRF-
I, mouse IRF -I is primarily poly-ubiquitinated and this ubiquitination promotes 
degradation through the proteasome. Studies by Pion et al. used a mutant of 
ubiquitin which cannot undergo linkages through its K48 residue. A significant 
loss of ubiquitination was detected when this mutant was used, however some 
ubiquitination remained. Other chain types such as Lys27 have been identified as 
degradation promoting chains (Komander 2009). Ubiquitin mutants are available 
in which each potential Lys is mutated to Arg, in addition to mutants that only 
contain a single ubiquitin conjugating lysine. Use of these mutants would help to 
discriminate which chain type(s) are most prevalent in IRF-l ubiquitination. In 
addition further understanding of the types of ubiquitination occurring would help 
in the identification of the E3 ligases responsible and the possible effects of the 
modification of IRF-I activity. The lack of any detectable ubiquitination in cells 
with active proteasome suggests that ubiquitin does not playa role in IRF-I 
activity that is independent of degradation. Alternatively, such as in the case of 
SRC-3, monoubiquitination which serves to promote protein-protein interaction is 
a short lived modification which initiates poly-ubiquitination and therefore 
destruction (Wu et al. 2007). As such mono ubiquitination that is independent of 
degradation of IRF-l may be an extremely short lived modification. It is also 
possible that other non degradative ubiquitin chain types are added to IRF-l, but 
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are either not highly abundant, or are removed by DUB enzymes making their 
identification difficult. Particular stimuli may also be needed to promote non 
degradative ubiquitination of IRF-1 such as viral infection. IRF-l has not been 
shown to contain a functional nuclear export signal (NES), and prediction 
programmes (NetNES 1.1) failed to detect a leucine rich NES in either human or 
mouse IRF-l. It is therefore likely that IRF-l is imported into the nucleus and 
degraded by the proteasome in the same compartment. 
Although produced from strong viral promoter (CMV) small differences in the 
protein levels of the alanine and phosphomimic mutants could be detected when 
lower levels of plasmid were transfected (data not shown). This led to the 
supposition that Thrl80 and Serl84 may regulate IRF-I stability through 
ubiquitination. The considerable precedence in the literature supported a role for 
GSK313 dependent phosphorylation in ubiquitination (Xu et al. 2009a) prompting 
the study of ubiquitination of the phosphorylation mutants used in this study. As 
for the wild type IRF -I no ubiquitination could be detected on any of the mutants 
without MG 132 treatment (not shown). All of the mutants were stabilised by 
MG 132 treatment suggesting a common route of degradation for all of these 
proteins (figure5.2). The levels of ubiquitination on the alanine mutants were 
significantly decreased in comparison to wild type IRF-I in which ubiquitination 
could be robustly detected. The levels of ubiquitination for the alanine mutant 
varied from no HA-Ubq incorporation, to 50% of wild type. The total amount of 
IRF -I immunoprecipitated in these assays was similar between different mutants 
showing that the proportion of HA-Ubq-IRF-I was dependent on the status of 
Thrl80 and Ser184. Serl84 behaved similarly to Thrl80 in these assays, as it also does 
in the reporter assays from chapter four (figure 4.2). In figure 5.3 the TS-A mutant 
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docs not appear to be ubiquitinated at all, although the amount of HA-Ubq in 
those extracts was less. Generally, the TS-A mutant was ubiquitinated to the same 
extent as the individual Thrl80 and Serl84 mutants. HA-Ubq was used in these 
assays as endogenous Ubq is a highly abundant protein, and determining changes 
in substrate ubiquitination is more problematic. This approach enables the amount 
of ubiquitin in the cell to be controlled with only the incorporation of HA-Ubq 
being studied. 
In contrast to the alanine mutants, the acidic mutants exhibited HA-ubiquitin 
incorporation that was similar or greater than wild type (figure 5.2). This inferred 
that charge on Thrl80 and Serl84 are promoting ubiquitination of IRF -1, as such 
IRF-l is likely to be a phosphorylation dependent ubiquitination substrate. To 
determine if GSK3p dependent phosphorylation was responsible for the increased 
ubiquitination, wild type and K85A GSK3p were co-transfected in ubiquitination 
assays with wild type IRF -1. The level of ubiquitination of wild type IRF -1 was 
increased when wild type GSK3p was co-expressed (figure 5.3). As over-
expression of GSK3 p promotes an increase in phosphorylation of IRF -Ion Thrl80 
it is likely that this promotes the enhanced ubiquitination. To be sure that this 
increase was not caused by the interaction with GSK3p rather than the 
phosphorylation, the K85A mutant was used. Kinase inactive GSK3p was not 
able to promote an increase in IRF-I ubiquitination, and sometimes promoted a 
decrease in ubiquitination. As the kinase inactive mutant of GSK3p does not 
induce phosphorylation of IRF -1, it could be assumed from this data that 
phosphorylation, particularly through Thrl80 is important for ubiquitination. 
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The relationship between ubiquitination and stability of IRF-I was confirmed by 
CHX chases, which enabled monitoring of the half lives of the various IRF-I 
mutants. The alanine mutants exhibit decreased ubiquitination and posses longer 
half lives than wild type (figure S.S). The TS-A mutant was found to be more 
stable than the individual mutants in CHX chases carried out HEK293 (not 
shown) and MRC-S cells. The reason for the discrepancy is not known as the TS-
A mutant was not less ubiquitinated than either single mutant alone. The acidic 
phosphomimetic mutants demonstrated a clear reduction in stability which was 
also consistent with their enhanced ubiquitination (figure S.6). Therefore addition 
of negative charge on Thr l80 and Ser l84 promotes enhanced ubiquitination and 
turnover of IRF -1. 
Collating data from chapter four and this chapter suggested that GSK3p is 
required for IRF-I transcriptional activity, but does not increase IRF-I activity 
when over-expressed (figure 4.6). However endogenous GSK3p is needed for 
IRF-I transcriptional activity as knockdown in MRC-S cells reduced reporter 
activity by -SO% (figure 4.4). The alanine substitution mutants of IRF-I display 
reduced activity, but increased stability, the K8SA mutant of GSK3p -HA 
provokes a dose dependent reduction in TRAIL reporter activity while it increases 
IRF-l half life in CHX assays and does not promote ubiquitination. The 
phosphomimic mutants of IRF-l are less transcriptionally active, but are also far 
less stable, and are more ubiquitinated. Together, this suggests there may be a link 
between IRF-I activity and stability. The proteasome is composed of numerous 
subunits (1.1.7) making a knockdown approach more problematic, however 
chemical inhibition of the proteasome was possible through the use of MG 132. 
Numerous prior studies have shown that TFs that require proteasome dependent 
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turnover for activity exhibit reduced reporter activity when cells are treated with 
MG 132. Most of these examples include nuclear receptors including RARa 
(Retinoic acid receptor a), PR (Progesterone Receptor), AR (Androgen Receptor) 
and ERa (Estrogen Receptor a), MR (Mineralocorticoid Receptor), RARy 
(Retinoid acid Receptor y) (Gianni et al. 2002, Lin et al. 2002, Andela and 
Rosier 2004, Dennis et al. 2005 and Tirard et al. 2007). The reporter activity was 
not increased by MG132 in any of the mutants tested, nor was there any change in 
basal TRAIL promoter activity. The activity of wild type IRF-I was reduced 
significantly by MGI32 treatment. Western blots of the protein lysates used in the 
reporter assays show a large increase in protein level for all of the IRF-I 
constructs. The amount of reporter plasmid was increased in these experiments to 
prevent any saturation. Previous experiments have shown that increased 
concentration of IRF-l in cells does not lead to a reduction in TRAIL reporter 
activity, rather the reporter activity plateaus (data not shown). Additionally, much 
higher levels of human IRF-I are induced in cells treated with IFNy or IFNy + 
retinoids, but this does not induce an inhibition of TRAIL promoter. High levels 
of IRF -1 protein are needed to promote a detectable increase in TRAIL mRNA 
(Clarke et al. 2004). This suggests that the decrease in activity is not caused by 
inhibition of the promoter construct by excess IRF-I. Instead other mechanisms 
must be responsible for the lack of activity of the stable IRF-l. The levels of 
~ G A L L (the transfection internal control) were not significantly altered in the 
MG 132 treated cells confirming a specific effect on transcriptional activity of 
IRF-l. 
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A lack of increase in reporter activity in the two phosphomimetic mutants of IRF-
1 after MG 132 treatment suggests that constitutive phosphorylation or negative 
charge results in other modifications or changes to IRF-l which inhibits activity 
on promoter. Alternatively other modifications that already exist independently of 
phosphorylation on transcriptionally active IRF-l inhibit activity when not turned 
over. 
Treatment of cells with MG 132 to block the proteasome is highly effective; 
however, MG132 treatment also activates c-Jun N terminal kinase pathway, and 
represses NFKB activation, in addition to numerous bystander effects caused by 
blocking the cells major route of protein destruction. MG 132 can consequently 
initiate cell stress responses which may impact on the ability of IRF-l to bring 
about transcription. A more fine tuned approach was used in which mutants of 
IRF-l lacking ubiquitin acceptor lysine residues were assayed for their 
transcriptional activity. While MG132 does not inhibit ubiquitination ofIRF-l, it 
does prevent the degradation, therefore this approach monitored the effects of 
ubiquitination on IRF -1 activity rather than the effects of degradation. 
Prediction of ubiquitin acceptor Lys residues is particularly difficult due to the 
lack of a strong ubiquitin consensus sequence (Tung and Ho 2008). The reason for 
this is not fully understood. It is possible that individual ubiquitin E3 ligases each 
have their lysine preference given the number of E3 ligases in the human genome 
(up to 600) and the potential for multiple E3 Ii gases to act on a single substrate 
this poses many complications. Working from previous biochemical analysis that 
suggested that IRF-l degradation predominantly occurred via the far C terminus 
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of IRF-I and likely involved K276 and K300 (K275 and K299 in human IRF-I) 
five residues clustered in the C terminus were studied. 
None of the five lysine residues were found to be essential for ubiquitination as 
substitution of Lys to Arg did not result in a stabilisation. This may suggest that 
IRF -1 can be ubiquitinated on multiple residues, with other Lys residues 
substituting when others are made unavailable. Occasionally proteins can be 
degraded through addition of ubiquitin to an N terminal amino acid that is not a 
Lys (the N end rule); also rarely ubiquitin has been shown to attach to cysteine 
residues (Williams et al. 2007). However, Lys240 and Lys255 may be important for 
ubiquitination as K ~ ~R mutants of each resulted in an increase in stability in CHX 
chase assays, and a decrease in HA-ubq conjugation. However neither protein was 
completely stable, they were sensitive to MG 132 treatment, and high molecular 
weight conjugates could be detected by western blot in cell extracts treated with 
MG 132, but not DMSO. Together this suggests that loss of Lys240 and Lys255 does 
not produce an ubiquitination insensitive species of IRF -1. Multiple mutations 
also did not yield an insentivive mutant; rather they may have adversely effected 
the folding of IRF-l protein. Secondary structure prediction was carried out to 
determine if any large predicted shifts in secondary structure could be caused by 
the various K ~ ~R substitutions. Although small shifts in helix formation were 
caused by K ~ ~R substitutions, the majority of the predicted changes were small 
(data not shown). Although without more knowledge of the IRF-l structure we 
cannot know the effects of these modifications. 
Reporter assays using the TRAIL promoter suggested that even small changes in 
IRF-l turnover can bring about large decrease in activity. Both the K240R and 
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K255R IRF-I exhibited a marked reduction in activity, similar to the reduction in 
wild type IRF-I following MG132 treatment. The K276R mutant that was as 
stable as the wild type was able to transactivate the TRAIL promoter to the same 
degree as wild type IRF -1, confirming the importance of ubiquitination / stability 
on IRF -1 activity. Although not tested in this study, it would be of interest to 
determine if K-7R mutants of IRF-I have dominant negative activity. This may 
help build a model for IRF-l transcriptional activity. For example, it is possible 
that when treated with MG132, IRF-I is ubiquitinated but not cleared from the 
promoter, preventing access to new IRF-l that is ready to initiate the formation of 
a new pre-initiation complex. Currently we do not have any data supporting a 
connection between DNA binding and ubiquitination, as such it is only theoretical 
that IRF-I is degraded and removed from the promoter following successful DNA 
binding. Some studies have utilised IRF-I lacking its C terminus as dominant 
negative mutants (Boucker et al. 2004). It has been noted that a DNA binding 
mutant of IRF -1 (YLP) has an increased half life compared to wild type IRF-l 
(Eckert et al. 2006) this supports the model in which IRF-l is degraded following 
DNA binding. The DNA binding domain oflRF-l has been used as a DN mutant 
in other works (Schaper et al. 1998) it is possible that the IRF-l DBD binds DNA, 
but cannot be removed because it lacks the degradation inducing Lys residues; 
however it also lacks the TAD which may explain some of its DN activity. It 
would be interesting to determine if IRF-l DBD mutants are able less 
ubiquitinated than wild type IRF-l. 
It has been observed that for some transcription factors, integrity of their 
T ADs is required to promote ubiquitination and degradation (Poukka et al. 2000) 
(Salghetti et al. 2000). Thus the transcriptional activation domain marks a protein 
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for etlicient destruction - the so called suicide I Kamikaze transcription factors 
(Thomas and Tyers 2000). It is therefore of interest that the three major ubiquitin 
acceptor Lys reside within the IRF-l TAD (K233, K240 and K255). Therefore 
there is a possibility that these residues are important for maintaining the structure 
of the TAD, rather than being acceptors of ubiquitin. Substitution to arginine may 
alter the structure of the TAD, reducing the transcriptional activity of IRF-l, 
which in tum reduces the recruitment of ubiquitin E3 ligases, and degradation of 
IRF-l. It would be interesting to substitute other non Lys residues in the TAD 
which disrupts its structure and detennine if this impacts IRF -1 ubiquitination I 
turnover. It might be potentially impossible to disconnect cause and effect from 
IRF-l activation and destruction. 
Variability in IRF-l phosphorylation at Thr180/Ser184 may be partially 
responsible for the reduced transcriptional activity of the K 7 R mutants. 
However, only the K240R mutant is shown to exhibit reduced phosphorylation, 
and that was not consistent between experiments. It is more likely that all of the 
K7R mutants are available to GSK3p mediated phosphorylation of Thr180/Ser184. 
This suggests that phosphorylation is upstream of ubiquitination and that GSK3p 
dependent phosphorylation of IRF-l promotes ubiquitination, which leads to 
proteasome dependent destruction. This turnover of IRF -1 protein is then required 
for IRF-l to fully transactivate the TRAIL promoter. In order to link 
phosphorylation of IRF -1 to its ubiquitination, a potential E3 ligase (SCFFbxw7) 
was identified by literature searches. An interaction of this E3 ligase with 
phosphorylated IRF-l and whether it could promote IRF-I ubiquitination was 
next investigated. 
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CHAPTER 6 
The SCFFbxw7 ubiguitin E3 
Ligase links IRF -1 
phosphorylation by GSK3B to 
ubiguitination/degradation. 
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6.1. Introduction 
A number of E3 ligases have been identified that recognise phosphorylated 
residues, most notably the SCF family of E3 ligases. SCF E3 ligases use 
variable Fbox proteins for substrate selection. On closer inspection, the 
phosphorylated motif of IRF-l constitutes an Fbxw7 phospho-degron.ln vivo 
GST pulldown assays demonstrated an interaction between Fbxw7a and 
Fbxw7j3 with IRF-l; this was confirmed by co-immunoprecipitation between 
HA-Fbxw7 and FLAG-IRF-l. An interaction could not be detected between 
IRF-l and a truncated form of Fbxw7a which does not have WD40 repeats 
(L\WD40). The interaction between IRF-l and Fbxw7a was reduced in the 
T180A mutant but increased in the T180D mutant. This suggests that a 
negative charge on Thr180 strengthens the interaction between IRF -1 and 
Fbxw7a. Finally, when HA-Fbxw7a is over-expressed in HEK293 cells, it 
accelerated the rate of degradation of IRF-l. The L\WD40 mutant; that 
cannot interact with IRF-l, had no significant effect on turnover. In 
conclusion phosphorylation of Thrlso promotes the interaction with the 
WD40 repeats of Fbxw7a which in turn promotes ubiquitination and 
degradation of IRF-l. 
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6.2. Phosphorylation of Thrlso produces a Fbxw7 phospho-degron. 
Phosphorylation induced degradation of IRF-J was examined in the previous 
chapter, although the E3 ligase responsible was not identified. Phosphorylation 
increases the affinity of substrate towards a group of E3 ligases termed the SCF 
family (Skowyra et al. 1997). A large number of GSK-3 phosphorylated 
substrates interact with three SCF E3 ligases, these being SCFFbxwI/PTRCPI, 
SCFFbxll/Skp2 and SCFFbxw7 (Xu et al. 2009a). Although the SCF family is quite 
large, there are the only three Fbox family members that have been well studied. 
Recognition motifs known as phospho-degrons have been identified for Fbxwl 
and Fbxw7, but Fbxll does not have a recognisable phospho-degron so Fbxll 
interactions cannot be predicted from amino acid sequences. The consensus 
sequence for Fbxwl is D-pS-G-X-X-(X)-pS. This does not match the amino acids 
surrounding Thr l8o, although the consensus for Fbxw7 (L-L-pT-P-X-X-
D/E/pT/Ps) closely matches. An alignment of the amino acids surrounding Thr l80 
with other validated Fbxw7 phospho-degrons is given in figure 6.1. The Fbxw7 
consensus sequence, requiring L-L prior to the phosphorylated Thr is not well 
conserved among most substrates. There are no other known E3 ligases that 
interact with this motif; consequently, Fbxw7 was pursued as a potential 
phosphorylation dependent ubiquitin E3 ligase for IRF-I. 
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Figure 6.1. Alignment of Fbxw7 phospho-degrons. A) All known Fbxw7 
phospho-degrons were aligned against one another. Yeast Fbxw7 (cdc4) 
substrates are also li sted . Substrates of cdc4 which contain multiple sub-optimal 
phospho-degrons have been omitted . The phosphorylated residues are highlighted 
in the boxes. The phospho-degI'on consensus proposed by Orlicky el at. 2003 is 
illustrated, and the precentage of residues which conform to the consensus is 
shown below. B) Diagram of Fbxw7 interaction with a phospho-degI·on. From 
Orlicky et al. 2003 . 
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6.3. FLAG-IRF-l interacts with GST-Fbxw7 
To detennine if IRF -1 is able to interact with the Fbxw7 subunit of the SCF E3 
ligase complex an in vivo GST pulldown assay was used. Fbxw7 exists as three 
isofonns, a, p and y. The a isofonn is the most highly expressed of the three, and 
is expressed in the nucleus, with the p isofonn residing in the cytosol and the y 
isofonn in the nucleolus (Spruck et al. 2002). IRF -1 is found almost exclusively in 
the nucleus when over-expressed in HEK293 cells, and has not been shown to be 
located in nucleoli. However it was decided that all three isofonns would be tested 
for their interaction with IRF -1. Although very weak; interactions with both the p 
and y isofonns were detected (see figure 6.2). The strongest interaction was with 
the a isofonn. This was as expected as the a isofonn and IRF-l are found in the 
same cell compartment. The p and y isofonn were also expressed at slightly lower 
levels than the a isofonn. In other reports the amount of p and y plasmid 
expressed has to be increased to allow for equivalent expression with the a 
isofonn (Grim et al. 2008). It is of interest that the p isoform interacted weakly 
with FLAG-IRF-l, since this isofonn is thought to reside in the cytosol. This may 
suggest that IRF -I can also be ubiquitinated in the cytosol. This will be discussed 
further later. The lack of interaction between FLAG-IRF-l and the GSH beads 
and the GST protein suggests that this interaction is specific. To confirm the 
interaction between GST-Fbxw7a and FLAG-IRF-I a co-immunoprecipitation 
was carried out with the FLAG Ab (figure 6.3). When both FLAG-IRF-I and 
GST-Fbxw7a were co-expressed in HEK293 cells a co-immunoprecipitation 
occurred, confirming that GST-Fbxw7a interacts with FLAG-IRF-l. No GST 
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protein was immunoprecipitated by FLAG-IRF-l , and there was no GST-Fbxw7a 
band in the lanes that contained FLAG-IRF-l alone. 
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Figure 6.2. FLAG IRF-l interacts with GST-Fbxw7a and GST-Fbxw7B in 
vivo. HEK293 cells were transfected with 5 Ilg of either GST or GST-Fbxw7 and 
5 Ilg of FLAG or FLAG-IRF-l wild type plasmids for 48 hours. 6 hours prior to 
lysis cells were treated with 10 11M MG 132. Protein extracts (0.5 mg) were 
incubated with GSH- sepharose beads for 3 hours at 4°C. Protein that were bound 
to the beads were immunoblotted with GST and FLAG Abs. Protein lysates (20 
Ilgl1ane) illustrate the expression of trans fee ted proteins in the lysates. 
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Figure 6.3 GST-Fbxw7a interacts with FLAG-IRF-l ill vivo. HEK293 cclls 
were transfected with 5 Jlg of either GST, or GST-Fbxw7 and 5 Jlg of FLAG or 
FLAG-IRF-I wild type for 48 hours. 6 hours prior to lysis cells were treated with 
) 0 JlM MG) 32. 1 mg of protein extracts wa irnmunoprecipitated with FLAG Ab 
and Protein G agaro e. Eluates were immunoblotted with FLAG and GST Ab. 
Protein Iysates (40 Jlg) were blotted with GST and FLAG Ab to determine the 
levels of transfected proteins in the Iysates. The lower band (25 kOa) i GST, and 
the higher bands GST-Fbxw7a. 
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6.4. FLAG IRF-l interacts with HA-Fbxw7 
The GST protein tag is quite large (-25 kOa) and as such has the potential to 
interfere with protein-protein interactions. Although the interaction between 
FLAG-IRF-l and GST-Fbxw7a was detectable, it was decided to use a smaller 
epitope tag. Full length Fbxw7a and Fbxw7J3 were sub cloned into pCMV-HA. 
Both proteins were expressed in HEK293 cells with and without FLAG-IRF-I 
(figure 6.4). The Fbxw7 proteins were immunoprecipitated with the HA Ab, 
subjected to SDS-PAGE and probed against FLAG. In agreement with figure 6.2 
both isoforms co-immunoprecipitated with FLAG-IRF-l. The two isoforms 
interacted with FLAG-IRF-I to a similar level, unlike figure 6.2 in which Fbxw7a 
interacted with IRF-l more strongly than the J3 isoform. The interaction between 
HA-Fbxw7a and FLAG IRF-l was confirmed by reciprocal co-
immunoprecipitation using the FLAG Ab to immunoprecipitate IRF-I (figure 
6.5). 
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Figure 6.4 FLAG IRF-l interacts with HA-Fbxw7a and HA-Fbxw7B in vivo. 
HEK293 cells were transfected with 5 ~ g g of HA, or HA-Fbxw7 and 5 J.lg of 
FLAG or FLAG-lRF-l wild type plasmid for 48 hours . 6 hours prior to lysis cells 
were treated with 10 J.lM MG132. Img of protein extracts were 
immunoprecipitated with HA Ab and Protein G agarose. Eluates were 
immunoblotted with HA and FLAG Ab. Protein Iysates (40 J.lg) were blotted with 
HA and FLAG Ab to determine the levels of the transfected proteins in Iysates . 
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Figure 6.5 HA-Fbxw7a interacts with wild type FLAG IRF-l ill vivo. 
HEK29.3 cells were tran fected with 5 Ilg of either HA or HA-Fbxw7a and 5 Ilg 
of FLAG or FLAG-IRF-I wild type plasmid for 48 hour. 6 hours prior to lysis, 
cells were treated with 10 11M MG132. Img of protein Iysates wa 
immunoprecipitated with HA Ab and Protein G agarose. Eluates were 
immunoblotted with HA and FLAG Ab. Protein lysate (40 Ilg) were blotted with 
HA and FLAG Ab to determine the levels of the tran fected protein in Iy atc . 
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6.5. Interaction between FLAG-IRF-l and HA-Fbxw7 is dependent on the 
WD40 repeats of Fbxw7 and IRF-l Thrlso. 
The previous data continns that Fbxw7a and IRF-\ interact with each other, but 
does not link the interaction to phosphorylation of IRF-\ at Thr180. To address 
this, HA-Fbxw7a was co-expressed with the Tl80A and Tl80D mutants of IRF-I 
in addition to wild type IRF-\ (figures 6.6). The HEK293 protein extracts were 
then subjected to immunoprecipitation with FLAG Ab and co-immunoprecipitated 
Fbxw7a was detected by immunoblot with the HA Ab. The wild type FLAG-IRF-
1 was immunoprecipitated with HA-Fbxw7a confinning the interaction between 
these proteins. 
The T180A mutant consistently immunoprecipitated less HA-Fbxw7a protein. 
Fbxw7a has a preference for phosphorylated threonine residues, and therefore 
implicates Thrl80 as a potential docking site for Fbxw7a. The interaction between 
these two proteins is however detectable, suggesting that Fbxw7a can interact 
with other residues beside Thrlso (figure 6.6A). The ability of Fbxw7 to fonn 
homo and heterodimers may also allow the formation of mUltiple contacts with 
sub-optimal phospho-degrons. In these experiments HA-Fbxw7a is over-
expressed at higher then physiological levels, this may promote the formation of 
dimers, which may not be able to form in normal conditions. When lower levels 
of Fbxw7a were co-transfected with FLAG-IRF-l the interaction between T180A 
IRF-l and HA-Fbxw7a was not detectable (figure 6.68). 
The importance of Thrl80 is highlighted by the interaction between the FLAG 
T180D mutant and HA-Fbxw7a. Consistently this interaction was significantly 
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stronger than the interaction between wild type IRF-I and HA-Fbxw7a. This 
suggests that either more Tl80D IRF-l is interacting with HA-Fbxw7a or that the 
interaction is stronger. Phosphorylation (and therefore addition of a negative 
charge) ofThr residues has been shown to greatly increase the interaction between 
the WD40 domain of Fbxw7a and its substrates The great majority of 
phosphorylation specific interactions between Fbxw7a and its substrates occur 
through the WD40 repeats. A truncation mutant of HA-Fbxw7a was made (aa 1-
373) which removed all eight WD40 repeats. This truncated Fbxw7a retains its 
Fbox, dimerisation domain and NLS, and subsequently can be recruited to the 
SCF E3 ligase complex, but cannot interact with substrates (We1cker et al. 2004). 
As expected the interaction between FLAG-IRF-l wild type and HA-Fbxw7a 
Ll WD40 is not detectable, thus indicating that the WD40 repeats interact with 
IRF-I (figure 6.6A). 
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Figure 6.6. Importance of lRF-l Thr l80 and the WD40 repeats of Fbxw7a. for 
interaction in vivo. A). HEK293 cells were transfected with 7.5 ~ l g g of empty 
(HA), HA-Fbxw7a. FL or HA-Fbxw7a. 11 W040 expresslon plasmid with 2.5 ~ g g
of FLAG-IRF-l pJasmids - WT (wild type), TA (T180A), and TO (T 1800) for 48 
hour . 6 hours prior to lysis, cells were treated with 10 11M MG 132. 1 mg of 
protein extract was immunoprecipitated with FLAG M2 Ab using Protein-G 
agarose beads. Eluates were probed with HA and FLAG. Lysates (40 ~ g ) ) were 
blotted with FLAG and HA Ab to determine expression level of tran fected 
proteins. B). As for A) but with the exception that 5 Ilg of HA-Fbxw7a. and 5 Ilg 
of FLAG-rRF-l were used. In addition the SA (S 184A) and TS-A (S 184A and 
T 180AlS 184A) mutants were included. 
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6.6. GST-JRF-I interacts weakly with Fbxw7a ill vitro 
To dctenlline if lRF- I and Fbxw7a interact directly, an in vitro GST puIJdown 
assay was used . Fbxw7a was in vitro transcribed and translated in the pre ence of 
esS] methionine and mixed with GST-IRF-J (figure 6.7). In agreement with 
previous data, an interaction between the two proteins was identified, a GST-
IRF- I pulled down the esS] Met labelled Fbxw7a. No interaction was visible in 
the GST only lane, showing that the interaction i occurring through lRF-\ , not 
the GST tag. The interaction was quite weak - perhaps 5% (compared to the 20% 
input). 
1 0 0 k D ~ ~ ~ ~ - - - - - - - - - - - - ~ ~
G8T + + 
GST-WT IRF-1 + 
8 35 Fbxw7 a FL + 
Figure 6.7 In vitro interactions between Fbxw7a and GST-IRF-1. GST 
pulldown a ay between esS] Met-Fbxw7a and G T-IRF-l. 20% input lane of 
esS] Met-Fbxw7a is to demonstrate relative quantity. 
252 
Post Translational Regulation of the Tumour Suppressor IRF-l 
6.7. Over-expression of HA-Fbxw7a. increases IRF-l turnover in HEK293 
cells. 
To date, the only known function of Fbxw7a is to act as a substrate recruitment 
module for the SCF E3 ligase complex. This recruitment in turn brings about 
ubiquitination, and subsequent proteasomal degradation of its substrates. To 
determine if the interaction with Fbxw7a brings about degradation of IRF-l, 
CHX chases were performed (fig. 6.8) in HEK293 cells co-transfected with either 
empty vector (HA), full length Fbxw7a. (FL) or the truncation mutant lacking the 
WD40 repeats ( ~ W D 4 0 ) . . The half life of IRF-l when Fbxw7a FL is expressed 
was approximately 20-25 minutes, while IRF-l transfected with empty HA vector 
had a half life of 35-40 minutes. The change in half life of IRF-l is directly 
related to its ability to interact with Fbxw7a., as the ~ ~WD40 mutant (which 
previously had been shown to be unable to interact with IRF-I see figure 6.6) did 
not significantly alter IRF -1 stability. 
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Figure 6.8 Ove.o-expression of HA-Fbxw7a increases IRF-t turnover. 
HEK293 cell wcre eeded on ix well plates and transfected with 2.5 /lg of HA, 
HA-Fbxw7a or HA-Fbxw7 L'l WD40 with 2.5 /lg of FLAG-IRF-I wild type. 24 
hours post transfection, cell were treated with CHX at 25 )lglmL for the indicated 
times. Extracts were made and immunoblotted (15 ug) against FLAG, HA and ~ ~
actin. A) Precentage remaining IRF-\ (as detennined according to chapter five) 
plotted against time from three independent expeIiments carried out in duplicate. 
8) Representative Immunoblots. 
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6.8 Discussion 
The Fbox family currently consists of 68 members with only a handful being 
matched to substrates (J in et a1. 2004). Many examples of multiple Fbox proteins 
interacting with the same substrate (sometimes on the same consensus, or on other 
regions of the protein) exist (see figure 6.9). It was decided to concentrate on one 
Fbox protein, which was predicted to interact with the Thr l80 consensus. As such 
Fbxw7 was chosen for further analysis. The alignment of known Fbxw7 and cdc4 
(yeast Fbxw7) phospho-degrons highlights the divergence from the proposed 
interaction motif, and experimentally validated regions. This suggested that even 
though IRF-l was not a complete match for the Fbxw7 phospho-degron it was 
valid to investigate. To determine if IRF-l may contain any secondary Fbxw7 
phospho-degrons a search was carried out on the amino acid sequences of mouse 
and human IRF-l. Several potential degrons were identified, although none of 
them matched the consensus as well as the degron surrounding Thrlso. 
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Figure 6.9. Multiple Fbox proteins can interact with the same substrate. 
Cartoon illustration of known Fbox-sub trate interaction . CyclinD I interacts with 
three diffe rent Fbox proteins via the same pho pho-degron (Santra el al. 
2009, Lin el al. 2006 and Okabe el al. 2006). Additional Fbox protein interact 
with CycJ in 01 independentl y of thi s degron (Skaar el al. 2009). S AIL interact 
with Fbxw l fo llowing pho phorylation by G S S 3 ~ , , while it can al 0 interact with 
Fbx l1 4 independently of GSK3 phosphorylation (Katoh 2006). Fbxw7 interacts 
with c-Myb ia multiple pho phorylated residue , but a creen of Fbox protein 
identified five other interaction not involving the phosphorylated residue 
(Kanei- I hii el al. 2008). Pho phorylation of Thr58 by G K K ~ ~ on c-Myc ind uce 
an interaction with Fbxw7 but Fbxll and Fbxw8 bind other regions of c-Myc 
(Welcker el al. 2004, Kim et al. 2003b and Koch el al. 2007). It is likely that 
individual ubstrate-Fbox interactions are induced by specific signalling events 
and that an Fbox protein can compensate for one another. For example, Fbxw I 
and Fbxw II are highly homologous proteins that recognise overlapping 
ub trates. 
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Figure 6.10. Sub-optimal Fbxw7 phospho-degrons in IRF-l. The mouse and 
human IRF-I sequence was searched for other potential Fbxw7 phospho-degrons, 
particularly those that did not fully match the proposed consensus. Potentially 
phosphorylated / acidic residues are highlighted in the boxes. Only the degrons 
conserved between human and mouse IRF-I is shown. The amino acid numbers 
are shown either side. 
As predicted, an interaction between IRF-I and Fbxw7 could be detected in co-
transfected HEK293 extracts (figure 6.2-6.5). This interaction could be 
demonstrated by reciprocal co-JP. An interaction between endogenous IRF-I and 
Fbxw7 could not be demonstrated because of the lack of sensitive antibodies 
against Fbxw7. The preference for an interaction with the Fbxw7a isoform was 
not surprising considering they reside in the same cell compartment. The 
interaction between HA-Fbxw7J3 and FLAG-IRF-l was as strong as HA-Fbxw7a 
in figure 6.4, which contrasted with figure 6.2. It is likely that the higher 
expression of HA-Fbxw7J3 compared to GST-Fbxw7J3 may account for this. It is 
possible that under the experimental conditions used GST -Fbxw7J3 or HA-
Fbxw7J3 also locates into the nucleus. Fbxw7J3 may also be able to locate to the 
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nucleus in the fonn of heterodimers with Fbxw7a or Fbxw7y as this has been 
reported in the literature (Zhang and Koepp 2006). 
The WD40 repeats which are required for phosphorylation dependent interactions 
are identical between the three isofonns of Fbxw7 as such the phosphorylation 
interaction domain is common to all isofonns (see figure 6.11). It is also feasible 
that IRF -1 can be phosphorylated outside the nucleus, consequently becoming a 
substrate for the cytosolic H A - F b x w 7 ~ . . It has not been discounted that 
phosphorylation at Thr l80 occurs away from DNA and the nucleus, and also that it 
has roles in protein turnover that are not coupled to transcription. Several reports 
suggest that the F b x w 7 ~ ~ isofonn is differentially expressed to the Fbxw7a 
isofonn. The ~ ~ isofonn is not found in as many cell types as the a isofonn, and is 
not as highly expressed as the a isofonn. In a more physiological context it is 
possible that F b x w 7 ~ ~ has a minimal effect on IRF-l turnover, and the interaction 
observed is an artefact of protein over expression. For this reason, the interaction 
between IRF-l and Fbxw7a was studied in more detail. 
The GST-Fbxw7y did not interact significantly with FLAG-IRF-l even though the 
amount of GST-Fbxw7y protein was similar to F b x w 7 ~ . . This is most likely due to 
the restricted nucleolar localisation of Fbxw7y. It has never been reported that 
IRF-l locates to the nucleoli and direct fluorescence microscopy ofYFP-IRF-l in 
HEK293 cells suggests that IRF-l is excluded from the nucleoli (data not shown). 
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Figure 6.1] Amino acid alignment between Fbxw7a, Fbxw7B and Fbxw7y. 
Amino acid sequences for (top to bottom) Fbxw7aJP/y (also known a Fbxw 
isoforms 112/3) were ali gned against one another using the Mutalign programme 
(http://bioinfo.genotoul. fr/multalin/multalin.html). The Fbox and WD40 repeat 
are highli ghted in boxe , The bottom line indicates the consensu ali gnment 
between the three i ofoml . 
Reciproca l co-immunoprecipitation u IIlg the FLAG tag to precipi ta te IRF-I 
demonstrated that HA-Fbxw7a interact with FLAG- IRF I. To fu rther prob the 
interaction between IRF-I and HA- Fbxw7a the T I80A and T I80D mutant of 
IRF-I were used. A expected the interaction between TI80A IRF-I and HA-
Fbxw7a was reduced suggesting that Thr ' 0 is important in making contact with 
Fbxw7a. To demon trate that addition of a negati ve charge in place of Thr l 80 
regulates a ociation with IRF-I , the TI 80D mutant was immunoprecipitated with 
HA-Fbxw7a. . Consistently this mutant precipitated more HA-Fbxw7a than the 
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wild type IRF-l (figure 6.6). Fbxw7a makes contact with its phospho-threonine 
via three conserved arginine residues (see figure 6.1) the positive charge of the 
Arg residues makes contacts with the negative charge which is supplied by the 
phosphate, or in this case aspartic acid. The increased association may explain the 
shorter half life of Tl80D IRF-l compared to wild type IRF-l (figure 5.5). 
Phosphomimetic mutants of Notch have been shown to restore interaction with 
Fbxw7a, which is lost in alanine mutants (O'Neill et al. 2007). It is also possible 
that inappropriate interaction between IRF-I and Fbxw7 reduces the activity of 
IRF -Ion its target genes. This suggests that the GSK3 phosphorylation signal has 
to be tightly controlled to prevent inappropriate degradation of IRF -1. 
It is important to consider that the Tl80A mutant can still interact with Fbxw7a, 
which suggests that Thrlso is not completely essential for the interaction. This 
could be for several reasons. Chapter 3 established that IRF-l is most likely dual 
phosphorylated at SerlS4 and Thrlso, although Fbxw7a is reported to prefer Thr 
over Ser residues (Welcker et al. 2004). the phospo-Serls4 itself could form a 
Fbxw7 phospho degron (A L ~ ~ P C A) as it contains a Leu residue and Pro residue 
before and after the phosphorylated Ser respectively. The S 184A and S 184E 
mutant were both tested for their interaction with HA-Fbxw7a and were found to 
behave exactly as their Thr counterparts. However, this could be due to the 
priming effect on Thrlso rather than being direct interactions themselves. The 
double TS-A mutant was also tested for its interaction and was also found to have 
a very weak residual interaction with HA-Fbxw7a (data not shown). This 
suggests that another residue is involved in this interaction. Some Fbxw7a 
interacting partners contain multiple phospho-degrons including PGCla and 
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Cyclin E (Welcker and Clunnan 2008). It is possible that the same phenomenon 
occurs with IRF-l, and a list of potential sites is given in figure 6.11. It is also 
possible that IRF-l makes stabilising contacts elsewhere on the Fbxw7a protein; 
these interactions may be independent of phosphorylation. When lower levels of 
Fbxw7a were used (5 )lg rather than 7.5 )lg) the interaction was weaker between 
HA-Fbxw7a and wild type IRF-I as well as T180D IRF-l, but the interaction was 
completely lost with FLAG T180A, S 184A and TS-A IRF-l. The lower level of 
HA-Fbxw7a is most likely more similar to the physiological levels of Fbxw7a. 
Consequently the interaction between T180A IRF-l and Fbxw7a may be a result 
of abnonnally high levels of Fbxw7a in cells. Deletion mapping of IRF-l with 
HA-Fbxw7a interactions may be of use in studying this. Mutation of either 
Leu 179 or Pro 183 could also be used to detennine the role of these residues in 
Fbxw7a interaction. Fbxw7a can fonn dimers which make contact with non 
phosphorylated residues that are not part of recognisable consensus (Zhang and 
Koepp 2006) potentially making any residue a possible contact. The over-
expression of HA-Fbxw7a may promote the fonnation of these dimers, and as 
such the remaining interaction may not be physiological. Mutations in the 
dimerisation domain of Fbxw7a or Fbxw7P could be used to detennine if 
dimerisation is required for interaction with the T 180A mutant ofIRF -1. It should 
also be noted that phosphorylated IRF -1 is most likely not a homogenous species, 
but rather a mix of different fonns of phosphorylated IRF -1 and as such there may 
be a fraction that is highly phosphorylated on numerous residues, offering a 
stronger interaction with Fbxw7a. A direct interaction between aSK3 and 
Fbxw7a has never been identified, but interaction between the SCF and HIPKI 
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has been demonstrated in the case of c-Myb (Kanei-Ishii et al. 2008). These 
interactions help stabilise the newly phosphorylated substrate with the SCFFhxw7 
complex. Chapter 3 showed that the alanine mutants are equally able to interact 
with GSK3p. should GSK3p be able to interact with Fbxw7a. an indirect 
interaction may occur. 
To further define the interaction between IRF-l and Fbxw7a, truncation of 
the Fbxw7a WD40 repeats was carried out. Loss of the WD40 repeats should 
render Fbxw7a incapable of interacting with substrates. When co-expressed with 
FLAG IRF-l, no co-immunoprecipitation of ~ ~WD40 HA-Fbxw7a occurred. This 
suggests that Fbxw7a uses its WD40 repeats to interact with IRF -1. A mutant of 
Fbxw7a encompassing just the WD40 repeats and the very far C terminus was 
constructed but expression of the protein could not be detected in protein extracts. 
This mutant would have been used to demonstrate that only the WD40 repeats are 
required for the interaction with IRF-l. All the interactions were assayed in the 
presence of MG 132 to block the proteasome and prevent degradation of the newly 
ubiquitinated IRF-l. It was assumed that following interaction with Fbxw7a, IRF-
I is rapidly poly-ubiquitinated and degraded, and as such the interaction would 
not be detectable without the addition of MG 132. It would be intriguing to 
determine if this interaction can be detected in the absence of MG 132. The 
interaction studies here is between murine IRF-l and human Fbxw7a, the 
phospho-degron is almost identical between human ad mouse IRF-l, suggesting 
that the interaction is also likely to be conserved. An interaction could be detected 
between GST-IRF-l esS] Met Fbxw7a; suggesting that an interaction can occur 
without phosphorylation of IRF-l. However as this was not an entirely in vitro 
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interaction it is also possible that other components (from the rabbit reticulocyte 
lysates - RRL) are allowing an indirect interaction to occur. It has been noted that 
other components of the SCF complex are present in RRL and so it is possible 
that this interaction is occurring with other SCF components. Future experiments 
will need to be conducted to confinn tha in vitro phosphorylation of GST -IRF-I 
enhance the interaction with Fbxw7a directly. The interaction between SREBP I 
and Fbxw7a was found to be very weak in vitro, but was significantly increased 
by addition of oligonucleotides containing SREBPI binding sites, while a DBD 
mutant of SREBP 1 was less able to interact with Fbxw7a (Punga et ai. 2006). 
Therefore it is possible that DNA binding is needed to enhance the interaction 
between IRF-l and Fbxw7a in vitro. Phosphorylation could occur directly 
between G S K 3 ~ ~ and IRF-I in vitro without DNA present (figure 3.3) although it 
is feasible that phosphorylation may be more efficient with DNA bound IRF -I. 
The binding of IRF-I to DNA could also aid phosphorylation / ubiquitination by 
immobilising IRF-I. 
CHX chase assays demonstrated that Fbxw7a was able to promote an increase in 
IRF-l turnover (figure 6.8), and that this depended on its ability to interact with 
IRF-I, as the ~ ~WD40 mutant had no effect. In a similar manner to the phospho-
mimic mutants it was not possible to cause a larger decrease in IRF-l stability, 
possibly because it is already an unstable protein that is readily degraded in 
HEK293 cells by alternative pathways. In addition Fbxw7a alone cannot promote 
degradation of IRF-l, but requires the other components of the SCF complex and 
the E2 enzyme. Since none of these proteins were over-expressed in combination 
it is possible that they were limiting factors in IRF-l degradation. In addition it 
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has already been shown that only a small fraction of IRF-l is phosphorylated by 
GSK3p, if the interaction between IRF-l and Fbxw7 is dependent on 
phosphorylation by GSK3p this could also have been limiting. It would be 
interesting to determine if combined over-expression of Fbxw7a and 
GSK3p promotes synergistic degradation of IRF-l. The K85A mutant of GSK3p 
could also be used to determine if it prevents the Fbxw7a dependent acceleration 
of IRF-I turnover. It is most likely that other E3 ligases playa role in IRF-I 
turnover, and subsequently increasing the expression of a single E3 component 
may only have a small overall effect, especially when phosphorylation may be 
limiting. It can also not be ruled out that phosphatases and de-ubiquitinases may 
hinder the GSK3p-Fbxw7a pathway of IRF-l degradation. Another method of 
determining the importance of Fbxw7a would be to deplete endogenous Fbxw7a 
in cells to determine ifit plays a role in IRF-l turnover. MEF cell lines that do not 
express Fbxw7a could also be used to determine ifIRF-l stability is greater than 
wild type cells. A number of cancer cell lines contain inactivating mutations in 
Fbxw7a (Strohmaier et al. 2001). It would be interesting to determine if IRF-l 
half life is different in these cells, and if rescuing Fbxw7a expression increases 
IRF-l turnover. A less specific approach for determining of SCF complexes are 
involved in IRF-l stability could be to use dominant negative mutants of CuI-I. 
These mutants cannot interact with Skp 1, and so form truncated SCF complexes 
which cannot associate with substrates (Sundqvist et al. 2005). Dominant negative 
Cul-l is disadvantageous due to the effects it has on all SCF complexes rather 
than just the SCFFbxw7a complex. It would however show that SCF is required for 
turnover, especially as multiple Fbox proteins may playa role in IRF -I turnover. 
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Additionally dominant negative mutants of the other CuI proteins (Cul-2/3/4/S) 
could be used to asses if other multi subunit E3 ligase complexes regulate IRF-I 
degradation. In conclusion, an interaction between IRF-I Thr l80 (at least 
partially) and the WD40 repeats of Fbxw7a is promoted by G S K 3 ~ ~ dependent 
phosphorylation. The interaction promotes increased turnover of IRF -I which 
explains the phosphorylation dependent turnover of IRF -I established in chapter 
five. 
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Chapter 7: Conclusions 
and future work 
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7.1 Conclusions 
Twenty years after the initial characterisation of IRF-l as a phospho-protein (Pine 
and Darnell 1989) no single amino acid - kinase pair has been described in vivo. 
Other members of the IRF family, particularly IRF-3 and IRF-7 have been 
extensively studied in the context of post translational modifications. Multiple 
kinases, acetyl-transferases, phosphatases and ubiquitin E3 ligases have been 
matched to other IRFs (see figure 7.1), while knowledge of IRF-l PTMs lags far 
behind. This thesis set out to identify a kinase and the amino acid(s) it 
phosphorylates, but also to reveal a functional consequence of the modification. 
Consequently G S K 3 ~ ~ was identified as an IRF-l kinase, which phosphorylated 
Thr180. This pathway was shown to be important for IRF -I transcriptional activity 
against an important pro-apoptotic target gene (TRAIL) both in reporter assays, 
and in breast cancer cells. 
Phosphorylation was then found to modulate the stability of IRF -1 protein. 
The stability of IRF-I proved to be crucial for its transcriptional activity, as 
stabilised IRF-I was a less effective transcriptional activator. The missing link 
between phosphorylation and ubiquitination was then identified as the SCFFbxw7a 
ubiquitin E3 ligase, which specifically recognises phosphorylated substrates. This 
work has identified the first in vivo phosphorylation event of IRF-l by G S K 3 ~ . . It 
is also the first evidence for an interaction between IRF-l and an ubiquitin E3 
ligase. Collectively by identifying a novel kinase for IRF-l, I have been able to 
describe a molecular pathway by which phosphorylation initiates ubiquitination 
and degradation of IRF-l, a process required for IRF-l to be able to transactivate 
the TRAIL promoter. 
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Acetylation Ubiquitination Glutathionation Prolyl Isomerisation SUMOylation ISG·15ylation 
IRF·7 ~ ~
IRF-S ~ ~
IRF·9 
Figure 7.1. Mapped PTMs in IRF family members. Only the PTM matched to 
a rc idue in vivo are included here, however IRF-4 is known to be prolyl 
i omerised, IRF-8 is ubiquitinated , IRF-2 is pho phorylated, and IRF-I is 
acetylated . All sites were acquired from the phosphosite database 
( www.phosphosite.org). 
Several questions rema1l1 to be answered from this work. Although it ha 
highlighted the importance of tumover in transcriptional activity, little i known 
about the mechanism by which lRF-1 degradation modulates transcription. The 
signalling pathway that initi ate phosphorylation al 0 need to be elucidated. Th 
global effects of phosphorylation on the IRF-I transcriptional programme need to 
be studi ed further. Most importantly the phenotypic effect of thi s modification 
on IRF-I in human di ease remain to be uncovered. Thi is summari ed in figure 
7.2 
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Does phosphorylation oflRF-l at Th/8o/Se/84 modulate other protein-protein 
interactions? 
Chapter 6 continns that phosphorylation of ThrI8°/SerI84 modulates the 
interaction between IRF-l and the Fbox protein Fbxw7a; however, other protein-
protein interactions may occur following the phosphorylation of these residues. 
As discussed in chapter six, it is possible that other Fbox proteins are able to 
recognise the Fbxw7 phospho-degron; as such multiple Fbox proteins could be 
recruited to phosphorylated IRF-1. The W040 repeats of Fbxw7a are responsible 
for phosphorylation dependent interactions with substrates, which would suggest 
that only other Fbxw proteins would be candidates for the interaction with IRF-I. 
Indeed, during preliminary experiments several additional Fbxw proteins were 
shown to interact with IRF-I by in vivo GST pull down assays, it is not known 
however, if these proteins are recognising the Thr180/Ser184 motif, or another 
phosphorylation site on IRF -1. In the case of phosphorylated T h ~ 8 6 6 of Cyclin 01, 
different classes of Fbox protein interact, one WD40 containing (Fbxw8) and two 
with other domains (Fbx031 and Fbx04). Each Fbox protein interacts with Cyelin 
01 under different conditions; consequently different Fbox proteins may interact 
with IRF-l depending on the cellular environment (Santra et al. 2009, Lin ef al. 
2006 and Okabe et al. 2006). 
Phosphorylation of T-P and S-P motifs also produces an interaction motif 
for the proline isomerase Pin 1. The interaction between substrate and Pin I occurs 
through the WW motif, which recognises phosphorylated TIS followed by proline. 
The Pro residue is consequently isomerised into its trans confirmation. This 
change has significant structural effects on the protein. In the case of c-Myc, 
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phosphorylation of Ser62 by ERK1I2 primes phosphorylation of Thr5s by GSK3p, 
this in tum leads to the recruitment of Pin 1 to phosphorylated Thr5x • Pin 1 
isomcrises pro59, and promotes interaction with the phosphatase PP2A (Protein 
Phosphatase 2A). This leads to removal of the phosphate on Ser62. Fbxw7 is then 
able to interact with c-Myc and bring about its ubiquitination. Consequently, Pinl 
is needed to edit the phosphorylation of c-Myc, making it available for destruction 
(Yeh et al. 2004). c-Myc could appear to be alone in its requirement for the 
removal of the phosphorylated priming site, as other Fbxw7 substrates are able to 
interact when both residues are phosphorylated. Phosphorylation of SRC-3 (later 
shown to be via GSK3 P) promotes interaction and proline isomerisation by Pin 1. 
This step is important for SRC-3-nuclear receptor interactions (Yi et al. 2005). It 
would be of interest to test if Pin I interacts and isomerises IRF -I, by interacting 
with either Thr l80 or Ser184, as both are flanked by Pro residues. Given the 
presence of the PxLxP motif, it would be especially interesting to determine if this 
modulates interactions with other proteins (such as the MYND domain proteins). 
In addition to WW and WD40 motifs, numerous other phospho-threonine and 
phospho-serine motifs are found in the proteome, further increasing the number of 
potential interacting partners for phosphorylated IRF-I (see table 1.2). A 
proteomic screen using the aanine versus wild type mutants of IRF-I would help 
elucidate the importance of these residues in protein-protein interactions. 
Identification of proteins that are recruited to phosphorylated IRF-I may be of use 
in exploring the requirement for phosphorylation for IRF -I transcriptional 
activity. Although ubiquitination and degradation are likely important for IRF-I 
activity, it cannot be discounted that phosphorylation affects IRF-I roles in the 
cell in a mechanism that is independent of recruiting ubiquitin E3 ligases. For 
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example, MafA phosphorylation by G S K 3 ~ ~ promotes an interaction with PCAF,. 
This interaction protects MafA from proteasomal degradation, yet 
phosphorylation increases MafA degradation. Hence phosphorylation can promote 
interactions with coactivators, while also marking the protein for destruction. The 
authors suggest that PCAF physically blocks access to E3 ligases, but 
disengagement of PCAF leaves phosphorylated MafA vulnerable to degradation, 
and therefore termination of its transcriptional activity (Rocques et al. 2007). It is 
also possible that PCAF acetylates the ubiquitin acceptor lysines on MafA, and 
that de-acetylation of MafA is needed for its degradation via an E3 ligase that 
recognises phosphorylated MafA. IRF-l is known to interact with the KAT 
enzymes C8P, p300, PCAF, SRC-2 and GCNS (see table 1.5), and it would be of 
interest to determine if phosphorylation modulates the interaction between IRF-l 
and these KAT enzymes, particularly if these enzymes are able to acetylate 
ubiquitin acceptor lysines in IRF-l. 
Although not studied here, the interaction between the IRF -1 PxLxP motif 
and MYND domain proteins could be perturbed or enhanced by phosphorylation 
of ThrI8°/SerI84. Many of the MYND domain proteins act as transcriptional 
repressors or adapters for transcriptional repressor complexes (8S69, RACK7, 
DEAF-I, and ETO). A subgroup of SET domain methyltransferases is also 
equipped with MYND domains (SMYDI-5). Some of these methyltransferases 
are transcriptional repressors, while SMYD3 is a transcriptional activator, 
possibly through its interaction with RNA Pol II (Hamamoto et al. 2004). SMYD3 
is also reported to act as a transcriptional coactivator of ERa (Kim et al. 2009). It 
would be of interest to detennine if IRF-I interacts with SMYD family members, 
partly because these proteins have established roles in transcription, but 
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additionally because they arc methyltransferases. As such an interaction could 
lead to methylation of IRF-\, a modification that has not yet been shown to occur 
on any IRF protein. Very little is known about PxLxP motifs, and the range of 
proteins to which they interact, and it is possible a far greater range of proteins 
interact with IRF -I through this motif, other than MYNO domain proteins. 
ThrI8°/SerI84 also resides within the heterodimerisation (lAD) domain of IRF-I 
(aa 164-219). This domain regulates the interaction between IRF-I and IRF-8. 
This interaction is not likely to have been significant in these studies as IRF-8 is 
not expressed in any of the cell types used, however it is not known if other IRF 
proteins (e.g. IRF-5 which is more widely expressed) also interact with this 
domain. Consequently phosphorylation could alter heterodimerisation between 
IRF-l and other IRFs. 
Is the phosphorylation and ubiquitination oflRF-l reversible? 
Increasing evidence suggests that PTMs are not static, but rather are constantly 
being removed or edited throughout the lifetime of a protein. It is possible that 
phosphorylation of IRF-I at ThrI8°/SerI84 is reversible; which may explain the 
relatively low levels of phosphorylation of IRF-I at these residues. Due to the 
requirement for phosphorylation on IRF-I for degradation, de-phosphorylation 
may promote stabilisation of IRF-l. This could in tum lead to reduction in IRF-I 
transcriptional activity towards the TRAIL promoter, although it is not known 
what effects this would have on other IRF-I target genes. It is difficult to predict 
which phosphatase will interact with IRF-l. The most suitable method of 
determining which phosphatases can antagonise Thr180/Ser184 phosphorylation 
would be to screen a selection of proteins for their ability to reduce IRF-I 
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phosphorylation. This method has been successfully used to determine which 
phosphatase was responsible for the removal of the G S K 3 ~ ~ phosphorylation on 
SRC-3 (Li ct al. 2008). As expected these phosphatases increased SRC-3 stability, 
and reduced the ability of SRC-3 to interact with nuclear receptors, leading to a 
reduction in SRC-3 transcriptional activity. No phosphatases have been shown to 
interact with IRF-I, however the tyrosine phosphatases SHPI (Protein tyrosine 
Phosphatase 1) decreases IRF-I phosphorylation at Tyrl09 (Kautz et al. 2001). 
Phosphorylation is a relatively simple on/off modification, unlike ubiquitination 
which occurs in chains and further complication arises from the diversity of chain 
types depending on the internal Lys used in chain formation. As such DUB 
enzymes may simply remove ubiquitin from IRF -I, or edit the ubiquitin chain 
types on IRF-l. Increasing evidence suggests that chain types may regulate 
protein-protein interactions, as so may have drastic effects on IRF-I activity. 
Popov et al. identified USP28 (Ubiquitin Specific Protease 28) as a c-Myc DUB, 
intriguingly USP28 is associated with Fbxw7a. and Fbxw7y (but not F b x w 7 ~ ) , ,
and is recruited to c-Myc along with Fbxw7a. (Popov et al. 2007). Although 
paradoxical it has been shown that a large number of ubiquitin E3 ligases are 
found in association with DUB enzymes. As expected, USP28 has oncogenic 
activity and is over-expressed in a number of cancers. USP28 is also involved in 
the DNA damage response, de-ubiquitinating a number of proteins involved in the 
p53 pathway (Zhang et ai. 2006). IRF -I protein is stabilised following DNA 
damage (Pamment et al. 2002), it would be of interest to determine if USP28 
reduces IRFI-l turnover, and why IRF-l needs to be stabilised during DNA 
damage. 
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What are the transcriptional effects oflRF-l phospllOrvlationlubiquitination? 
Loss or reduction in phosphorylation of ThrI8°/SerI84 was found to result in a 
reduction in reporter activity. This suggests that phosphorylation of IRF-l at 
ThrI8°/SerI84 is not essential for its DNA binding, as this was the first critical step 
in IRF-l transactivation - DBD mutants of IRF-l cannot transactivate the TRAIL 
promoter (Eckert et al. 2006). It is however possible that loss of phosphorylation 
reduces the strength or duration of protein-DNA interaction. Studies using EMSA 
and ChIP would help establish if phosphorylation is important for IRF-I-DNA 
interactions in vitro and in vivo respectively. Given that alanine phosphorylation 
mutants of IRF -1 are more stable, it is possible that the strength of interaction 
between IRF-J and the TRAIL promoter could be greater. FRAP (Fluorescence 
Recovery After Photo-bleaching) could be utilised to determine if IRF-I mobility 
is effected by its phosphorylation. Although it has not been demonstrated, it could 
also be possible that phosphorylation alters the physical characteristics of the 
DBD, possibly changing its DNA recognition and hence the promoters it 
recognises. 
GSK3p phosphorylates many proteins involved in transcription. Several GSK3p 
substrates are known to interact with IRF-J, including NFKB p50/p65, C/EBPa, 
HIFla, GRa, p53 and STAT-J (see table 1.5). Consequently GSK3p may 
phosphorylate IRF-l and its TF partners at the same time; it is also possible that 
IRF -I recruits GSK3 p to promoters, allowing phosphorylation of other proteins. 
Microarray studies on GSK3p phosphorylation resistant mutants of BCL-3, MafA 
and GRa (Viatour et al. 2004, Rocques et al. 2007 and Galliher-Beckley et al. 
2008) have shown not all of the target genes for these transcriptional regulators 
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are sensitive to the phosphorylation status. In fact phosphorylation only affected a 
small subset of Bcl-3 target genes, while it had a much more profound effect on 
GRa transcriptional programmc. In this study selection of a sensitive target gene 
may fortuitous. For example one study on MafA activity following G S K 3 ~ ~
dependent phosphorylation concluded that G S K 3 ~ ~ does not alter MafA 
transcriptional activity, while another study suggests it is important for MafA 
dependent transcription. The divergence between these two studies was that the 
first used reporter assays based on the insulin promoter, which was transactivated 
equally by wild type and phosphorylation mutants, while the other study used a 
multimerised synthetic reporter that was highly sensitive to phosphorylation of 
MafA. The two groups also used different cell lines (Han et al. 2007)and 
Rocques et al. 2007). 
Phosphorylation by a single kinase through certain residues is unlikely to have a 
completely global effect on transcriptional activity. This is most likely due to the 
variability in composition and structure of each promoter. Additionally 
transcription factors will have different degrees of requirement on each promoter, 
so loss of activity may only have a small effect on genes in which other 
transcription factors can compensate. It is most likely that the IRF-l gene 
programme would not be completely reliant on IRF-l phosphorylation. This could 
be because IRF-l is undergoing other modifications which may be able to 
override the Thr180/Ser184 phosphorylation. IRF-l alanine mutants were not 
completely stable; and thus other pathways are capable of degrading IRF-l 
protein. In addition, although the phosphorylation of IRF-l may be involved in 
several interesting protein-protein interactions, other interactions will occur 
independently. 
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One of the most compelling reasons to carry out transcriptional profiling of IRF-I 
and its phosphorylation mutants is that it may shed light on how IRF -1 selects its 
target genes. Several distinct roles are played by IRF -1, but it is not likely that 
IRF-I will cause all of these responses to occur at the same time. Accumulating 
evidence suggests that IRF-l can select between causing cell cycle pausing, or 
apoptosis, (Prost et al. 1998 and Bouker et al. 2005). The potential for this 
phosphorylation-ubiquitination pathway to act as a transcriptional switch is worth 
investigating. Transcriptional profiling would also give us a better understanding 
of the impact phosphorylation has on IRF -I activity. The only gene tested here is 
TRAIL, so it would be useful to know if other important IRF-l targets also 
require IRF-I turnover for their transcription. The apparent drugability of this 
pathway would depend on which pathways phosphorylated IRF-I regulates. 
Recent work has suggested that GSK3p is involved in inflammation, although the 
mechanisms of this action are usually attributed to GSK3p phosphorylation of 
NFKB proteins. Many inflammatory genes are co-regulated by NFKB and IRF-l 
proteins. A table of genes that are known IRF-l transcriptional targets, whose 
expression is modulated by GSK3p, is given below. 
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Gene Effect of Effect of Reference 
IRF-l GSK3p 
C095 l' l' Beurel et 01. 2004 
ICAM l' l' Gotschel et 01. 2008 
IL-12p35 l' l' Rodionova et 01. 2007 
IL-12p4O l' l' Martin et 01. 2005 
iNOS l' l' Gotschel et 01. 2008 & Yuskaitis and Jope 2009 
RANTES l' l' Wang et 01. 2009 & Gong et 01. 2005 
TRAIL l' l' Wang et 01. 2002 
VCAM l' l' Eto et 01. 2005 
Table 7.1. Genes that are co-regulated by IRF-l and GSK3(3. Reported 
instances of IRF-\ target gene expression being altered by GSK3p inhibition, 
knockdown or absence in knockout mice. 
Does phosphorylation offer a therapeutic route to regulating IRF-J activity? 
Clinically, IRF-l expression is druggable, due to its induction by IFNs and 
retinoids. Evidence suggests that IRF-I is an important cellular mediator of these 
agents in human diseases (see 1.4.1-1.4.5). Presently little is known about the 
control of IRF-l activity post translation, pursuing inhibitors of IRF-I activity 
could therefore be of use in a number of diseases associated with inappropriate 
IRF-I action - most of these are inflammatory conditions, although IRF-I is also 
required for HIV replication (Sgarbanti et af. 2008 and Remoli et af. 2006). 
GSK3p inhibitors are currently being investigated for their roles in cancer, 
diabetes and bi-polar disorder (Martinez et al. 2002). The anti-inflammatory 
actions of some of these inhibitors has been attributed to their action of NFKB, 
however IRF-I is well known to co-operate with NFKB family members in the 
induction of genes, consequently GSK3p inhibitors may act on both IRF-l and 
NFKB. 
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b.' Fhxw7a a novel coactivator ofIRF-I? 
It has not been fully established if Fbxw7a is a direct a coactivator of IRF-l 
transcriptional activity. Knockdown of Fbxw7a was not carried out to determine 
its effects on IRF -I activity. However, mutation of either Thr l80 or Ser l84 to 
alanine reduces the interaction between Fbxw7a and IRF-I, and consequently 
IRF -I transcriptional activity;. 
This would infer that Fbxw7a acts as a coactivator of IRF-I on the TRAIL 
promoter. Fbxw7a serves as a coactivator of SRC-3 by promoting multi-mono 
ubiquitination which may be involved in protein-protein interactions with nuclear 
receptors (Wu et al. 2007). Consequently Fbxw7a may serve as a coactivator of 
IRF-I by modulating its stability. A number of ubiquitin E3 ligases act as co-
activators towards their substrate TFs. HectH3 promotes K63 linked ubiquitination 
of c-Myc, which is required for interaction with p300, this interaction is needed 
for c-Myc transcriptional activity on a subset of promoters (Adhikary et al. 2005). 
Another ubiquitin E3, Skp2 also acts as a co-activator of c-Myc function by 
promoting degradation (von der Lehr et al. 2003) RNF6 (RING Finger 6) 
promotes ubiquitination of AR (Androgen Receptor) via K6 and K27 linkages. 
Depletion of RNF6 or substitution of the ubiquitinated Lys residues results in an 
alteration in the AR transcriptional programme. Ubiquitination of AR was found 
to be essential for its promoter recruitment and its interaction with the co-activator 
ARA54 (AR Associated Protein 54), which contains ubiquitin interaction domains 
(Xu el al. 2009b). A number of RING finger ubiquitin ligases serve as co-
activators of transcription factors, including RNF4, RNF8, RNF25 and RNF31 
(Takano et al. 2 0 0 4 ~ ~ Perry et al. 2008 and Ehrlund et al. 2009) Further 
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experiments are needed to determine how Fbxw7a regulates IRF-l activity, 
whether through regulating IRF-I abundance or ubiquitin dependent protein 
interactions with the transcriptional machinery. Fbxw7 is also mutated in a 
number of cancers (Welcker and Clurman 2008) and therefore it would be 
interesting to determine ifIRF-I is active in these cancers. 
Is Se/84 essential for IRF-l activity? 
Perhaps neglected in this study, Ser l84 nether-the-Iess deserves further study. The 
indication that it is required for Thr lso phosphorylation suggests that Ser l84 
phosphorylation is critical for IRF-I activity. Although the two alanine and 
phosphomimic mutants appear to phenocopy one another in a number of assays, it 
is important not to discard Ser l84 phosphorylation as merely a priming event. The 
signalling up-stream of the Ser l84 kinase will likely have major effects on the IRF-
I transcriptional programme. It should also be considered that the activity of 
Ser l84 has only been studied in the context of the TRAIL promoter and a synthetic 
construct. Other promoters could therefore be dependent on the phosphorylation 
of Ser l84 completely independently of its ability to prime Thr l80 phosphorylation. 
As mentioned elsewhere, GSK3p is a tightly controlled kinase, and presence of a 
priming mark on a substrate does not necessarily pre-requisite Thr lso 
phosphorylation. Studies on c-Myc have suggested that Ser62 phosphorylation is 
required for directing c-Myc towards promoters involved in the clearance of free 
radicals. Loss of Thr58 phosphorylation (through use of alanine mutants) had no 
effect on c-Myc recruitment or activity on these promoters. This opens up the 
possibility that Ser l84 phosphorylation could be involved in targeting IRF-I to 
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certain promoters, and Thrlso phosphorylation promotes clearance from these 
promoters. 
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Figure 7.2. Further work on the IRF-l phosphorylation-ubiguitination axis 
I) The signall ing pathways that regulate the IRF -1 ki nases, and the potential for 
extra-cellular stimuli to regulate IRF-I phosphorylation. 2) Effect of 
phosphorylation / ubiquitination on protein-protein interactions and structure / 
DNA binding. Phosphorylation has been shown not to effect IRF-l locali ation . 3) 
Subcellular location of IRF-I during phosphorylation and ubiquitination. 4) 
Effect of IRF-l phosphorylation on the transcription cycle, and the specificity of 
this event in detelmining promoter selection. Thus potentially affecting the IRF-l 
transcriptional programme. 5) The effects of IRF-I phosphorylation in human 
disease, does this pathway offer a route for therapeutic intervention in IRF-I 
activity? 
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A fundamental control mechanism is the cell's ability to regulate the expression of 
IRF-l. Most cell types express very low levels of IRF-I protein, with 
transcriptional induction inducing high, transient expression of IRF-I protein. 
IRF-l protein is highly unstable. As such, unless the exposure to the IRF-l 
stimulating agent is chronic, the IRF-l protein levels quickly drop to basal levels. 
Many IRF-l target genes impact on cell survival, therefore an effective shut-off 
mechanism needs to be in place to prevent chronic activation of IRF-l. The 
destruction of proteins may be regulated by cellular signalling in the case of IRF-
l. This occurs through phosphorylation of Thr180• The acquisition of a 
phosphorylation mark on IRF -1 is likely to be tightly regulated, and therefore the 
destruction of IRF-l proteins needs to be timed correctly. The timing of this 
modification has not been studied. It could be assumed that the phosphorylation 
occurs following active engagement of the TRAIL promoter. Kinases can localise 
to transcriptionally active genes, as such it is possible that localised G S K 3 ~ ~
phosphorylated IRF-l while bound to DNA. G S K 3 ~ ~ has been detected by ChIP at 
promoters alongside its substrate SREBP (Punga et al. 2006). although not 
investigated here, it would be interesting to determine if G S K 3 ~ ~ can be recruited 
to the TRAIL promoter. It is also possible that G S K 3 ~ ~ phosphorylates IRF-I that 
has not formed a functional pre-initiation complex on the TRAIL promoter. This 
would cause it to be cleared away, allowing new IRF-I to be recruited and re-start 
complex assembly. Given the number and complexity of proteins that need to be 
recruited to promoters, and the stringent controls placed on transcription it could 
be possible that such mechanisms are in place to regulate IRF-l. It would also 
explain why increasing G S K 3 ~ ~ expression/activity does not increase TRAIL 
transactivation, since G S K 3 ~ ~ only promotes clearance of aberrant IRF-l. A third 
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potential mechanism is that GSK3 ~ ~ phosphorylation occurs on IRF -I not bound to 
promoters, and rather controls local concentration of IRF-l. Overly high 
concentrations of IRF-l in the vicinity of promoters may interfere with other 
proteins gaining access to the DNA. Phosphorylation also allows specific protein-
protein interactions. One such interaction has been shown in this study (Fbxw7a), 
however it cannot be discounted that other interactions occur through 
Thrl80/Serl84. The ability of the K -7 R mutants to be phosphorylated (figure 5.16), 
at ThrI8o/SerI84, but exhibited reduced activity on the TRAIL promoter (figure 
5.15) suggests that the main activity of Thrl80 is in promoting ubiquitination of 
lysine acceptor residues. Therefore this work has identified phosphorylation 
dependent degradation of IRF-l as being crucial for its transcriptional activity. 
IRF-l plays essential roles in terms of tumour suppression and immune 
defence, but IRF-l expression can also be extremely detrimental to cells. This in 
part explains the molecular "short leash" which IRF-l is kept on by various 
control pathways. While IRF -1-1- mice may be severel y immune-compromised and 
more prone to tumour development, they are resistant to experimentally induced 
diabetes, colitis, sepsis, arthritis, thyroiditis, allergic encephalomyelitis, arteritis, 
lupus and graft rejection (Baron et al. 2004, Streetz et al. 2001, Jaruga et al. 
2004, Tsung et al. 2006, Siegmund et al. 2004, Gysemans et al. 
2009 Nakazawa et al. 2001, Tada et a/. 1997, Tani et al. 2002, Afrouzian et al. 
2002, Cordoba et al. 2006 and Reilly et al. 2006). Additionally excessive levels 
of IRF -1 can be found in biopsies of celiac disease, brain haemorrhage and 
chrohns disease (De Stefano et al. 2006, Paschen et al. 1998 and Clavell et al. 
2000). Clearly, when IRF-l expression is not properly controlled it can lead to 
severe pathological defects. It is highly likely that the ability of IRF-I to regulate 
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TRAIL expression would need to be tightly regulated. Although TRAIL posses a 
selective preference for promoting cell death in cancer cells, it is also able to 
promote cell death in normal tissue also, as such this pro-apoptotic death ligand 
needs to be expressed in a controlled manner (Koschny et at. 2007). 
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CHAPTER 8: 
SUPPLEMENTARY 
DATA 
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S 1 Testing "3396-TetR clones. 
To detennine expression level of the TetR protein in transfected H3396 
cells, immunoblots were carried out against TetR. All ten clones expressed TetR 
at the expected molecular weight of 25 kDa. The ratio of TetR to ~ - a c t i n n was 
calculated to compensate for protein loading. Clones 05, D 10, C6, 06, E4, G2 
and E8 were expanded further, however C6, 05, E4 and E8 were the only clones 
to survive. The activity of the TetR was measured by a pcONA4-TO-Luc reporter. 
In this system, upon transfection the Luc reporter is repressed by the TetR protein 
within the cells. Treatment with dox relieves the repression by altering the 
structure of the TetR protein, allowing Luc expression. The fold change (de-
repression) between untreated and dox treated is then measured. All clones except 
E8 exhibited de-repression. Clone E4 was chosen for stable transfection with 
pcONA4-TO-IRF-l. 
S2 Testing H3396-TetR- IRF-l clones. 
Immunoblots of mouse IRF-1 (M20) expression in the stable cell lines is 
shown in figure S2. The levels of IRF -1 protein were corrected for actin 
expression, and the fold was used to choose which cell lines to continue growing. 
Clones that failed to express IRF-I, or expressed IRF-I without dox treatment 
were discarded. 
S3 Localisation of YFP-IRF-l in Cos and HEK293 cells. 
The localisation of YFP tagged IRF-I was investigated in Cos7 and 
HEK293 cells. All IRF-1 constructs were expressed diffusely throughout the 
nucleus. 
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Figure 81. Testing and selection of TetR 03396 cell lines. (A) lmmunoblot (20 
~ g / l a n e ) ) of TetR and ~ - a c t i n n expression in extracts from TetR expressing clones. 
The ratio between TetR and ~ - a c t i n n is given below each clone name. The 
expression ratio is illustrated in (B). (C) pcDNA4-TO-Luc de-repression reporter. 
4 clones were transfccted with either 50 (grey) or 100 ng pcDNA4-TO-Luc and 
treated with 1 1lg/IlL dox or vehicle for 24 hours. Bar indicate the told induction 
between vehicle and dox . 
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Figure S2. Expression of mlRF-l following dox treatment. 48 clones were 
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aga in t IR F- I and p actin were perfO nlled to deteJ111ine induction effici en y. -
denote bl ank media and + indicate dox treatment. 
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YFP Hoechst Merge 
Figure S3 Localisation of va.-ious YFP-IRF-l con tructs in Cos-l cells . Direct 
flu ore cencc (YFP) of the proteins indicated at the left are hown in green. D A 
ta ining (H oech t) is h wn in blue and a merged image to illu tratc the 
tran fccti on effi c iencie are pre ented . Mea ure bar represent IOflm . 
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1.6.1. Glycogen Synthase Kinase 3 
. 
Glycogen Synthase Kinase 3 is a ubiquitously expressed serine I threonine kinase. 
GSK3 exits as two isoforms (alp) encoded by separate genes. GSK3a/p exhibit 
very high homology in their kinase domains, but are divergent elsewhere 
(Woodgett 1990). Studies in mice devoid of each isoform suggest specific 
functions, as the GSK3a is not able to compensate for the loss of G S K 3 ~ , , leading 
to early embryonic lethality. The GSK3a-l • mice are viable, but demonstrate a 
different phenotype to the G S K 3 ~ · I I mice. The regulation and substrate specificity 
of the two isoforms is also divergent (Liang and Chuang 2007). 
GSK3 regulates the activity of a number of its substrates, many of which are 
crucial regulator of cell physiology. As such the activity of GSK3 is under tight 
control. Most of the control is exerted post-translationally. The best studied 
regulatory modification of GSK3 is phosphorylation of Ser9 in G S K 3 ~ ~ and Ser21 
in GSK3a. Phosphorylation of these residues promotes the formation of a 
pseudosubstrate, which blocks the kinase domain of GSK3 and prevents 
phosphorylation of substrates A number of kinases have been shown to 
phosphorylate Ser9/21 , including PKA, PKB, and PKC as such signalling cascades 
are able to regulate the activity of GSK3 (Frame and Cohen 2001). Tyrosine 
phosphorylation of T ~ 1 6 6 ( G S K 3 ~ ) ) and T ~ 7 9 9 (GSK3a) has the opposite effect 
and is important for the kinase activity of GSK3. It is not yet known which 
kinases modulate tyrosine phosphorylation of GSK3 (Frame and Cohen 200 I). In 
addition to post translational modification, protein-protein interactions with GSK3 
also regulate its activity. During Wnt signalling, interaction with FRAT 
(Frequently Rearranged in T cell Lymphoma) prevents G S K 3 ~ ~ from 
87 
